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Introduction 1 
1 Introduction 
1.1 The immune system 
Organisms are confronted with a plethora of detrimental influences from their environment. 
Mechanical and biochemical barriers are the first line of defense against radiation, pollutants and 
pathogens. The elimination of pathogens that nevertheless enter the body is the task of the cellular 
and humoral immune defense. 
The human immune system consists of the rather unspecific, broadly effective, fast innate 
immunity and the slower, but specific, adaptive immunity with its immunological memory. In 
addition to the complement system that represents the humoral component, the innate immune 
response is mediated by several cell types: Natural killer (NK) cells, granulocytes (neutrophils, 
basophils, and eosinophils), macrophages, mast cells, and dendritic cells (DCs). Those cells 
recognize pathogen-specific molecules, so called pathogen-associated molecular patterns, with a 
diverse set of pattern recognition receptors. Phagocytic cells such as DCs, macrophages, and 
neutrophils are able to engulf particles and pathogens while mast cells, eosinophils, and basophils 
release granules that contain a multitude of antimicrobial, cytotoxic, inflammatory substances. This 
response in turn leads to activation and recruitment of other cells and compartments of the 
immune system. NK cells, on the other hand, do not attack invading pathogens directly but play an 
important role in recognizing infected and abnormal host cells.  
The adaptive immune system comes into play when antigen presenting cells (APCs) of the innate 
immune system present relevant antigens to B and T lymphocytes. B cells are able to produce 
specific antibodies targeting those antigens and are part of the humoral branch of the adaptive 
immune system. The cellular branch is represented by the T cells that can kill abnormal or infected 
cells directly or help the immune response by secreting cytokines. B and T cells can provide a long-
lasting protection against pathogens by differentiating into memory cells. This immunological 
memory is the hallmark of adaptive immunity and is responsible for the fast and efficient immune 
response upon subsequent encounters with a pathogen. 
 
1.2 T cell-mediated immune response 
1.2.1 Major histocompatibility complex 
The ability of T cells to distinguish between healthy host cells and infected or abnormal cells 
depends on the recognition of specific antigens presented by major histocompatibility complex 
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(MHC) molecules. MHC molecules are transmembrane glycoproteins that are not only responsible 
for the presentation of antigenic peptides to T cells but also play a crucial role in modulating the 
activity of NK cells.  
The MHC, in humans known as human leukocyte antigen (HLA) complex, is a gene cluster that 
extends over at least 4 million base pairs on chromosome 6 and contains more than 200 genes [1, 
2]. Three major groups can be distinguished: HLA class I (HLA-I), HLA class II (HLA-II), and HLA class 
III. HLA-I and -II mainly contain genes for classical peptide-binding molecules while class III genes 
encode proteins that participate in antigen processing or presentation or have other functions in 
the immune response. The class I region contains the classical HLA-A, -B, and -C genes and non-
classical genes such as HLA-E, -F, and -G. The class II region contains three pairs of HLA-II α and β 
chain genes: HLA-DP, -DQ, and DR. However, many individuals possess an additional HLA-DR β 
chain gene. The HLA genes are among the most polymorphic genes in the genome with many 
different alleles throughout the population. In total, sequences for more than 25,000 HLA-I and -II 
alleles were listed in the international ImMunoGeneTics (IMGT) database [3] by September 2019. 
Due to the polygenic nature, the polymorphism, and the codominant expression of the HLA 
complex, up to six different HLA-I and eight different HLA-II molecules can be expressed in one 
individual. It is therefore highly unlikely that two individuals, apart from identical twins, express the 
same set of HLA molecules.  
 
1.2.2 Structure of HLA molecules and their ligands 
HLA-I and -II molecules differ in their expression pattern, structure, binding motif, peptide origin 
and the T cell type they can activate. While HLA-I can be expressed by almost all nucleated cells, 
HLA-II is only expressed by B cells, dendritic cells, macrophages, and thymic epithelial cells. 
However, malignant transformation of cells and the stimulation with Interferon (IFN)-γ can lead to 
the expression of HLA-II in other cell types [4, 5].  
HLA-I molecules are heterodimers that consist of a 43 kDa α chain and a 12 kDa β2-microglobulin 
(β2m) that are non-covalently associated [2]. The β2m gene is not located within the HLA complex 
but on chromosome 15 [6]. The α chain consists of three domains: the membrane-spanning α3 
domain and two polymorphic domains (α1 and α2) that create a cleft on the surface of the 
molecule. This is the peptide-binding site, also known as the peptide-binding groove [7]. The 
allotype of the α chain is determined by the amino acids forming the binding groove; they have a 
major influence on which peptides will bind [8]. HLA-II molecules consist of two non-covalently 
associated chains – both of which span the membrane: the 34 kDa α chain and the 29 kDa β chain. 
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Both chains have two domains: α2 and β2 are anchored in the membrane and α1 and β1 form the 
peptide-binding groove. The two domains forming the binding groove are non-covalently bonded. 
The fact that the binding groove is open at both ends is another difference to HLA-I molecules. The 
structural differences in the binding groove of the two classes cause distinctive peptide-binding 
specificities. The HLA-peptide binding is mediated by non-covalent interaction of amino acid 
residues in both the HLA binding groove and the peptide. The peptide-binding cleft of HLA-I 
allotypes forms six pockets (A-F), which accommodate different amino acid residues of the binding 
peptide [9]. Those residues are essential for the binding and are therefore called anchor residues. 
The position and the identity of anchor residues differ depending on the HLA molecule [10] and can 
be defined as an allele-specific motif [8]. This results in the fact that a peptide can normally bind 
well to only one HLA allotype. However, HLA allotypes with similar amino acid sequence in the 
binding groove tend to bind similar peptides. Such allotypes can be clustered into groups and are 
termed ‘supertypes’ [11, 12]. Several CD8+ T cell epitopes have been found to show promiscuous 
binding to more than one HLA allotype within supertypes [13-16] but also between different 
supertypes [15, 16]. Peptides presented on HLA-I molecules are usually eight to ten amino acids 
long, 9mers on average. Longer peptides with up to 14 amino acids can either bind [17] by bulging 
when both terminal amino acids are accommodated within the A and F pockets [18] or in some 
cases by extending out of the binding groove at the C-terminus [19, 20]. Peptides bound by HLA-II 
are less constrained in their length due to the open ends of the binding groove; peptides with up to 
25 amino acids can be presented while only a 9 amino acid long core sequence harbors the anchor 
residues that determine the binding specificity [10, 21]. HLA-II molecules display highly 
promiscuous peptide binding compared to their class I counterpart [22, 23]. 
Nevertheless, the specific peptide-binding motif of each HLA allotype allows the prediction of 
possible ligands with online tools such as SYFPEITHI (www.syfpeithi.de) [24], NetMHC 
(https://services.healthtech.dtu.dk/) [25], and the Immune Epitope Database (IEDB, 
https://www.iedb.org/) [26]. 
 
1.2.3 Antigen processing and presentation 
Not only the length of peptides bound to HLA-I and -II molecules differs but also their origin and 
their processing pathway. HLA-I peptides originate mainly from cytosolic proteins degraded by the 
proteasome. The constitutive 26S proteasome is a holoenzyme with a barrel-shaped 20S core 
particle and two 19S regulatory cap particles. The 19S regulatory particles recognize 
polyubiquitinated proteins and guide them to the core particle. The proteolytic activity is mediated 
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by the 20S core with its four stacked hetero-heptameric rings with the stoichiometry α7β7β7α7. 
Three β-subunits, β1, β2, and β5, constitute the active sites, with β1 mainly cleaving on the C-
terminal side of acidic residues, β2 after basic residues, and β5 after hydrophobic residues [27].  
 
Figure 1: HLA-I antigen processing. HLA-I molecules are assembled in the endoplasmic reticulum (ER) with the help of 
CNX. A monoglucosylated N-linked glycan at the HLA heavy chain mediates the interaction with CNX and the peptide 
loading complex. Intracellular proteins are cleaved by the proteasome and the resulting peptides are transported into the 
ER by TAP, where they can be N-terminally trimmed by the aminopeptidases ERAP1 and ERAP2. In addition to TAP, HLA-I 
molecules and the chaperones tapasin, ERp57, and CRT are part of the peptide loading complex that mediates the 
stabilization of HLA-I molecules and the loading with their ligands. The terminal glucose of the N-linked glycan can be 
removed by the enzyme glucosidase II. In cases of suboptimal peptide binding, the enzyme UDP-glucose glycoprotein 
transferase-1 (UGT1) can re-glucosylate the glycan, enabling the HLA-I molecule to maintain or re-enter interaction with 
the PLC. Stable HLA-I-peptide complexes are then transported to the cell surface. An alternative processing pathway is the 
endosome-to-cytosol cross-presentation pathway shown in the lower right of the figure. It allows the presentation of 
peptides originating from extracellular proteins on HLA-I molecules. CNX, calnexin; Gls, glucosidase; CRT, calreticulin; 
ERAP, ER aminopeptidase; TAP, transporter associated with antigen processing; DRiPs, defective ribosomal products. 
Source: [28] (License No. 4793100440077). 
Proteasomal products are about 1 to 26 amino acids long [29-31]. Stimulation of cells with IFN-γ 
induces the expression of special β-subunits (LMP2, MECL1, and LMP7) and the regulatory cap 
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particle PA28, leading to the formation of the immunoproteasome. It has different cleavage 
preferences [31, 32] and an enhanced ability to degrade short peptide substrates instead of 
ubiquitinated proteins [33]. Therefore, the nature of peptides generated by immunoproteasomes is 
altered compared to the constitutive 26S proteasome [34-36]. In general, only about 15% of the 
cleavage products have the appropriate size for binding to HLA-I molecules, most are too short [36, 
37]. The rest needs to undergo N-terminal trimming by aminopeptidases in the cytosol [38, 39] or in 
the ER [40, 41]. Peptides that are not rapidly degraded in the cytosol [42] can be transported into 
the endoplasmic reticulum (ER) by the heterodimeric transporter associated with antigen 
processing (TAP). N-terminal trimming in the ER is then mediated by the IFN-γ regulated ER 
aminopeptidase 1 (ERAP1) [40, 43] and ERAP2 [44, 45]. TAP, consisting of the subunits TAP1 and 
TAP2, associates with several other proteins to form the peptide loading complex (PLC), which 
mediates the assembly of HLA-peptide complexes. Other parts of the PLC are the chaperones 
tapasin, calreticulin (CRT), and ERp57 as well as HLA-I molecules. The HLA-I-β2m dimers assemble in 
the ER with the help of the chaperone calnexin before they are recruited to the PLC. The 
chaperones of the PLC stabilize the empty HLA-I molecule and keep the binding groove in a 
conformation that favors the binding of high affinity peptides [46]. Stable HLA-peptide complexes 
are then released and transported to the cell surface where they can be recognized by CD8+ T cells. 
In case of suboptimal peptide binding, the glycan at position 86 of the HLA-I heavy chain can be re-
glucosylated by the enzyme UDP-glucose glycoprotein transferase-1 (UGT1) [47, 48]. This 
monoglucosylated N-linked glycan is the substrate of CRT [49] and therefore important for the 
interaction with the PLC. Accordingly, the re-glucosylation enables the re-entry of the HLA-I 
molecule in the PLC. 
While most of the HLA-I bound peptides are of cytosolic origin, peptides from internalized proteins 
can also be loaded onto HLA-I by a process called cross-presentation [50, 51]. There are several 
pathways by which peptides from extracellular proteins can be loaded onto HLA-I molecules [52]. 
Figure 1 shows parts of the endosome-to-cytosol pathway [53]. 
The other major processing pathway enables the presentation of peptides derived from 
extracellular antigens on HLA-II molecules (Figure 2). The HLA-II dimers fold and associate in the ER 
with a third glycoprotein, the invariant chain (Ii) [54]. Ii can form a homotrimer that binds to three 
HLA-II dimers, building a nonameric complex [55]. Targeting motifs of Ii [56] direct the complex first 
to the Golgi compartment and then either directly [57, 58] or after recycling them from the cell 
surface [59, 60] to late endosomal acidic compartments called MHC-II compartments (MIIC). There, 
cathepsins and the acidic environment lead to the proteolysis of the invariant chain, leaving a short 
fragment in the binding groove of HLA-II molecules. This class II-associated invariant chain peptide 
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(CLIP) is a placeholder peptide and needs to be released by the enzyme HLA-DM, thereby 
facilitating the binding of high affinity peptides to HLA-II molecules [61]. Thus, HLA-DM acts as an 
exchange catalyst similar to tapasin in the HLA-I antigen processing pathway [62]. The activity of 
HLA-DM, in turn, is regulated by HLA-DO [63]. Stable HLA-II-peptide complexes are released from 
the interaction with HLA-DM and transported to the cell surface for the recognition by CD4+ T cells.  
 
Figure 2: HLA-II antigen processing. HLA-II α and β chains assemble in the ER and form with the homotrimer Ii a 
nonameric complex, which is transported via the Golgi complex to the endocytic compartment MIIC. HLA-II-Ii complexes 
that were first transported to the cell surface are recycled and directed to the MIIC. There, Ii is cleaved and only the 
placeholder peptide CLIP (class II-associated invariant chain peptide) remains in the binding groove of HLA-II molecules. 
The enzymatic activity of the non-classical HLA-II protein HLA-DM is necessary for the exchange of CLIP with high affinity 
peptides. The activity of HLA-DM is, in turn, regulated by HLA-DO. The main source of antigenic peptides for HLA-II 
molecules are extracellular proteins that are internalized by endocytosis, phagocytosis, or pinocytosis. However, 
intracellular proteins can enter this pathway via autophagy. The antigenic proteins are degraded by unfoldases and 
proteases such as GILT (gamma-interferon-inducible lysosomal thiol reductase) and cathepsins. Source: [28] (License No. 
4793100440077). 
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Extracellular or membrane proteins, the main source of HLA-II ligands, are internalized by 
endocytosis, phagocytosis, or pinocytosis and degraded by unfoldases and proteases such as GILT 
(gamma-interferon-inducible lysosomal thiol reductase) and cathepsins [64, 65]. Intracellular 
source proteins can enter the endocytic and phagocytic pathway for example via autophagy [66]. 
1.2.4 The T cell receptor 
T cells are lymphocytes that are defined by the presence of the T cell receptor (TCR) on their cell 
surface. With this receptor T cells are able to recognize diverse antigens in the form of peptides 
presented by HLA molecules. The T cell receptor consists of two different transmembrane 
glycoprotein chains, TCRα and β, that are linked by a disulfide bond. A minority of T cells possesses 
a TCR that is composed of a γ and a δ chain, so called γδ T cells [67]. In this work, TCR refers always 
to the αβTCR. Each chain consists of a variable and a membrane-proximal constant region, which is 
followed by a transmembrane region and a short cytoplasmic tail. The variable region of the α and 
β chain is generated by VJ and VDJ recombination, 
respectively, and forms three hypervariable 
complementarity determining regions (CDRs). The 
immense variability of CDRs directly translates to 
antigen-binding diversity and is a result of somatic 
recombination during T cell development [68]. Insertions 
and deletions of nucleotides at the joining sites further 
increase the possible diversity [69] so that theoretically 
1018 different receptors could be formed [70]. The actual 
number of unique T cell clonotypes is assumed to be 
around 106 [71]. 
The TCR does not have an intracellular signaling domain 
and the α and β chains alone are not expressed on the 
cell surface [72, 73]. It is non-covalently associated in an 
octameric complex with CD3εγ and CD3εδ heterodimers 
and a TCRζζ homodimer which together mediate 
transduction of extracellular stimuli into intracellular signaling (Figure 3). Each CD3 subunit contains 
an extracellular Ig domain and a single immunoreceptor tyrosine-based activation motif (ITAM), 
whereas the ζ chains contain only a short extracellular domain and three intracellular ITAMs each 
[74]. Tyrosine phosphorylation within the ITAMs leads to T cell activation following binding of the 
receptor to its ligand [75]. 
 
Figure 3: T cell receptor complex. The 
functional complex consists of the antigen-
binding αβ heterodimer that is flanked by the 
heterodimeric signalling chains εγ and εδ 
(together CD3). Created with BioRender. 
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1.2.5 T cell subsets 
αβ T cells can be divided into two major groups according to co-receptor expression: CD4 and CD8. 
Cytotoxic T cells (CTLs) express CD8 on their cell surface and can recognize a specific antigen 
presented by HLA-I molecules. They are able to directly kill cancerous or infected cells by releasing 
cytotoxic granules that contain perforin and granzymes [76]. 
T helper cells (TH cells) express CD4 on their surface and recognize antigens presented on HLA-II. 
They mainly support or regulate other cells during an immune response but can also have direct 
cytotoxic functions [77, 78]. While TH subtypes can be increasingly differentiated, three major, well-
characterized types with distinctive cytokine secretion profiles and target cells can be described: 
TH1, TH2 [79], and TH17 cells. TH1 cells are required for the defense against intracellular bacteria, 
viruses, and cancer. They mainly secret the pro-inflammatory cytokines IFNγ and IL-2 and support 
the cell-mediated response by macrophages [80] and CTLs [81, 82]. In contrast, TH2 cells rather 
support the humoral part of the immune response against extracellular pathogens by secreting IL-4, 
IL-5, IL-9, IL-10, IL-13, and IL-25 and induce antibody production by B cells [83, 84]. TH17 cells 
produce IL-17 and play an important role in both mucosal immunity and autoimmune disorders 
[85]. 
Regulatory T cells (Treg) are another CD4-positive subtype [86] and express CD25 and the 
transcription factor FOXP3 (forkhead box p3) [87, 88]. Tregs have immunosuppressive functions to 
prevent damage by exaggerated immune responses and are responsible for the maintenance of 
immunological tolerance [86]. 
 
1.2.6 Development of CD4+ and CD8+ T cells 
T cells originate from pluripotent hematopoietic stem cells in the bone marrow that differentiate 
into common lymphoid progenitor cells [89]. They then migrate to the thymic cortex where they 
lose the ability to differentiate into B and NK cells [90]. Instead, they become double-negative (DN, 
CD4-CD8-), committed T cell precursors that progress through four different stages (DN1-4) with 
distinct surface expression patterns of CD44 and CD25 [91]. DN3 cells can differentiate into both αβ 
and γδ T cells. Cells of the αβ pathway start to express an invariant pre-TCRα together with a 
rearranged TCRβ. This rearrangement is mediated by the recombination activating genes (RAG) 1 
and 2 [92, 93], which are upregulated in stage DN2. Cells that pass the β selection start to rearrange 
the TCRα locus during DN4 to form a mature TCR [90]. Those cells also begin to express the co-
receptor proteins CD4 and CD8 and are then double-positive (CD4+CD8+) immature T cells. Only 
cells that recognize HLA-peptide complexes presented by cortical thymic epithelial cells receive 
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essential survival signals, a process called positive selection, and differentiate into CD4 or CD8 
single-positive T cells. The fraction of autoreactive T cells that binds strongly to self-peptides and 
could therefore cause autoimmune diseases is then removed by negative selection in the medulla. 
Only about 2-5% of the generated, immature T cells survive both positive and negative selection 
and leave the thymus as naïve T cells to constitute the peripheral T cell repertoire [94].  
 
1.2.7 Activation of T cells and their response 
Naïve T cells circulate through the blood to the lymphatic system until they come into contact with 
their specific antigen presented by an APC. This usually occurs in peripheral lymphoid organs where 
DCs migrate to after the uptake of foreign antigens [95]. The homing of naïve T cells to lymphoid 
organs is mediated by the surface molecule L-selectin (CD62L), which interacts with addressins 
expressed on high endothelial venules in lymph nodes and enables the T cells to roll along the 
surface of these cells [96]. This initiates the entry of naïve T cells into lymphoid organs. There, the 
binding of the TCR to its specific HLA-peptide complex is the first of three signals required for 
activation of naïve T cells. Binding to an HLA-peptide complex alone indicates the recognition of a 
self-peptide and leads to T cell anergy or apoptosis [97, 98]. The second signal is provided by 
costimulatory molecules on activated APCs. There is a plethora of different stimulatory and 
inhibitory molecules and their ligands [99], with CD28 being the most prominent stimulatory 
molecule. CD28 is expressed on the majority of T cells and binds CD80 and CD86 on APCs [100]. 
CD28 signaling promotes T cell survival and proliferation [99] and strongly upregulates IL-2, an 
autocrine proliferation factor of T cells [101]. Signal three is provided by DC-derived cytokines and 
induces T cell polarization that determines the effector functions of the T cell [102, 103]. The first 
activation of naïve T cells is called priming. Primed T cells undergo clonal expansion for several days 
and give rise to effector and memory T cells that leave the lymph node and can be activated by the 
first signal alone. To recognize this signal, each T cell bears about 30,000 copies of a unique T cell 
receptor on its surface [104, 105]. Early in vitro experiments proposed that, depending on the 
affinity of the TCR-ligand binding and the number of HLA-peptide complexes, the engagement of 
about 500 to almost all TCRs on one cell is necessary for T cell activation [106]. In contrast, around 
100 HLA-peptide complexes for T helper cells [107, 108] and even single complexes for CTLs [109] 
are sufficient for T cell activation. It is assumed that one HLA-peptide complex can serially engage 
and trigger up to 200 TCRs [110] although this model is still disputed [111, 112]. 
The T cell-mediated immune response can be divided into three phases: expansion, contraction, 
and memory. After the first contact with the pathogen, the priming of specific T cells and their 
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clonal expansion, effector memory T cells start to fight the pathogen. The T cell response usually 
has its peak at around 7-15 days after initial antigen contact. The antigen or pathogen clearance is 
followed by a contraction phase in which the vast majority of effector cells dies by apoptosis and 
only a small population of long-lived memory T cells remains. The half-life of T cell memory is about 
8-15 years [113] while the half-life of single cells is 1-12 months [114, 115]. This indicates that the 
memory is maintained by a continuous turnover. 
Memory T cells can be usually identified by their expression of CD45RO [116, 117] and the lack of 
the longer isoform CD45RA, which is expressed on naïve T cells. On the basis of the lymph node 
homing CC-chemokine receptor CCR7 expression, T cells of the peripheral blood can be divided into 
four populations. Naïve T cells (CCR7+CD45RA+) uniformly express CCR7, which reflects their 
predominant location in the lymphoid organs. Central memory T cells (TCM) (CCR7+CD45RA-) also 
traffic to lymphoid organs while effector memory T cells (TEM) (CCR7-CD45RA-) are able to migrate 
to peripheral tissues [118]. In contrast, terminal effector memory T cells re-express CD45RA 
(CCR7+CD45RA+) (reviewed in [114]). Another memory T cell subpopulation can be identified with 
further surface markers; T memory stem cells are CD45RA+CD45RO− and express high levels of 
CD27, CD28, IL-7 receptor α chain (IL-7Rα), CD62L and CCR7. They have a high proliferative capacity 
and can differentiate into TCM and TEM cells [119]. 
1.3 Epstein-Barr virus 
The Epstein-Barr virus (EBV), also known as Human herpesvirus 4, is a lymphotropic 
gammaherpesvirus. It was discovered by Michael Anthony Epstein, Budd Achong, and Yvonne Barr 
when they cultured cells from African Burkitt’s lymphoma in 1964 [120]. Early studies uncovered 
the virus’ potential to transform B cells into lymphoblastoid cell lines [121-123]. Evidence that EBV 
is not only a concomitant but could be the cause of cancer was published 1978 [124]. It was 
therefore the first oncogenic virus identified in humans.  
EBV is highly prevalent and infects more than 90% of the human population worldwide. Primary 
infection is often asymptomatic but can cause infectious mononucleosis (IM) [125], especially when 
it occurs during or after the second decade of life [126]. In all cases, infection results in a lifelong 
persistence of the virus in the host. The virus has since been linked to a large variety of 
malignancies. 
There are two major genotypes of EBV, type 1 and type 2 (originally A and B). These two types were 
distinguished by their variations in the EBNA2 genes and differ in their transforming and 
reactivation capabilities [127]. Most other genes differ by less than 5% in their sequence [128]. 
While both types are equally prevalent in sub-Saharan Africa, type 1 is the most common 
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throughout the world [129, 130]. Type 1 and 2 can be subdivided into different virus strains; mainly 
on the basis of LMP-1 variations [131]. The strains B95-8 and AG876 are prototype strains for type 1 
and type 2, respectively. 
In comparison to other human herpesviruses, EBV stands out for its extensive gene expression 
during the latent infection and its ability to induce proliferation of latently infected cells. 
 
1.3.1 Structure and genome 
EBV virions are relatively large, multi-layered particles with a diameter of 110-180 nm [120, 132]. 
The double-stranded, linear DNA is surrounded by a nucleocapsid with 162 capsomers, which is in 
turn surrounded by a protein tegument. The envelope with its embedded glycoproteins builds the 
outer layer.  
The viral genome has a length of about 184,000 base pairs (184 kb) and about 90 open reading 
frames (ORFs). The 172 kb large genome of strain B95-8, derived from an IM patient, was 
completely sequenced in 1984 [133]. However, this extensively studied laboratory strain is missing 
a 12 kb segment in comparison to the majority of isolates [134]. But apart from a decreased 
expression of the gp220 envelope protein, the biological properties of B95-8 are indistinguishable 
from those of other strains [135]. The viral genome has 0.5 kb long terminal repeats at both ends 
and several internal repeats. They divide the genome in short and long unique sequence domains. 
The viral DNA builds circular episomes in host cells [136].  
The nomenclature of the EBV ORFs was established according to the BamHI-restriction fragments in 
which they were found. The fragments were ordered from A to Z based on their sizes [137, 138]. 
BARF1 would therefore be the first rightward reading frame in the BamHI A restriction fragment. 
Many characterized genes are also known by more common names describing their functions. 
The EBV ORFs can be divided in latent and lytic genes. Different sets of latent genes are expressed 
depending on the latency program. All latent gene products such as EBV nuclear antigens (EBNA1, -
2, -3, -3A, -3B, -3C, and -LP), latent membrane proteins (LMP1, -2A, and -2B), and Epstein-Barr virus-
encoded small RNAs (EBERs) are expressed in Latency III. In Latency II, only EBNA1, the EBERs, and 
LMP1 and -2A are expressed. Latency I is characterized by the exclusive expression of EBNA1 and 
the postulated Latency 0 by the complete arrest of viral gene expression [131]. Epstein-Barr virus 
BamHI A fragment transcripts (BARTs) are detectable in all three forms of virus latency [139]. Lytic 
genes are expressed in three consecutive stages: immediate-early, early, and late. 
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Table 1: Different EBV transcription programs. Adapted from [140]. 
Transcription 
program 
Expressed 
proteins 
Description or function 
Pre-latency 
BZLF1, BRFL1, 
BMRF1, BCRF1, 
EBNA2, BHRF1, 
EBNA-LP 
The expression of various latent and lytic proteins 
improves survival and immune evasion of newly 
infected B cells. 
Latency III 
EBNA1, -2, -3A, -
3B, -3C and –LP, 
LMP1, -2A and 
LMP2B 
Expression of the full complement of latent proteins 
serves to activate naïve B cells and leads to their 
proliferation as B cell blasts. 
Latency II 
EBNA1, LMP1, 
LMP2A 
Mimics T cell help and BCR signaling so that GC B cells 
are rescued into the memory compartment. 
Latency I EBNA1 
The expression of EBNA1 enables the viral genome to 
be replicated along with the host genome during 
memory B cell homeostasis. 
Latency 0 None 
The absence of EBV antigens enables immune escape 
and ensures survival of long-lived memory B cells 
Lytic 
More than 80 
viral genes are 
expressed 
The production of virions promotes the continued 
infection of permissive cells within the same host and 
enables the horizontal transfer of virions to other 
individuals. 
 
1.3.2 Biology of EBV infection and life cycle 
EBV can be transmitted via saliva, semen, and blood. The oral route is the main route of 
transmission but sexual intercourse as well as organ transplantation and blood transfusions can 
lead to virus spread [141, 142]. Although B cells are the main target and reservoir of EBV, the virus 
can infect epithelial cells, T cells, and NK cells [143-145]. Primary infection usually happens in the 
epithelium of the tonsils. There are different mechanisms of entry depending on the infected cell 
type (Figure 4). B cell entry is initiated by the binding of the viral glycoprotein gp350/220 to the 
cellular complement receptor CR2 (CD21) [146] or CR1 (CD35) [147]. The core fusion proteins gH, 
gL, and gB are required for the entry and for the fusion of the viral envelope with the cellular 
membrane. The non-covalently linked gH/gL heterodimer, formed by membrane-bound gH and 
soluble gL, functions as a regulator for gB-mediated fusion. gH/gL builds a complex with gp42, 
which induces B cell entry after engaging cellular HLA-II. In contrast, entry into epithelial cells is 
thought to be mediated by a direct interaction of gH/gL with integrin receptors [148] rendering 
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gp350/220 and gp42 dispensable for this process. Gp42 acts as a switch of cellular tropism 
promoting B cell infection while inhibiting infection of epithelial cells [149].  
 
 
Figure 4: Entry of EBV into B cells (A, B) and epithelial cell (C, D). A) EBV entry into B cells is mediated by endocytosis. 
Afterwards, the viral membrane fuses with the endocytic membrane and the viral capsid is released into the cytoplasm. 
B) The entry into B cells is initiated by the binding of the viral glycoprotein gp350 to the cellular complement receptor CR2 
or sometimes CR1. Gp42 then forms a complex with the heterodimer gH/gL. After the binding of gp42 to cellular HLA-II, 
the gp42/gH/gL complex activates gB, which in turn mediates the fusion of the viral envelope with the cellular, endocytic 
membrane. C) In contrast, the EBV entry into epithelial cells is endocytosis independent. The viral envelope fuses directly 
with the cellular membrane and releases the capsid into the cytoplasm. D) The entry is probably mediated by the direct 
interaction of gH/gL with cellular αvβ6/αvβ8 integrin receptors. This causes a conformational change of the fusion protein 
gB, which mediates the fusion of the viral and cellular membrane. Adapted from [150]. Created with BioRender. 
Once EBV entered the cell, the viral capsid is released into the cytoplasm and disassembled. The 
viral genome is then transported to the cell nucleus and replicated by DNA polymerases during the 
lytic or productive phase of the viral life cycle. Lytic genes are then expressed in three phases: 
immediate-early (IE), early, and late. IE proteins such as BZLF-1 and BRLF-1 act as further 
transactivators of the lytic program [151]. Early gene products have a variety of functions including 
replication, metabolism, and inhibition of antigen processing while late gene products are mainly 
structural proteins or proteins responsible for immune evasion. The infection of epithelial cells is 
believed to be mainly lytic in nature while EBV establishes latency in memory B cells. How the virus 
gains access to the memory compartment is still controversial. The germinal center model 
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postulates that, after a short pre-latent phase with both lytic and latent gene expression, EBV 
initiates a growth and proliferation program in naïve B cells (Latency III). These infected B cells 
become activated lymphoblasts and migrate to the follicle of a lymph node where they expand to 
form a germinal center. Survival of such B cells usually depends on signals from antigen-presenting 
DCs and antigen-specific TH cells. Those signals are assumed to be mimicked by EBV using the 
Latency II program [152, 153]. Virus-carrying, quiescent memory B cells (Latency 0) subsequently 
exit the lymph node to circulate in the peripheral blood. Those memory B cells are able to evade 
immune recognition since no viral antigens are expressed in this phase. During cell division, only 
EBNA1 is expressed to ensure the replication of the viral genome (Latency I) [154]. The number of 
infected B cells in the peripheral blood can vary considerably between individuals but is quite stable 
during latency with 1-50 per million B cells [155]. 
Spontaneous reactivation into the lytic cycle in infected B cells can occasionally happen and leads to 
the infection of other cells and virus shedding in the saliva. Since contact with foreign antigens and 
the subsequent terminal differentiation into plasma B cells can trigger reactivation, any new 
infection can lead to lytic replication [156]. Reactivation in immunocompetent carriers usually 
causes no symptoms because cytotoxic T cells efficiently control the infection. However, 
reactivation due to immunodeficiency or immunosuppression can lead to various 
lymphoproliferative diseases [157].  
 
1.3.3 EBV-associated diseases and their treatment 
While EBV infection is usually asymptomatic, it can be associated with a vast number of non-
malignant, pre-malignant, and malignant diseases. EBV is best known as the main cause of 
infectious mononucleosis [158], a non-malignant clinical manifestation of primary EBV infections. 
The disease owes its name from the atypical, large lymphocytes that were observed and that are 
now known as Downey cells. They are activated, mostly EBV-specific CD8+ T cells. The substantial 
expansion of this highly activated CD8+ compartment correlates with the severity of IM symptoms, 
which supports the view that IM is an immunopathologic disease [159, 160]. Symptoms can vary 
considerably but fatigue, fever, a sore throat, and swollen posterior cervical lymph nodes are 
typical. The disease is generally self-limiting, and the acute symptoms resolve in two to four weeks. 
The fatigue, however, can last for months [161]. Rare complications include airway obstruction, 
meningoencephalitis, hemolytic anemia, thrombocytopenia, splenic rupture, and many more [151].  
In cases of insufficient viral replication control, chronic active EBV (CAEBV) infection is a rare but 
life-threatening lymphoproliferative disorder. It is characterized by chronic infectious 
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mononucleosis-like symptoms for more than 6 months, viremia, and infiltration of organs with EBV-
infected lymphocytes. CAEBV is often associated with the infection of T and NK cells. Untreated 
patients will develop immunodeficiency and eventually suffer from opportunistic infections, 
hemaphagocytosis, lymphomas or multi-organ failure. Although many treatments including 
antiviral therapy, immunosuppressive agents, interferon, and chemotherapy have been tried, 
hematopoietic stem cell transplantation is currently the only curative treatment for this disease 
[162]. 
EBV is also causally associated with most post-transplant lymphoproliferative diseases (PTLD). 
Those diseases range from benign polyclonal B cell proliferation to malignant B cell lymphomas and 
are due to the immunosuppressive treatment after transplantation. The occurrence of this often 
fatal disorder correlates with the type and dose of the immunosuppressant medication, and 
reduction of this treatment is key for the successful therapy of PTLD [163, 164]. The standard 
therapy after reduction of immunosuppression includes the CD20 monoclonal antibody rituximab 
[165, 166] combined with chemotherapy (doxorubicin, cyclophosphamide, vincristine, prednisone) 
[167]. However, reduced immunosuppression can lead to graft rejection while the therapy with 
rituximab combined with chemotherapy can be associated with rare but severe side effects such as 
leukopenia, infection, or even death. Further treatment options are other chemotherapeutic 
regiments, interferon therapy, radiation, or antiviral therapy [168]. New therapies such as adoptive 
T cell transfer are being studied in clinical trials [169, 170] and achieve promising results.  
There is a plethora of malignant lymphoproliferative disorders linked to EBV including non-Hodgkin 
lymphoma, diffuse large B cell lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, gastric 
carcinoma, T cell and NK cell lymphomas and many more [171]. In general, it is assumed that EBV is 
associated with around 200,000 malignancies worldwide each year [172]. Recent studies further 
suggested that EBV could increase the risk of developing other major diseases such as systemic 
lupus erythematosus, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, 
inflammatory bowel disease, celiac disease, type 1 diabetes, and others [173, 174]. Altogether, this 
led to an increasing interest in an EBV vaccine [140]. 
1.3.4 Immune response against EBV 
Although a large part of the population is infected with EBV, symptoms occur only in some, mostly 
post-pubescent, individuals. The many cases of EBV-associated diseases during immunosuppression 
impressively demonstrate the involvement of the immune system in the EBV-specific defense. 
While EBV triggers a humoral as well as a cellular immune response, the cellular arm, especially 
cytotoxic T cells, seems to be more effective in limiting EBV infections [160, 175]. However, the 
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serological response to EBV is used as a diagnostic tool and can help to define the EBV disease 
status. Antibodies against viral capsid antigens (VCA), EBNA1, early antigens, and gp350 are 
detectable. The first exposure to EBV usually triggers an early VCA-IgM reaction that decreases 
again before convalescence. It is therefore a marker for acute primary infection. IgG antibodies 
against VCA arise shortly after, can persist throughout the whole life and indicate a recent or a past 
infection. Neutralizing EBNA-IgG only arises months after primary infection and is also detectable 
for life [176]. However, 5-10% of infected individuals never develop an antibody response against 
this protein [131]. Due to this and other variations in individual antibody responses, the 
interpretation of serological tests is challenging [176]. Although studies suggested that the 
induction of neutralizing antibodies could prevent the development of IM [177], little attention has 
been given to such antibodies as therapeutic option [160]. 
The innate cellular immune system, mainly represented by NK cells, also participates in the fight 
against EBV. The exact role of NK cells in EBV infection is, however, not yet fully understood. An 
increase in the number of blood NK cells can be detected in infectious mononucleosis patients, 
which is often but not always associated with a decreased viral load [178]. Furthermore, NK cells 
are able to affect viral lytic replication and can kill infected B cells [179, 180]. The fact that a specific 
EBV-reactive NK cell population (early differentiated NK cells, CD56dim NKG2A+ KIR−) decreases 
during the first decade of life, suggests that an age-dependent defect in the NK cell response may 
lead to a compensation by cytotoxic T cells, which in turn causes IM [181].  
As previously described, IM is accompanied with an immense expansion of the CD8+ T cell 
compartment that mainly contains T cells specific for lytic EBV proteins. Following a clear hierarchy, 
T cells specific for immediate-early proteins are the most abundant T cells while a smaller number is 
specific for early proteins and only few are specific for late proteins [182]. This mirrors the 
increasing effect of immune evasion in the progression of the lytic cycle. CD8+ T cell responses 
against latent proteins have low frequencies and are mainly directed against the EBNA3 family of 
proteins [183, 184]. Responses of CD8+ cells against EBNA1, however, are hardly ever detected due 
to an internal glycine-alanine repeat domain that diminishes the messenger RNA translation [185] 
and protects the mature protein from proteasomal degradation thereby inhibiting the presentation 
on HLA-I molecules [186, 187]. The majority of EBV-specific T cells are highly activated with 
expression of HLA-DR, CD38, and CD45RO and show downregulation of the lymph node homing 
marker CD62L [188]. 
During asymptomatic primary infection, the total number of CD8+ T cells in the blood is not 
elevated. Nevertheless, high frequencies of activated EBV-specific CD8+ T cells can be detected, 
although lower in magnitude than in IM patients [189]. While responses to individual lytic epitopes 
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can constitute up to 50% of the whole CD8+ T cell compartment during acute infection [190], this 
proportion shrinks in persistent infection to up to 2% and 0.5% for lytic and latency-specific 
responses, respectively [160]. EBV-specific CD8+ memory T cells show differences in their 
phenotype depending on whether they are specific for epitopes derived from lytic or latent 
proteins. While latent epitope-specific CD8+ memory T cells are uniformly CD45RO+ and CD28+, lytic 
epitope-specific populations are heterogeneous in CD45RO/RA and CD28 expression. They are 
negative for the activation markers CD69 and CD38 but show peptide-specific cytotoxicity with 
type 1 cytokine (IFNγ and TNF) production upon stimulation [191].  
The absolute CD4+ T cell number expands considerably less in IM patients compared to that of CD8+ 
T cells. However, single EBV-specific CD4+ T cell populations can strongly amplify during acute 
infection, reaching frequencies of 1% of CD4+ T cells in the blood [160], decline rapidly thereafter 
and are still detectable in healthy virus carriers [192, 193]. Similar to their CD8+ counterparts, EBV-
specific CD4+ T cells express high levels of CD38 and CD45RO and lack the lymph node homing 
markers CCR7 and CD62L [193]. 
Epitope-specific CD4+ memory T cell populations can constitute up to 0.1% of the whole CD4+ T cell 
pool, 10- to 20-fold less than those of the CD8+ T cell pool [160]. The CD4+ response also shows 
differences in comparison to the CD8+ response in its epitope hierarchy with a broader distribution 
of lytic and latent cycle proteins as targets [194]. Moreover, the response to EBNA1 is atypical with 
a hardly detectable response during acute infection and a delayed but significant EBNA1-specific 
CD4+ T cell response 2-13 months after primary infection [193]. Almost all EBV-specific CD4+ 
memory T cells are part of the central memory (CD45RA− CD45RO+ CCR7+) or the effector memory 
(CD45RA− CD45RO+ CCR7−) compartment with an average ratio of 1:1 and express CD28 and mostly 
CD27 [193]. 
 
1.4 Human cytomegalovirus (HCMV) 
HCMV or Human herpesvirus 5 (HHV-5) is a double-stranded DNA virus that belongs to the genus 
Cytomegalovirus and subfamily Betaherpesvirinae within the family of Herpesviridae. It takes its 
name from the characteristic morphological changes that are induced after infection; the cells 
round up and increase their volume. HCMV infects the majority of adults, with a seroprevalence 
ranging from 45% in some European countries to almost 100% in developing countries [195]. While 
primary infection is usually asymptomatic, HCMV can cause severe disease in immunocompromised 
individuals such as AIDS patients or transplant recipients. Infection or reactivation from latency in 
those individuals can result in hepatitis, pneumonitis, retinitis, gastroenteritis, encephalitis, 
18  Introduction 
transplant rejection, or even death. Congenital infection of the fetus can also damage the central 
nervous system leading to motor deficits, sensorineural hearing loss, and mental retardation 
(reviewed in [196]). 
It is further thought that subclinical infections with HCMV are involved in a variety of diseases such 
as inflammatory [197], hypertensive [198], and possibly pulmonary diseases [199]. Although HCMV 
is not yet classified as an oncogenic virus, it expresses several potential onco-proteins with 
transforming capacities [200-203], and HCMV gene products are present in many tumors [204-207].  
The primary infection is followed by lifelong latency with recurrent reactivation. 
1.4.1 Structure and genome 
HCMV is a relatively large virus with 150-200 nm in diameter [196]. The virion’s linear genome is 
densely packed in an icosahedral capsid embedded in a proteinaceous tegument, which in turn is 
surrounded by the lipid envelope. The capsid has a diameter of approximately 130 nm and consists 
of 162 capsomers (12 pentons and 150 hexons) and 320 triplexes arranged on a T = 16 lattice. 
Capsomers contain five (pentons) or six (hexons) major capsid proteins (MCP, UL86). In hexon 
capsomers, one smallest capsid protein (SCP, a short ORF between UL48 and UL49, also UL48/49) is 
located on top of each MCP. The triplex structures are composed of the minor capsid protein-
binding proteins (mC-BP, UL46) and minor capsid proteins (mCP, UL85) in a ratio of 2:1 [208].  
The tegument contains at least 39 different viral proteins with phosphoprotein 65 (pp65) being the 
most abundant (reviewed in [209]). Not only viral but also cellular proteins are part of the 
tegument [210]. Upon virus entry, those proteins are directly released into the cytoplasm of the 
infected cell and are able to function before the onset of viral protein production in this cell. The 
lipid bilayer of the envelope contains at least 17 viral glycoproteins including gB (UL55) [211, 212], 
gM (UL100) [213, 214], gH (UL75) [215], gL (UL115) [216], gO (UL74) [217], gN (UL73) [218], gp48 
(UL4) [219], TRL10 (RL10) [220], UL33 [221], US27 [222], UL128, UL130, UL131 [223], UL1 [224], 
UL78 [225], UL116 [226], and UL132 [227]. Many of those envelope proteins are required for the 
attachment to the host cell, the virus entry, and immune evasion. 
With its almost 236 kbp long double-stranded DNA genome, HCMV has the largest genome among 
human herpesviruses [228]. The genome consists of two unique regions, UL and US, that are flanked 
by inverted repeats (TRL, IRL, TRS, and IRS). The complete DNA sequence of HCMV was uncovered 
long ago [228, 229]. After initial estimates of 165 ORFs [228], the number of identified ORFs has 
risen steadily ever since [230, 231]. Conservative estimates of less than 200 ORFs probably do not 
capture the complexity of the HCMV genome and its coding capacity. With its over 100 splicing 
sites, short ORFs, upstream ORFs, transcript polycistrony, and antisense transcripts, the HCMV 
Introduction 19 
genome has a highly complex transcriptome [232]. Consequently, Erhard et al. recently postulated 
a staggering number of 944 ORFs using ribosome profiling [233]. Uniprot, however, currently lists 
solely 193 reviewed proteins for the strain AD169 (accessed 04.03.2020) [234]. 
The HCMV strain AD169, found 1957 in adenoid tissue cultures, was the very first to be sequenced 
and has since been the model laboratory strain in HCMV research [229, 235]. However, a study of 
Cha et al. in 1996 revealed that high-passage strains such as AD169 and Towne suffered substantial 
deletions in the UL/b’ region in comparison with the virulent low-passage strain Toledo and clinical 
isolates [236]. The repeated passaging of virus strains in cultured cells leads to a rapid selection of 
mutations in distinct genes including RL13, UL128, UL130, UL131A, and UL140-UL145 [237]. The 
clinical isolate Merlin was therefore sequenced after passage 3 [228] and has since become the first 
World Health Organization International Standard for HCMV [238]. 
Cloning of HCMV genomes as bacterial artificial chromosomes (BACs) offers the possibility to work 
with stable, genetically defined virus strains. The basis of the BAC used in this work, strain 
AD169varL, contains most of the UL/b’ region including ORFs UL150, UL149, UL148A/B/C/D, UL148, 
UL147A, UL147, UL146, UL145, UL139, UL138, UL136, UL135, UL134, and UL133 but is lacking 
UL140-UL144 [239]. 
 
1.4.2 HCMV life cycle 
The virus is transmitted via body fluids such as saliva, tears, blood, urine, and breast milk or via 
transplanted organs. HCMV has a very broad cell tropism including epithelial cells, endothelial cells, 
connective tissue cells (e.g. fibroblasts), hepatocytes, smooth muscle cells, and some leukocyte 
populations (reviewed in [240]). Especially, the infection of endothelial and hematopoietic cells 
facilitates the fast, systemic distribution throughout the whole body. 
As all human herpesviruses, HCMV requires two highly conserved envelope glycoproteins for the 
entry into target cells, also called core fusion proteins: gB [241] and the disulfide-linked dimer 
gH/gL [242]. gH/gL can either assemble with gO [243] or with the three proteins UL128, UL130, and 
UL131 forming a trimer and a pentamer [244], respectively. The latter is essential for the entry into 
epithelial, endothelial, and myeloid cells while the trimer is sufficient for the infection of fibroblasts 
[244]. Defects in the genes UL128, UL130, and UL131 of the laboratory strain AD169 are the reason 
for its inability to infect epithelial and endothelial cells [245, 246]. A recent study found another 
protein, UL116, to be able to form dimers with gH [226]. However, its exact function and receptor 
remain unclear. 
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Virus attachment is probably mediated via binding of cell-surface heparan sulfate proteoglycans by 
the disulfide-linked heterodimer gM/gN [247, 248]. The binding of gH/gL complexes to their 
receptors leads then to the initiation of virus entry and the fusion of the viral envelope with the 
host membrane. The platelet-derived growth factor receptor alpha (PDGFRα) was found to be the 
receptor of the gH/gL/gO trimer [249, 250] while neuropilin-2 is the cell entry receptor of the 
pentamer [251]. The role of the homotrimer gB in entry of HCMV is controversial. While it functions 
only as a fusogen in other herpesviruses (reviewed in [252]), several cell-surface proteins have been 
proposed to be gB receptors in HCMV entry: the epidermal growth factor receptor (EGFR) [253], 
PDGFRα [254], and integrins [255, 256]. However, another study by Wille et al. supports the 
hypothesis that gB does not need to bind receptors but is the fusion protein which is activated by 
gH/gL after its binding to gH/gL receptors [257]. The current view of the entry process of HCMV is 
shown in Figure 5. Many more molecules (i.e. CD147, CD151, CD90) were reported to be receptors 
in HCMV entry (reviewed in [258]). Considering the wide cell tropism of HCMV, it seems not 
unlikely that those molecules function as co-receptors affecting downstream events in different cell 
types during the entry [258]. 
 
 
Figure 5: Receptors of HCMV gH/gL complexes. The trimer gH/gL/gO binds to PDGFRα and drives a pH-independent entry 
that involves macropinocytosis. The pentamer gH/gL/UL128–131 binds to Nrp2 initiating a pH-dependent entry that 
involves endocytosis. The entry via the pentamer is promoted by CD147 although the exact mechanism is unknown. 
Adapted from [258]. 
After fusion of the viral envelope with the host membrane, tegument proteins and the capsid are 
released into the cellular cytoplasm. Facilitated by the microtubule network and tegument 
proteins, the capsid with the viral genome is transported to the nucleus [259] and gene expression 
is initiated. HCMV gene expression during lytic or productive cycle happens in a sequentially 
ordered manner conventionally divided into immediate-early (IE, also called α), early (E, β), and late 
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phases (L, γ) [260]. IE genes are the first viral genes transcribed after infection (0-4 hours post 
infection (h.p.i.)) and do not rely on prior de novo viral protein synthesis but on the activation of the 
major immediate-early promoter (MIEP), which in turn is activated by tegument proteins and 
cellular transcription factors [261]. In contrast, early genes require the prior synthesis of viral IE 
proteins and cellular proteins for their transcription (4-48 h.p.i.) [262]. Late genes usually code for 
structural proteins and proteins required for viral egress (48-72 h.p.i.) [261]. A fourth class of genes 
was defined as early-late or leaky-late (E-L, γ1) that is expressed at low levels early and at greatly 
amplified levels after DNA replication [263]. “True late” genes (γ2), on the other hand, are 
completely dependent on viral DNA replication late in infection [261]. In contrast to the 
conventional functional classification, Weekes et al. found five different temporal protein profiles, 
Tp1, Tp2, Tp3, Tp4, and Tp5. While Tp1, Tp2, Tp3, and Tp5 resemble the functional IE, E, E-L, and L 
class, respectively, Tp4 peaks at 48 h and has a so far unclear functional profile [264]. The viral DNA 
replication for the production of new virions occurs in the nucleus within viral replication centers 
[265].  
The viral gene expression and the infection outcome is strongly regulated by the cellular 
environment (reviewed in [266]). While many cell types promote lytic infection, latency is usually 
established in cells of the myeloid lineage including CD14+ monocytes [267] and their CD34+ 
progenitors in the bone marrow [268]. One would assume that the virus expresses no or only a 
limited number of genes, as seen in HHV-4, to evade the host immune system during latency. In 
fact, earlier studies found only few genes to be latency-associated such as UL138, an UL81-82 
antisense transcript, US28, and a splice variant of UL111A, a viral IL-10 homolog [269-272]. Even 
fewer latency gene products could be assigned a function. However, two recent studies by Cheng et 
al. and Shnayder et al. revealed that the set of transcripts during latency is much broader than 
previously assumed [273, 274]. Moreover, they found no specific latency-associated expression 
program but a gene expression that largely mirrors the late lytic transcriptional program, albeit at 
much lower levels of expression [274]. 
The process of reactivation of the lytic lifecycle is not fully understood. However, the cellular 
differentiation of monocytes to a macrophage or a DC is known to be a key trigger in this event 
suggesting that the cellular environment regulates reactivation (reviewed in [275]). Moreover, the 
earliest events in reactivation from latency are the reactivation of IE gene expression, which is 
regulated by MIEP and enhancer regions. 
After the reactivation, the virus replicates its genome and produces proteins required for its 
packaging and egress. After the genome is packed in the capsid it is translocated to the cytoplasm, 
a process called nuclear egress. The capsid thereby receives its primary envelope by budding at the 
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inner nuclear membrane and gets uncoated at the outer nuclear membrane. Virion maturation and 
final envelopment by budding into vesicles of the trans-Golgi network then occurs in the cytoplasm 
after which the vesicle membrane fuses with the cellular membrane and releases the virions from 
the cell (reviewed in [276]). 
The replication cycle of HCMV is compared to other viruses relatively slow with 2-3 days. 
 
1.4.3 Immune response against HCMV 
Immunocompetent hosts can effectively control acute HCMV infection with a multifaceted immune 
response. The virus triggers the innate and the adaptive immune system including the humoral 
response and cellular responses by NK cells as well as by CD4+ and CD8+ T cells. 
One of the earliest events in the immune response to HCMV is the recognition of HCMV or its 
particles directly after virus entry by the Toll-like receptor 2 (TLR2). TLR2 is able to recognize the 
envelope proteins gB and gH and activates the NF-κB pathway, which in turn mediates the 
induction of inflammatory cytokines and IFN-stimulated genes [277, 278]. 
While the important role of NK cells in murine cytomegalovirus (MCMV) infection is evident [279, 
280], the extent of their involvement in controlling HCMV is less clear. In general, individuals with 
NK cell defects can suffer from recurrent virus infections (reviewed in [281]). The recovery of 
patients with HCMV disease after bone marrow transplantation was shown to correlate positively 
with the NK cell activity [282]. Another indicator that the NK cell-mediated response is important in 
fighting HCMV is the immense effort of the virus to evade NK cell activation (see 1.4.4). 
Besides NK cell responses, HCMV also triggers the humoral response with antibodies directed 
against numerous HCMV antigens. A major target for antibody-mediated neutralization is the 
pentamer gH/gL/UL128-131 [283] and trimer gH/gL/gO [284], which are required for the cell entry. 
There are, however, antibody responses against other envelope proteins (mainly gB and gH), 
tegument proteins (pp65 and pp150) as well as non-structural proteins such as IE1 (reviewed in 
[285]). 
HCMV-specific CD8+ T cells seem to play the crucial part in the immune response to this virus. In 
mouse models, MCMV-specific CD8+ T cells efficiently protected mice from lethal MCMV challenge, 
even in the absence of CD4+ T cells [286, 287]. In humans, numerous studies with bone marrow 
transplantation patients showed that their protection from HCMV disease strongly correlates with 
the recovery of HCMV-specific CD8+ T cell populations [288-290]. Successful adoptive T cell 
transfers of ex vivo proliferated HCMV-specific CD8+ T cells that protect from primary infection and 
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reactivation additionally demonstrate the effectiveness of this arm of the immune response [291-
293].  
The targets of HCMV-specific CD8+ T cells are manifold. The immunodominant antigens are clearly 
pp65, IE1, and to a lesser extent pp150 with often very strong T cell responses in almost every 
seropositive individual [292, 294-296]. Thus, the majority of studies screening for T cell epitopes is 
focused on those proteins [285, 297]. However, several studies demonstrated the broad repertoire 
of antigens. A bioinformatics prediction approach by Elkington et al. observed CD8+ T cell-mediated 
responses against 13 out of 14 tested proteins (pp65, pp50, pp28, pp150, IE1, US2, US3, US6, US11, 
UL16, UL18, gB, and gH) [296]. A study, where PBMCs of healthy seropositive donors were 
stimulated with fibroblasts infected with a ΔUS2-US11 deletion mutant virus, identified high 
frequency responses against pp65, IE1, pp150, and gB. In addition to these proteins, T cell 
responses against undefined IE and early proteins were detected [298]. The most comprehensive 
study tested 13,687 predicted peptides covering 213 different ORFs for their ability to elicit a CD4+ 
or CD8+ T cell response. A remarkable number of 151 ORFs were recognized by T cells. Three of 
them elicited a T cell response in more than half of the tested donors: UL83 (pp65), UL123 (IE), and 
UL48 [299]. 
During primary infection, pp65-specific T cells are detectable shortly after the appearance of 
HCMV-specific antibodies [300], show a great expansion [301], and exhibit an activated, cytolytic 
phenotype with high expression of ki67, granzyme B, and perforin, as well as a CD45RO+, CD27+, 
CCR7−, CD28- phenotype. After the contraction phase, many specific CD8+ memory T cells re-express 
CD45RA and are functional as they express perforin and granzyme. Most HCMV-specific CD8+ 
memory T cells are CD28-CCR7- and have variable expression of CD27 (reviewed in [285]). 
The total pool of HCMV-specific CD8+ memory T cells can reach up to 30% of the peripheral blood T 
cell population and regularly reaches 5-10% although individuals vary greatly in their CD8+ T cell 
response [299]. This is, inter alia, due to the phenomenon termed memory inflation. While the 
memory T cell population usually contracts after infections and only a small specific population is 
preserved, the HCMV-specific CD8+ memory T cell pool is mostly maintained and undergoes 
prolonged expansion (reviewed in [302]). The size of this population is therefore usually 
extraordinarily large and increases with age [303]. Memory inflation does not focus on 
immunodominant epitopes since also subdominant responses can inflate at later time points [304]. 
There is a presumption that the selection of epitopes in memory inflation is based on their 
independence of the immunoproteasome in processing [305, 306].  
The HCMV-specific CD4+ part of the adaptive cellular immune response was shown to be essential 
for an effective CD8+ T cell response [292, 293]. Moreover, HCMV-specific CD4+ T cells do not only 
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have a helper function but also cytotoxic activity [307]. They arise even before the anti-HCMV 
antibody response and play a critical role in the protection against HCMV disease [308]. 
CD4+ T cells have similar target ORFs as CD8+ T cells with several particular ORFs (reviewed in [285]). 
The response is very broad with individuals responding to a median of 12 different ORFs of which 
five ORFs (UL55, UL83, UL86, UL99, and UL122) were recognized by more than half of the tested 
donors in the previously mentioned study by Elkington et al. [296]. 
HCMV-specific CD4+ T cells generally constitute around 5% of the total peripheral CD4+ T cell pool 
but can reach up to 20% [299], which is less than the CD8+ population. They also hardly show 
memory inflation with age [309, 310]. The majority of HCMV-specific CD4+ memory T cells has an 
effector memory phenotype with CD45RO+, CD27−, CD62L−, CD11ahigh, and CCR7− [285, 309]. There 
is also a significant population of CD45RAhigh cells in the HCMV-specific CD4+ memory pool [309]. 
CD4+ T cells which lack the costimulatory receptor CD28 are usually rare in peripheral blood. 
However, this subset is frequently detectable in HCMV-infected individuals and can execute HCMV-
specific cytotoxicity via granzyme B and perforin [311]. 
The fact that a T cell-mediated immune response develops despite the extensive immune evasion 
strategies of HCMV (see 1.4.4) is probably also due to the fact that a large part of T cell priming 
takes place via cross presentation [312]. 
HCMV is also able to induce HCMV-specific Treg responses [313] and γδ T cells [314, 315]. However, 
their exact role in the interplay of HCMV and host immune system needs to be further investigated. 
 
1.4.4 Immune modulation and evasion mechanisms of HCMV 
Although immunocompetent individuals are usually able to control acute HCMV infection, the virus 
establishes a lifelong latency from which it can repeatedly reactivate. To achieve this, the virus is 
known to effectively evade the host immune system by employing sophisticated immune-
modulation strategies. The fact that about 70% of the ORFs of AD169 are not essential for viral 
replication in fibroblasts mirrors the focus of HCMV on immune evasion and its broad cell tropism 
[316]. Most of the immune evasion proteins are encoded in the US region of the HCMV genome and 
some in the UL region. They can be divided into four families, the UL18, US6, US12, and RL11 
family (Table 2, reviewed in [317]). 
One major evasion strategy is the modulation of antigen presentation on infected cells to prevent 
the recognition by CD8+ T cells. Members of the US6 family (US2-US11) are responsible for the 
downregulation of HLA-I by impairing its stability and localization. The glycoproteins US2 and US11 
bind HLA-I molecules and mediate their reverse transport into the cytosol for subsequent 
degradation by the proteasome [318-320]. The gene product of US3 directly binds to tapasin and 
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inhibits tapasin-dependent peptide loading, thereby blocking maturation and translocation of HLA-I 
molecules to the cell surface [321, 322]. US6 also prevents the assembly of HLA-I-peptide 
complexes by inhibiting the transport of peptides into the ER via TAP [323, 324]. It therefore binds 
TAP and inhibits the binding of ATP to TAP and the subsequent conformational changes necessary 
for the peptide transport [325]. Apart from inhibiting the maturation of classical HLA-I molecules, 
US10 seems to specifically target the non-classical HLA-G [326, 327]. 
The downregulation of HLA molecules on the cell surface prevents the recognition by T cells but 
triggers the activation of NK cell via a process called “missing-self recognition”. NK cells are usually 
kept inactive by the interaction of inhibitory NK cell receptors with self-ligands on HLA-I molecules. 
Thus, downregulation of HLA-I results in the loss of the inhibitory signal and subsequent target cell 
lysis by the NK cells [328, 329]. Therefore, HCMV developed several mechanisms to limit the 
activation of NK cells, mainly with the help of surrogate ligands that can be recognized by inhibitory 
NK cell receptors. One example is the HLA-I homologue UL18 that can associate with β2m and 
peptide and binds to the inhibitory receptor leukocyte immunoglobulin-like receptor subfamily B 
member 1 [330, 331].  
NK cells also monitor HLA expression via the recognition of HLA-E that presents peptides derived 
from the leader sequence of classical HLA molecules [332, 333]. HCMV uses a peptide from the 
glycoprotein UL40 to mimic these cellular peptides thereby preventing NK cell activation [334, 335]. 
However, HCMV can not only mimic ligands of inhibitory NK cell receptors but can also 
downregulate the surface expression of ligands for activating receptors such as NKG2D and others 
(reviewed in [317]).  
On the other hand, immunoevasins of the RL11 cluster are able to bind to the Fc region of CMV-
specific antibodies to block the antibody-dependent cellular cytotoxicity by NK cells [317, 336]. 
HCMV is not only able to mimic NK cell ligands, Fc receptors, and HLA molecules but also expresses 
a viral IL-10 encoded by the ORF UL111A [337]. Viral IL-10 has the same anti-inflammatory effects 
as its human counterpart and inhibits the activation and maturation of DCs [338], upregulates the 
production of cellular IL-10 [338, 339], suppresses the production of pro-inflammatory cytokines 
[340], and hampers the expression of HLA-I and -II [341]. Another mechanism to reduce HLA-II on 
the cell surface is the direct degradation of HLA-II molecules by US2 and US3 [342, 343]. 
In total, the multifaceted and sophisticated immune evasion strategies of HCMV demonstrate its 
high degree of host adaption and allow the virus to establish a lifelong infection in its host. 
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Table 2: Immunoevasins of HCMV. Adapted from [317]. 
Immunoevasin Target Mechanism 
US2a MHC-I, MHC-II, HFE, 
CD1d 
Proteasomal degradation 
US3 MHC-I-tapasin ER retention 
US6 MHC-I-TAP Prevents peptide translocation into the ER 
US10 MHC-I, HLA-G Delayed maturation of MHC-I, degradation of HLA-G 
US11 MHC-I Proteasomal degradation 
pp71 (UL82) MHC-I May block surface expression 
pp65 (UL83)a MHC-II Lysosomal degradation 
miR-376aa HLA-E Blocks surface expression 
miR-US4-1 ERAP1 Blocks processing of viral peptides 
UL18 LIR1 Direct binding 
UL40b CD94-NKG2A, LIR1 Promotes surface expression of HLA-E and UL18 
US2a Nectin 2 Proteasomal degradation 
US9 MICA*008 Proteasomal degradation of NKG2D ligand 
US12 ULBP2 Downregulation of NKG2D ligands 
US13 MICA, MICB, ULBP2 Downregulation of NKG2D ligands 
US18 MICA, B7-H6 Lysosomal degradation of activating receptor ligands 
US20 MICA, MICB, B7-H6, 
ULBP2 
Lysosomal degradation of activating receptor ligands 
UL16 MICB, ULBP1, ULBP2, 
ULBP6 
Intracellular retention of NKG2D ligands 
UL141a Nectin 2/nectin-like 
protein 5 
ER retention of activating receptor ligands 
UL142 MICA, ULBP3 Intracellular retention of NKG2D ligands 
UL148A MICA Lysosomal degradation of NKG2D ligand 
pp65 (UL83) NKp30 Dissociates CD3ζ adaptor module 
miR-UL112 MICB Downregulates expression of NKG2D ligand 
RL11 IgG1-IgG4 Block FcγR activation and ADCC 
UL119 IgG1-IgG4 Block FcγR activation and ADCC, lysosomal degradation 
RL12 IgG1, IgG2 Binds to Fcγ 
RL13 IgG1, IgG2 Internalizes Fcγ to endosomes 
US2a Integrin-α Degradation 
UL11 CD45 Direct binding 
UL141a TRAILR1 and TRAILR2 Retains death receptors in the ER to prevent apoptosis 
Abbreviations: 7-TM, seven-transmembrane; ADCC, antibody-dependent cellular cytotoxicity; dUTPase; 
deoxyuridine triphosphatase; ERAP1, endoplasmic reticulum aminopeptidase 1; LIR1, leukocyte 
immunoglobulin-like receptor subfamily B member 1; MIC, MHC class I polypeptide-related sequence; ND, 
not defined; TAP, peptide transporter involved in antigen processing; TRAILR, tumor necrosis factor-related 
apoptosis-inducing ligand receptor; ULBP, UL16-binding protein.  
a Immunoevasins that fit into more than one category.  
b Inhibitory receptor surrogate ligands that are also recognized by activating receptors. 
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1.4.5 Treatment of HCMV 
Four antiviral drugs are mainly used for systemic treatment and prophylaxis of HCMV infections: 
ganciclovir (and valganciclovir), cidofovir, foscarnet and the recently approved letermovir. 
Ganciclovir was the first therapy approved for HCMV infections and is the first line treatment 
against HCMV. Ganciclovir is a synthetic analogue of deoxyguanosine and becomes ganciclovir 
triphosphate after its phosphorylation. Its incorporation into DNA leads to the preferential 
inhibition of the viral DNA polymerase UL54 [344]. Valganciclovir is a prodrug with an improved 
bioavailability [345]. Common adverse effects are neutropenia, anaemia, thrombocytopenia, a 
possible long-term reproductive toxicity, and many more [346]. Drug resistance can occur via 
mutations in UL97, the kinase which is responsible for the first phosphorylation of ganciclovir, and 
its target UL54 [347]. 
Cidofovir and foscarnet are second-line drugs that both mainly inhibit the viral DNA polymerase. 
Cidofovir has limited benefit since it is slowly absorbed, has a poor bioavailability and causes 
nephrotoxicity. Foscarnet can cause renal impairment [346].  
Letermovir is a relatively new antiviral drug that inhibits the viral replication via the viral terminase 
complex UL51/UL56/UL89 [348]. It has two advantages over the conventional antiviral drugs: It is 
only mildly toxic and targets the terminase complex instead of the DNA polymerase and can 
therefore not induce cross-resistance. However, resistance can still occur via mutations in the ORFs 
coding for the terminase complex proteins (reviewed in [349]). Other drugs such as maribavir, 
brincidofovir, and filociclovir are under investigation in advanced clinical trials [350]. 
Neutralizing antibodies targeting envelope proteins such as gB and gH are another treatment 
strategy. Therapeutic approaches using hyperimmune globulin and monoclonal antibodies showed 
promising results in several studies and clinical trials [351-354]. However, no antibody is so far used 
as a standard treatment in the clinics. 
In accordance with the central role of T cell-mediated immune responses in the natural defence 
against the virus, adoptive transfer of HCMV-specific T cells is another attractive approach; 
especially in the context of hematopoietic stem cell transplantation where viral infections and 
reactivations cause morbidity and mortality in immunosuppressed patients. Early studies in mice 
demonstrated the effectiveness of transferred CMV-specific T cells in controlling the virus [355-
357]. First studies by Riddell et al. in humans also showed that HCMV-specific CD8+ T cells from 
autologous donors could be generated ex vivo and were able to prevent HCMV infections without 
causing graft-versus-host disease [291, 292]. This method however required extensive cell culture 
of 8-10 weeks. Thus, following studies focused on a faster generation of cellular therapy products. 
HCMV-specific T cells can be enriched by the ex vivo co-culture with HCMV lysate [358], proteins 
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[293, 359], overlapping peptide pools [360], or APCs either pulsed with peptides [361] or 
transfected with vectors that encode viral proteins [362]. The direct isolation of specific T cells from 
seropositive donors can be performed either on the basis of HLA-peptide multimer binding [363] or 
the induction of cytokine secretion (e.g. IFNγ catch technology) [359, 364]. The main limitation of 
all those approaches remains the time-consuming preparation of specific T cells. A prophylactic 
preparation of virus-specific T cells for each transplant patient is, however, not feasible since only a 
small proportion of them suffers from HCMV infection. Moreover, the generation of personalized 
specific T cells under “good manufacturing practice” conditions is labor- and cost-intensive. 
Another major drawback is the need for HCMV seropositive transplant donors, which would once 
more radically limit the choice of possible donors. Therefore, the establishment of biobanks with 
seropositive third-party donors has been a major goal in recent years [365-367]. This allows for a 
rapid “off-the-shelf” treatment of severe viral infections after stem cell transplantation. 
Although there are several options available or in development, the search for novel therapies is 
still ongoing due to the limitations of current treatment options, such as side effects, 
ineffectiveness, drug resistance, limited availability, and high costs. Much effort is therefore 
invested in the development of an HCMV vaccine (reviewed in [368]). The first attempt was to 
attenuate HCMV strains that were isolated for laboratory work, AD169 and Towne [369, 370]. 
AD169 was quickly abandoned but the Towne strain underwent extensive testing. However, while 
the vaccine was safe [371, 372] and could protect against severe HCMV disease [373], it did not 
protect against primary HCMV infection [374] and was only as effective as naturally induced 
immunity for low-dose challenges [375]. Vaccines comprising the protein gB and different adjuvants 
provided also only moderate protection with quickly fading neutralizing antibody levels [376, 377]. 
In contrast, the proteins of the pentameric complex (gH, gL, UL128-131) caused higher levels of 
neutralizing antibodies than gB [244].  
One exemplary peptide-based vaccine comprised an HLA-A*02:01-restricted, pp65-derived peptide 
(pp65495–503, NLVPMVATV) fused to a tetanus TH epitope (tt830–843, QYIKANSKFIGITE) and a TLR9 
agonist as adjuvant [378, 379]. Safety and immunogenicity were demonstrated in phase Ib trials 
[379, 380]. In another study, Schmitt et al. administered the NLVPMVATV peptide together with the 
adjuvant Montanide ISA 51 to HCMV seropositive patients after allogeneic hematopoietic stem cell 
transplantation [381]. Of the treated patients, 80% showed a clearance of HCMV after four 
vaccinations. Increasing frequencies of HCMV-specific CD8+ and γδ T cells could be observed as well 
as rising titers of neutralizing antibodies. However, both peptide vaccines are limited in their 
applicability since they are restricted to HLA-A*02-positive individuals. 
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Many vaccine candidates of various approaches (vector-based, DNA, mRNA, peptide, attenuated or 
replication-defective strains) are in development but so far none in phase III trials (reviewed in 
[368]). Promising candidates should induce both antibody and T cell responses.
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1.5 Aims of the thesis 
Although both HCMV and EBV are usually well controlled in immunocompetent individuals, they 
can cause severe diseases in immunocompromised hosts such as AIDS patients or transplant 
recipients. EBV can also be responsible for a variety of diseases and malignancies in 
immunocompetent individuals. Due to the limited effectiveness and often serious side effects of 
current treatment options, the search for new therapies is still ongoing. Both viruses are mainly 
controlled by CD4+ and CD8+ T cells and knowledge about the T cell targets is essential for the 
development of a vaccine or immunotherapies such as adoptive T cell transfer. 
The landscape of EBV-derived epitopes is actually well studied and characterized. While dominant 
epitopes for many common HLA allotypes are described, there is, however, a significant gap for 
HLA-A*01. Therefore, the aim of the first part of the work is to close this gap by characterizing the 
HLA-A*01-restricted T cell response to EBV and identifying novel EBV-derived epitopes. The basis of 
this part is the in silico prediction of potential, HLA-A*01-restricted T cell epitopes from the entire 
EBV proteome. Screening of memory responses in healthy blood donors via IFNγ ELISpot assays 
should then allow the identification of T cell epitopes. Functionality of peptide-specific T cells and 
their HLA restriction will be evaluated subsequently. 
The second part of this thesis aims at the identification of HCMV-derived T cell epitopes. The 
considerable size of the HCMV proteome has made a comprehensive characterization of HCMV-
derived T cell targets very difficult. Therefore, the majority of previous studies focused on few 
immunodominant antigens. However, a new approach, established by Stefanie Spalt and Anne 
Halenius, allows the identification of HCMV-derived HLA ligands on infected fibroblasts via mass 
spectrometry. This is an unbiased basis for the identification of naturally presented viral epitopes 
and should enable a comprehensive and systemic assessment of the repertoire of anti-HCMV T cell 
specificities in infected, seropositive individuals. The infection of different cell lines allows for the 
isolation of ligands of a diverse set of HLA allotypes. HCMV-derived HLA ligands will be screened for 
their immunogenicity via IFNγ ELISpot assays with healthy seropositive blood donors. Functionality 
and specificity of activated T cells will then be assessed by intracellular cytokine staining and 
tetramer staining. 
The viral T cell epitopes identified in this work will contribute to our understanding of the anti-EBV 
and anti-HCMV T cell response and can be used in the development and improvement of 
therapeutic approaches. 
Material and Methods 31 
2 Material and Methods 
2.1 Material 
2.1.1 Chemicals, reagents and complete solutions 
“Complete Protease Inhibitor” tablet   Roche 
HEPES       Gibco (Life technologies)  
Acetonitrile (MS-Grade)    Thermo Scientific 
Alkaline phosphatase, avidin-conjugated  Sigma-Aldrich 
Ampicillin sulfate     Roth 
ATP       Sigma-Aldrich 
Bacto Trypton      Difco 
Bacto Yeast Extract     Difco 
BCIP/NBT tablet     Sigma-Aldrich 
Bovine serum albumin, BSA    Sigma-Aldrich 
Bradford reagent, Roti Nanoquant   Roth 
Chloramphenicol     Sigma-Aldrich 
Cytofix/Cytoperm     Becton Dickinson 
D-Biotin      Sigma-Aldrich 
Dimethyl sulfoxide (DMSO)    WAK-Chemie 
DMEM (Dulbecco’s Modified Eagle Medium)  Gibco (Life technologies) 
DNAse       Roche 
DTT (Dithiothreitol)     Sigma-Aldrich 
Ethanol       SAV LP 
Ethylenediaminetetraacetic acid, EDTA   Roth 
Fetal calf serum (FCS)     Capricorn Scientific 
Ficoll (Biocoll)      Millipore 
Formaldehyde      Fluka 
Formic acid      Merck 
Gentamycin      Gibco 
Glycerol      Roth 
Glycine       Roth 
GolgiStop      Becton Dickinson 
Guanidinium chloride     Roth 
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HSA (human serum albumin)    Biotest 
Hydrochloric acid (HCl)     Roth 
IL-2, human recombinant    R&D Systems 
IMDM (Icove’s Modified Dulbecco’s Medium)  Lonza 
Ionomycin      Sigma Aldrich 
Isopropyl-beta-D-thiogalactopyranoside (IPTG)  Thermo Fischer Scientific 
L-arginine      Sigma-Aldrich 
Leupeptin      Roche 
LIVE/DEAD Fixable Dead Cell Stain   Invitrogen (Life technologies) 
Lysozyme      Roche 
Methanol      Merck 
Monosodium phosphate, NaH2PO4   Merck 
Oxidized glutathione     Sigma-Aldrich 
PBS (Phosphate buffered saline)   Gibco (Life technologies) 
Penicillin (103 x U/ml)/Streptomycin (10 g/ml)  Sigma-Aldrich 
Pepstatin      Roche 
PHA (Phytohaemagglutinin)    Sigma-Aldrich 
PHA-L       Roche 
PMA (Phorbol myristate acetate)   Sigma-Aldrich 
PMSF (Phenylmethylsulfonylfluoride)   Roche 
Reduced glutathione     Sigma-Aldrich 
Saponin      Sigma-Aldrich 
Sodium acetate, CH3COONa    Roth 
Sodium azide, NaN3     Merck 
Sodium bicarbonate, NaHCO3    Sigma-Aldrich 
Sodium chloride, NaCl     VWR Chemicals 
ß-Mercaptoethanol, ß-Me    Roth 
Streptavidin-PE      Invitrogen (Life technologies) 
Tris (Tris(hydroxymethyl)aminomethane)  Sigma-Aldrich 
Tris-Base      AppliChem 
Triton X-100      Sigma-Aldrich 
Trypan blue      Gibco (Life technologies) 
Trypsin 2.5%      Gibco (Life technologies) 
Tween 20      Merck 
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Tween       Sigma-Aldrich 
Urea       Roth 
Water (MS-Grade)     Baker 
2.1.2 Media and buffers  
FACS buffer 0.01% NaN3, 2 mM EDTA, 2% FCS in PBS 
Freezing medium 10% DMSO in FCS 
Injection buffer 10 mM Sodium acetate, 3 M Guanidinium chloride in 
ddH2O; pH 4.2 
LB medium 0.5% NaCl, 0.5% Bacto Yeast, 1% Bacto Trypton in ddH2O 
LB-Amp/Cam-agar plate 1.5% agar, 100 μg/ml ampicillin sulfate, 50 μg/ml 
chloramphenicol in LB medium 
PBS-BSA 0.5% BSA in PBS 
PBS-EDTA 1 mM EDTA in PBS 
PBS-Tween 0.05% Tween in PBS 
Permwash buffer 0.01% NaN3, 0.1% saponin, 0.5% BSA in PBS 
Refolding buffer 6.97% L-arginine in ddH2O; pH 7.76 
Resuspension buffer 0.1% NaN3, 1 mM EDTA, 1 mM DTT, 100 mM NaCl, 
50 mM Tris in ddH2O 
TBS (Tris-buffered saline) 20 mM Tris, 150 mM NaCl in ddH2O; pH 8 
TCM 50 µM β-Me, 1% Pen/Strep, 5% human plasma in IMDM 
Tetramer freezing buffer 48% glycerol, 1.5% HSA, 0.06% NaN3, 1x protease 
inhibitor in 20 mM Tris 
Thawing medium 3 µg/ml DNAse, 50 µM β-Me, 1% Pen/Strep, 10% human 
plasma in IMDM 
Triton buffer 0.1% NaN3, 1 mM EDTA, 1 mM DTT, 0.5% Triton X 100, 
100 mM NaCl, 50 mM Tris in ddH2O 
Trypsin solution 0.5% Trypsin in PBS 
TSB 50% FCS in PBS 
Urea buffer 8 M Urea, 10 mM Tris (pH 8.0), 10 mM NaH2PO4, 0.1 mM 
EDTA, 0.1 mM DTT 
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2.1.3 Antibodies 
Anti-IFNγ primary antibody, clone 1-D-1k  MabTech 
Anti-IFNγ secondary antibody, biotinylated  MabTech 
clone 7-B6-1 
 
Table 3: Antibodies used for flow cytometry. Abbreviations: APC, allophycocyanin; PE, R-phycoerythrin; 
PerCP, peridinin chlorophyll protein. 
Antigen Fluorochrome Source Clone Dilution Manufacturer 
CD8 PerCP Mouse RPA-T8 1:100 BioLegend 
CD4 APC-Cy7 Mouse RPA-T4 1:100 BioLegend 
IFNγ PE Mouse B27 1:200 BioLegend 
TNFα Pacific Blue Mouse Mab11 1:120 BioLegend 
 
2.1.4 Healthy blood donors 
Blood samples of healthy donors were kindly provided by the Institute for Clinical and Experimental 
Transfusion Medicine in Tübingen after obtaining written informed consent. Healthy blood donors 
were typed for HLA-A and -B if necessary. The CMV status of most of the donors was known. 
2.1.5 Cell lines 
Table 4: Cell lines.  
Name Origin Source HLA 
Culture 
conditions 
HF-99/7 
Human foreskin 
fibroblasts 
kind gift from Anne 
Halenius 
A*01:01; A*03:01; 
B*08:01; B*51:01; 
C*01:02; C*07:01 
DMEM 
+ 10% FCS 
+ 1% PenStrep 
HF-99/5 
Human foreskin 
fibroblasts 
kind gift from Anne 
Halenius 
A*11:01; A*24:02; 
B*08:01; B*52:01; 
C*07:01; C*12:02 
DMEM 
+ 10% FCS 
+ 1% PenStrep 
HF-γ 
Human foreskin 
fibroblasts 
kind gift from Anne 
Halenius 
A*03:01; A*23:01; 
B*15:01; B*44:02; 
C*03:03; C*05:01 
DMEM 
+ 10% FCS 
+ 1% PenStrep 
MRC-5 
Human fetal 
lung fibro-blasts 
kind gift from Anne 
Halenius and 
Stefanie Spalt 
A*02:01; A*29:02; 
B*07:02; B*44:02; 
C*05:01; C*07:02 
DMEM 
+ 10% FCS 
+ 1% PenStrep 
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2.1.6 Viruses 
The AD169VarL-based bacterial artificial chromosome (BAC) mutants [239] were propagated on 
MRC-5 cells. The recombinant HCMV mutants ΔUS2-6, ΔUS2-6/ΔUS11 and ΔUS2-11 were generated 
according to a previously published procedure [382] using the BAC-cloned AD169varL genome 
pAD169 [239] as parental BAC. Briefly, a PCR fragment was generated using the primers KL-
DeltaUS11-Kana1 CAAAAAGTCTGGTGAGTCGTTTCCGAGCGACTCGAGATGCACTCCGCTTCAGTCTATAT-
ACCAGTGAATTCGAGCTCGGTAC and KL-DeltaUS11-Kana2 TAAGACAGCCTTACAGCTTTTGA-
GTCTAGACAGGGTAACAGCCTTCCCTTGTAAGACAGAGACCATGATTACGCCAAGCTCC and the plasmid 
pSLFRTKn [383] as template DNA. The PCR fragment containing a kanamycin resistance gene was 
inserted into the parental BAC by homologous recombination in E. coli. Correct mutagenesis was 
confirmed by Southern blot and PCR analysis. Recombinant HCMVs were reconstituted from HCMV 
BAC DNA by Superfect transfection into permissive MRC-5 cells. Virus titers were determined by 
standard plaque assay. 
 
Table 5: HCMV virus strain used for the infection of cell lines. 
Virus Short name Deletions 
AD169VarL ΔUS2-11 ΔUS2-11 
US2, US3, US4, US5, US6, 
US7, US8, US9, US10, US11 
 
2.1.7 FASTAs 
The proteome data used for prediction and as search database in the mass spectrometry analyses 
were obtained from the UniProt database and are listed in Table 6.  
Table 6: FASTAs used for MS analyses and epitope predictions. 
Organism Date of access No. of sequences 
EBV (strain B95-8) 07/03/2016 109 
HCMV (strain AD169, Merlin, Towne) 11/03/2014 400 
HCMV (AD169 and UL133, UL135, 
UL136, UL138-142, UL144-148, 
UL150, and UL147A from Merlin) 
29/09/2015 207 
Homo Sapiens 11/03/2014 20,271 
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2.2 Methods 
2.2.1 Peptide synthesis and storage 
All peptides were synthesized in-house by standard 9-fluorenylmethyloxycarbonyl/tert-butyl 
strategy using peptide synthesizers ABI 433A (Applied Biosystems), Activo-P11 (Activotec), or 
Liberty Blue (CEM). Purity was assessed by reversed phase HPLC (e2695, Waters) and identity 
affirmed by nano-UHPLC (UltiMate 3000 RSLCnano, Dionex) coupled online to a hybrid mass 
spectrometer (LTQ Orbitrap XL, Thermo Fischer Scientific). Lyophilized peptides were dissolved at 
10 mg/ml in DMSO and diluted 1:10 in bidestilled H2O. Peptide dilutions were stored at -80°C. 
Thawed aliquots were further diluted in cell culture medium and sterile filtered if necessary.  
2.2.2 Synthesis of recombinant HLA chains 
First, the DNA sequence of the respective HLA heavy chain was altered by deleting the 
transmembrane domain and adding a BirA biotinylation sequence at the C-terminus. The sequence 
of the respective chain was then cloned into the expression vector pET-3a (in some cases pET-3d). 
Approximately 1 ng of vector was added to 100 µl of competent BL21(DE3) E. coli cells that carry 
the plasmid pLysS. The mixture was incubated on ice for 20 min and was then transferred in a 42°C 
water bath for 90 s. After a fast cooling down on ice for 2 min, 1 ml LB medium without antibiotics 
was added and incubated for 30 min at 37°C. Finally, 100 µl of this mixture were spread onto an LB-
Amp/Cam agar plate (LB medium with 1.5% agar, 100 µl/ml ampicillin and 34 µg/ml 
chloramphenicol) and incubated overnight at 37°C. Cloning and seeding was performed by Beate 
Pömmerl. Colonies from the plates were picked and transferred into 5 ml of LB-Amp/Cam. Bacteria 
suspensions were incubated in a shaker (250 rpm) for about 6 h at 37°C, transferred into 300 ml LB-
Amp/Cam, and incubated overnight at 37°C and 180 rpm. 
The next day, ten baffled 2 l Erlenmeyer flasks were filled with 1l LB medium containing 100 mg 
ampicillin and 34 mg chloramphenicol and adjusted to at least room temperature. To each flask, 25 
ml of the overnight culture was added and incubated in a shaker at 37°C and 180 rpm. Optical 
density (OD)600 was measured regularly with the spectrometer Ultraspec 3000 (Pharmacia) until an 
OD600 between 0.5 and 0.6 was reached. To induce recombinant protein expression, 0.5 ml of a 1 M 
IPTG solution was added to each flask and incubated additional 4-5 h. The bacterial suspension was 
centrifuged in a SLA 3000 rotor at 5,000 rpm for 15 min. The pellets were resuspended in 180 ml 
PBS in total, distributed into six 50 ml tubes and stored in -80°C.  
All following steps were performed at 4°C or on ice, unless described otherwise. After thawing the 
samples in a water bath (RT), 300 µl of 1 M MgCl, 150 µl of 10 mg/ml DNAse, and 30 µl of fresh 
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100mg/ml lysozyme were added to each sample. The aliquots were then treated four times with 
ultrasound (Sonifier 250, Branson Ultrasonic) for 30 s each (output 5, duty cycle 50%). The lysates 
was centrifuged in a SS-34 rotor at 15,000 rpm for 15 min. The supernatant was discarded and the 
slimy, brown, upper layer of the pellet (cell wall and membrane debris) was carefully removed with 
a spatula. The more dense and whitish layer beneath was resuspended and homogenized in triton 
wash buffer. This washing step was repeated four to six times until only one white layer was still 
visible after centrifugation. The inclusion bodies were then washed twice with resuspension buffer 
and finally dissolved in 15-30 ml urea buffer - depending on the size of the pellet. The solution was 
incubated rotating overnight. The following day, insoluble components were separated by 
centrifugation for 15 min at 15,000 rpm. The approximate concentration and the purity were 
determined with a nanodrop spectrophotometer (Thermo Fisher Scientific). The purity was 
considered acceptable if the ratio of absorbance at 260 nm and 280 nm was around 0.6. The 
concentration was determined with a Bradford assay (see 2.2.4). Concentration of heavy chains was 
adjusted to 20 mg/ml in urea buffer and divided into 8 mg aliquots. The original concentration of 
the light chain (β2m) was maintained and aliquots of 7 mg were made. Both were stored in -80°C. 
 
2.2.3 Refolding of HLA-I-peptide complexes 
For the production of HLA-peptide complexes (monomers), the peptide of interest was refolded 
with β2m and the respective heavy chain. 385 mg of reduced glutathione, 77.5 mg of oxidized 
glutathione and 250 µl PMSF (200 mM stock in methanol) were added to 250 ml refolding buffer. 5-
7 mg of peptide was dissolved in DMSO to a final concentration of 10 mg/ml and pipetted into the 
mixture. Heavy chain and β2m were thawed at room temperature. The heavy chain was diluted 
with 700 µl injection buffer; β2m with 780 µl. Both were added with a syringe and a 26G needle 
while the injection buffer was stirred vigorously in order to avoid direct aggregation of the chains. 
The mixture was then incubated gently shaking for approximately 12 h at 10°C. The next day, heavy 
chain was added in the morning and in the evening (ideally 12 h interval) as described above. On 
the third day, the mixture was filtered through a 0.22 µm vacuum filter to remove aggregates of 
misfolded molecules. To separate correctly folded monomers from single chains and free peptide, 
the mixture was then filtered and concentrated in a stirred Amicon pressure cell (30-kDa NMWL 
filter, 4 bar, Millipore) to a volume of about 25 ml. The retentate was stored at 4°C and the 
permeate was used to start a second refolding reaction. Therefore, all steps described above were 
repeated. Since glutathione and peptide were supplied in excess before, they were not added 
again. Afterwards, the retentates of both reactions were pooled, centrifuged for 10 min at 4,000 
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rpm and 4°C to remove aggregates, and concentrated with a 10-kDa NMWL filtration tube to a final 
volume of 5 ml. A size exclusion chromatography was performed with an ÄKTA prime (Amersham 
Biosciences) using a Superdex 75 column with TBS as running buffer and a flow rate of 3 ml/min. 
The UV absorption at 280 nm was determined and 4 ml fractions collected. The fractions containing 
the monomer were collected and pooled in a 50 ml tube. Protease inhibitors PMSF (f.c. 0.2 mM), 
leupeptin (f.c. 1 µg/ml), and pepstatin (f.c. 0.7 µg/ml) were added immediately to avoid protein 
degradation. The solution was concentrated again to 5 ml using a 10-kDa NMWL filtration tube at 
4,000 rpm. To enable binding and tetramerization via streptavidin, the monomers were 
enzymatically biotinylated with BirA. Therefore, 400 μl 1 M Tris (pH 8), 25 μl 1 M MgCl2, and 250 μl 
100 mM ATP were added and the solution was carefully mixed. Afterwards, 10-20 μg BirA enzyme 
and 28.5 μl 100 mM biotin were added, mixed and incubated for 12-16 h at 27°C. A second size 
exclusion chromatography was performed as described above to separate biotinylated monomers 
from, unbound biotin, enzyme, and aggregates. Fractions containing the monomer were collected 
and PMSF, leupeptin, and peptstatin were added as depicted before. The monomer solution was 
concentrated again with a 10-kDa NMWL filtration tube to 250-400 µl. The concentration was 
determined with a Bradford assay (see 2.2.4) and adjusted to 2 mg/ml with TBS. Aliquots of 50 µg 
were stored at -80°C. The presence of the correct peptide was tested by Claudia Falkenburger or 
Michael Ghosh with ESI-QTOF mass spectrometry. 
 
2.2.4 Bradford assay 
The protein concentration of heavy chains, light chain, and refolded monomers was determined by 
Bradford assay [384]. The Roti® Nanoquant (Roth) used is a Coomassie Brilliant Blue G-250 dye and 
has its absorption maximum in its unbound cationic form at 450 nm. Upon protein binding, the 
anionic form of the dye is stabilized and the absorption maximum shifts to 590 nm. The protein 
concentration is determined by measuring the OD at 450 nm and 590 nm and comparing the 
quotient OD590/450 with a standard curve of a protein with known concentration. BSA was used as 
reference. For the measurement of monomer concentration it was diluted to 0, 10, 20, 40, 60, 80, 
and 100 μg/ml in TBS while it was diluted to 0, 10, 25, 50, 75, and 100 μg/ml in 8 M Urea for HLA 
heavy chains. 50 µl sample or reference protein was mixed with 200 µl Roti® Nanoquant and 
incubated for approximately three minutes before ODs were measured with the ELISA reader 
Spectramax 340 and the software Softmax Pro 2.1 (Molecular Devices). Samples were measured in 
triplicates while standard protein was measured in duplicates. 
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2.2.5 UV-induced peptide exchange of monomers 
Monomers loaded with UV-sensitive peptide allow for the UV-induced degradation of the loaded 
peptide and the fast substitution with the peptide of interest. UV-sensitive peptides contain the 
UV-labile amino acid J (3-Amino-3-(2-nitrophenyl)propanoic acid) and can be cleaved with UV 
irradiation (366 nm). Monomers with UV-sensitive peptides were produced as described above (see 
2.2.3) with the small difference that they need to be protected from light at every step of the 
procedure. After thawing the UV-sensitive monomer of the desired HLA, it was diluted 1:10 with 
2 mM PBS-EDTA (PBS-E). The peptide of interest was dissolved to 10 mg/ml in DMSO and diluted 
1:25 to a final concentration of around 400 µM in 2 mM PBS-E. 65 µl of the peptide and 65 µl of 
monomer were added to one well of a 96 well polypropylene microplate with V-bottom and mixed 
well. The plate without a lid was exposed to 366 nm UV light for 1 h with 2-5 cm distance to the UV 
lamp. Afterwards, the plate was centrifuged for 5 min at 4000 rpm at room temperature. 100 µl of 
supernatant were transferred to a 1.5 ml tube and stored at 4°C for maximum one week and 
otherwise at -80°C. The exchange efficiency depends on the binding affinity of the exchanged 
peptides. For further use, an exchange rate of 50% and a concentration of 50 µg/ml monomer were 
assumed. 
2.2.6 Tetramerization of HLA-peptide complexes 
The protein streptavidin is produced by the bacterium Streptomyces avidinii and possesses four 
binding sites for biotin. Therefore, it can mediate the tetramerization of biotinylated monomers. 
The streptavidin is coupled to a fluorescent dye allowing the later detection of bound tetramers via 
flow cytometry. R-phycoerythrin (Pe)-coupled streptavidin was added to monomers in a 
stoichiometric ratio of 1:4. Ten percent of 78.5 µl streptavidin-PE were added in ten steps to 50 µg 
of monomer. The solution was incubated in between for at least 20 min on a spinning wheel at 4°C 
in the dark. For long-term storage, tetramers were diluted 3:1 with tetramer freezing buffer and 
stored at -80°C. Tetramers of UV-exchanged monomers were diluted 1:6 with tetramer freezing 
buffer for UV-exchanged monomers. 
2.2.7 Freezing and thawing of cells 
Frozen cells were stored at -80°C. Cells were therefore harvested by centrifugation, resuspended in 
cold freezing medium (4°C) and 1-2 ml was distributed in cryotubes. Cryotubes were immediately 
transferred to a freezing container (4°C), which was then stored in -80°C. Isopropanol in the 
freezing container allowed a slow cooling down of 1°C/min.  
For thawing, frozen cells were warmed up until almost thawed and then transferred into 10 ml of 
cold thawing medium. After centrifugation (7 min, 1,400 rpm), the cells were resuspended in 10 ml 
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warm thawing medium and centrifuged again. The cell pellet was resuspended in the appropriate 
culture medium. 
2.2.8 Cell counting 
Prior to cell counting, cells were pre-diluted in PBS to a reasonable concentration and then mixed 
with 0.05% trypan blue (in PBS). Approximately 10 µl of the cell suspension was pipetted under the 
cover glass of a Neubauer counting chamber. Trypan blue accumulates in dead cells and allows the 
differentiation of dead and living cells. Viable cells were counted in two to four big squares and the 
cell number calculated as shown below.  
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(DF, dilution factor; 104, chamber factor) 
2.2.9 Cell culture of cell lines and PBMCs 
All cells used were cultured in humidified incubators at 37°C and 7.5% CO2. Human foreskin 
fibroblasts were cultured in DMEM supplemented with 10% FCS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin in cell culture flasks up to a confluence of 90%. Cell splitting was done two to three 
times a week in a ratio of 1:2 to 1:5 depending on the proliferation of the cells. For harvesting, 
culture medium was removed, the cells washed with PBS to remove residual medium and then 
detached with 0.5% Trypsin in PBS for 2 min at 37°C. The reaction was stopped with medium 
containing FCS that inhibits trypsin. The cells were either used directly or were split into fresh cell 
culture flasks for further expansion. Prior to mass spectrometric analysis, the cells were collected 
by scraping, washed three times with PBS and frozen as cell pellet in -80°C. 
PBMCs were cultured in IMDM supplemented with 5% heat-inactivated pooled human plasma, 
isolated from healthy blood donors (see 2.2.10), 100 U/ml penicillin, 100 µg/ml streptomycin, 
25 µg/ml gentamicin (Life technologies), and 50 µM ß-mercaptoethanol. 
2.2.10 Isolation of PBMCs from buffy coats 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats, whole blood or 
leukapheresis products by Ficoll-Hypaque density gradient centrifugation. Buffy coats are 
leukocyte-enriched blood products of heparinized whole blood where most of the plasma and 
erythrocytes were removed. When PBMCs were isolated from whole blood, plasma was first 
separated by centrifugation. The blood was centrifuged in 50 ml tubes for 20 min (2,000 rpm, RT, 
without brake), allowing the plasma to separate from the buffy coat and the erythrocytes. The 
plasma, as top layer, was removed first and heat-inactivated for 30 min at 56°C followed by two 
Material and Methods 41 
centrifugation steps (15 min, 2,500 rpm, RT) where the supernatant was always transferred in fresh 
50 ml tubes. It was then either used directly for the preparation of donor-specific T cell medium or 
frozen in -20°C for later use. The buffy coat was extracted and diluted 1:2 with PBS. In contrast to 
this, buffy coats and leukapheresis products received from the blood bank were diluted 1:4 and 
1:10, respectively. 30 ml of the cell suspension were then carefully layered on top of 15 ml Ficoll in 
50 ml tubes and centrifuged (20 min, 2,000 rpm, RT, without brake). After removing the PBS-diluted 
plasma, the lymphocyte layers were collected and pooled into fresh 50 ml tubes. The cells were 
then washed three times with 50 ml PBS at declining centrifugation speed (1,500 rpm, 1,300 rpm, 
1,100 rpm, each 10 min, RT). The cell number was determined as described in 2.2.8. The PBMCs 
were then either frozen as described in 2.2.7 or resuspended in the respective culture medium. 
2.2.11 Expansion of memory T cells (12-day pre-stimulation) 
Specific memory T cells appear in very low frequencies in the blood of healthy individuals without 
an acute infection. Those frequencies are usually below the detection limits (about 0.1% of specific 
T cells in the T cell population) of the T cell assays used in this work and epitope-specific T cells 
need to proliferate to allow for detection. The cells were therefore stimulated with the peptides of 
interest and IL-2 for a period of 12 days. 
Frozen PBMCs of healthy blood donors were thawed on day 1 as described in 2.2.7. 2-3 x 107 cells 
were resuspended in 2 ml TCM and plated in wells of a 6-well plate. On the second day, cells were 
stimulated with peptides in a final concentration of 1 µg/ml. Peptides were added in 500 µl TCM 
per well. On day 3, 6, and 8, IL-2 was added in 0.5-1 ml TCM in a final concentration of 20 U/ml. 
Cells were provided with fresh TCM on day 10 if necessary and incubated for two more days prior 
to T cell assays. 
2.2.12 Enzyme-linked immunospot assay (ELISpot) 
Enzyme-linked immunospot (ELISpot) assays enable the detection of cytokine-secreting cells at the 
single-cell level. In this work, IFNγ ELISpots were performed to identify activated antigen-specific 
memory T cells among the PBMCs of blood donors. Therefore, 96-well ELISpot plates containing 
nitrocellulose membranes (MSHAN4B, Millipore) were coated with the first antibody directed 
against IFNγ. IFNγ, produced by activated T cells after peptide stimulation, binds to the first 
antibody and is recognized by a biotinylated secondary antibody. The streptavidin-coupled enzyme 
alkaline phosphatase can then bind to the biotin of the secondary antibody and catalyzes a reaction 
with the substrates BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro-blue tetrazolium 
chloride) yielding an insoluble black/purple dye. Each spot represents one activated IFNγ-secreting 
cell. 
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For coating the nitrocellulose membrane, the first antibody 1D1-K was diluted 1:500 in PBS. 100 µl 
of this solution was added to each well and incubated 12-72 h at 4°C. The wells were washed twice 
with 200 µl IMDM to remove unbound antibody. For all washing steps, the appropriate buffer was 
added to each well and removed by emptying the plate into a sink and tapping it dry on tissue 
towels. After washing with IMDM, 50 µl TCM containing human serum was added to each well and 
incubated for at least 1 h at 37°C to block free binding sites on the membrane. In the meantime, 
cells were harvested, counted and resuspended in TCM with a density of 107 cells per ml. Peptides 
of interest and negative control peptide (1 mg/ml stock) were diluted with TCM to a concentration 
of 3 µg/ml (final conc. in wells 1 µg/ml). One well without any stimulus (cells with medium) and two 
wells containing either DMSO or an HLA-matched non-immunogenic peptide (human or HIV) served 
as negative controls in each donor. Phytohaemagglutinin (PHA, final conc. 5 µg/ml) was used as 
unspecific positive control since it activates T cells by crosslinking their T cell receptors on the cell 
surface. 50 µl of peptide solution and 50 µl of cell suspension were added to the 50 µl TCM already 
contained in each well. Finally, the ELISpot plate was incubated for 22-26 h at 37°C. Any vibration 
had to be absolutely avoided during this incubation, since moving cells lead to “snail trails” instead 
of well-defined spots. The next day, plates were washed twice with PBS-Tween, twice with ddH2O 
and three times with PBS-Tween. Afterwards, 100 µl of secondary antibody, diluted 1:3,000 in 
PBS-BSA, were added to each well and incubated for 2 h at RT. The plates were then washed six 
times with PBS-Tween and 100 µl of alkaline phosphatase (1:1,000 in PBS-BSA) were added. After 
45-60 min incubation at RT, the plates were washed three times with PBS-Tween and three times 
with ddH2O before the substrate was added. One tablet of BCIP/NBT was dissolved in 10 ml ddH2O 
and filtered through a 0.2 micron filter. 50 µl of the substrate was added to each well and 
incubated for 7-10 min. The reaction was stopped by washing the plates several times with 
deionized water. After drying the plates overnight, the spots were automatically counted using an 
ImmunoSpot S5 analyzer and ImmunoSpot 5.1.29 software (Cellular Technologies Ltd). T cell 
responses were considered to be positive when the mean spot count per well was > 10 spots and at 
least 3-fold higher than the mean number of spots in negative control wells. Background staining 
due to excess cytokine and overlapping spots hamper the detection of reliable counts in wells of 
highly responsive donors. Therefore, spot counts of > 1,000 or “too numerous to count” were set to 
1,000. 
2.2.13 Tetramer staining of specific T cells 
Tetramer staining was performed to identify and quantify peptide-specific T cell populations with 
flow cytometry. Due to the low binding affinity and high dissociation rate of HLA-peptide 
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monomers, they are not able to establish a stable binding to T cell receptors [385]. The 
tetramerization of monomers by streptavidin allows the binding of multiple receptors by one 
tetramer and leads to a higher avidity and more stable binding. The whole protocol was carried out 
at 4°C or on ice if not mentioned otherwise. Washing steps were performed by vigorously adding 
150 µl of appropriate washing buffer and centrifuging the plate for 2 min at 1800 rpm. Supernatant 
was removed by flicking the plate upside down over a sink. 
For the tetramer staining, cells were harvested either 1-2 days after thawing or after a 12-day 
pre-stimulation. Cells were counted and 0.5-1 x 106 cells per well in medium or PBS were plated 
into a 96-well plate. After washing twice with PBS-E, cells were resuspended in 50 µl Aqua live/dead 
diluted in PBS-E to stain dead cells. Depending on the storage period of Aqua live/dead, it was 
diluted either 1:200 (if storage period was longer than 2 weeks) or 1:400. After 20 min incubation in 
the dark, the cells were washed once with PBS-E and tetramer staining performed. Therefore, 
tetramers were diluted in TBS to a concentration of 5 µg/ml. To prevent the appearance of 
tetramer aggregates, the dilution was prepared in excess and centrifuged for at least 10 min at 
maximum speed. 50 µl of tetramer solution were added to each well and incubated 30 min at RT in 
the dark. After a washing step with FACS buffer, the surface molecules CD4 and CD8 were stained. 
Therefore, CD8-PerCP and CD4-APC-Cy7 were diluted 1:100 in FACS buffer and 50 µl were added to 
each well. After 20 min incubation in the dark, the cells were washed twice with FACS buffer. 
Finally, the cells were resuspended in 200 µl FACS buffer per well. If the measurement was not 
carried out the same day, the cells were fixed with 100 µl of 1% formaldehyde in FACS buffer for 10 
min. After two washing steps with FACS buffer, the cells were resuspended in 200 µl FACS buffer 
and stored at 4°C in the dark until the measurement with the flow cytometer FACS Canto II and the 
software BD FACSDiva (Becton Dickinson). 
2.2.14 Intracellular cytokine staining (ICS) 
Upon peptide stimulation, activated T cells react with the secretion of several cytokines. It is 
possible to block this secretion by inhibiting the intracellular protein transport with brefeldin A and 
monensin (GolgiStop). This leads to the accumulation of cytokines in the Golgi complex. These 
cytokines can be bound by intracellular fluorescent antibodies enabling the identification of the T 
cell subset that is activated by a specific stimulus. 
For the ICS, cells were harvested either 1-2 days after thawing or after a 12-day pre-stimulation. 
Cells were counted and 1-2 x 107 cells per ml resuspended in 1 medium. 50 µl cell suspension per 
well were plated into a 96-well plate. Three wells per donor were prepared in order to test a 
peptide of interest and to have a positive and a negative control. Human or HIV peptides of the 
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same HLA restriction as the peptide of interest were used as negative control and ionomycin and 
PMA (Phorbol 12-myristate 13-acetate) as positive control. Ionomycin is a calcium ionophore 
derived from Streptomyces conglobatus and is able to rapidly raise the intracellular calcium level 
[386] while PMA is an activator of the protein kinase C [387]. Together they serve as unspecific 
activators of T cells and stimulate the cytokine production. To the 50 µl of cell suspension, 50 µl of 
either peptide of interest, negative peptide (both 10 µg/ml final concentration) or ionomycin (f.c. 
1 µM) and PMA (f.c. 50 ng/ml) were added to each well. Afterwards, 50 µl of brefeldin A (f.c 
10 µg/ml) and GolgiStop (1 µl/well) were added to each well and plates were incubated at 37°C for 
6-14 h. After the incubation, the staining was performed. All following steps were carried out at 4°C 
or on ice if not mentioned otherwise. Washing steps were performed by vigorously adding 150 µl of 
appropriate washing buffer and centrifuging the plate for 2 min at 1,800 rpm. Supernatant was 
removed by flicking the plate upside down over a sink. 
Cells were washed twice with PBS-E and were resuspended in 50 µl Aqua live/dead diluted in PBS-E 
to stain dead cells. Depending on the storage period of Aqua live/dead, it was diluted either 1:200 
(if storage period was longer than 2 weeks) or 1:400. After 20 min incubation in the dark, the cells 
were washed once with PBS-E. Surface molecules CD4 and CD8 were stained by adding 50 µl of 
CD8-PerCP and CD4-APC-Cy7, both diluted 1:100 in FACS buffer, to each well. After 20 min 
incubation in the dark, the cells were washed once with FACS buffer and 100 µl of 
Cytoperm/Cytofix were added. After permeabilization of the cells in the dark for 20 min, they were 
washed once with 100 ml of permwash buffer. Antibodies IFNγ-PE and TNF-PacificBlue for 
intracellular cytokines were diluted 1:200 and 1:120, respectively, in permwash buffer and 50 µl 
were added to each well. After 20 min incubation in the dark, cells were washed twice with 
permwash buffer and resuspended in FACS buffer for analysis by flow cytometry. All measurements 
were performed with the flow cytometer FACS Canto II and the software BD FACSDiva (Becton 
Dickinson). Data were subsequently analyzed with the software FlowJo v10 (Tree Star Inc). 
2.2.15 Infection of human foreskin fibroblasts 
Infection of human foreskin fibroblast cells HF-99/7, HF-99/5, and HF-γ prior to mass spectrometry 
analyses was performed by Liane Bauersfeld from the group of Anne Halenius (Institute of Virology, 
Freiburg).  
Approximately 2-3 x 108 HF-99/7 cells were infected with an MOI of 5. In contrast, HF-99/5 and HF-γ 
cells were infected with an MOI of 1. At 48 h.p.i. (HF-99/7) or 4 d.p.i. (HF-99/5 and HF-γ), the cells 
were collected by scraping and washed three times with PBS. Cell pellets were stored at -80° C. 
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2.2.16 Flow cytometry analysis of infected cells 
Cells were detached with accutase (Sigma) and stained with antibodies diluted in 3% FCS/PBS. Cells 
were washed in 3% FCS/PBS supplemented with DAPI and fixed in 3% paraformaldehyde. For 
intracellular staining of viral Fc-receptors, cells were fixed and permeabilized using the BD 
Cytofix/Cytoperm™ Kit and stained with Fc-FITC (Rockland Immunochemicals Inc). Cells were 
measured with a BD FACSCanto™ II system (BD Biosciences) and acquired data was analyzed by 
FlowJo (v10.1, Tree Star Inc.). 
2.2.17 Preparation of cells for HLA immunoprecipitation 
The preparation of cells was performed at 4°C or on ice. The cell pellet was thawed by adding one 
volume of 2x solubilisation buffer and vortexing it until it was completely resuspended. The cell 
suspension was transferred to a beaker. The original vial was washed twice with 1x solubilisation 
buffer and the suspension was transferred to the beaker. It was stirred at 4°C for 1 h and 
homogenized afterwards by sonication with an output level of 5 for 20 s. Sonication was repeated 
three times with 20 s breaks in between. The lysate was then incubated on a shaker for 1 h and 
centrifuged subsequently at maximum speed for 45 min to remove cell debris.  
2.2.18 HLA immunoprecipitation 
HLA-I ligands were isolated as described before [388, 389] using standard immunoaffinity 
purification employing the pan-HLA-I-specific monoclonal antibody W6/32. Therefore, the in-house 
produced antibody W6/32 was coupled to cyanogen bromide-activated (CNBr) sepharose beads in 
a ratio of 1:40 (w/w). The appropriate amount of sepharose was covered with approximately 45 ml 
1 mM HCl and rotated for 30 min at RT to activate the reactive group. The sepharose beads were 
then centrifuged 4 min at 300 rpm without brake and the supernatant was discarded. After 
resuspending the beads in about 20 ml coupling buffer, the antibody was added and the mixture 
filled up to 45 ml with coupling buffer. For coupling the antibody to the beads, the mixture was 
rotated for 2 h at RT. Afterwards, the sepharose-antibody mixture was centrifuged as described 
above and the supernatant was discarded. The beads were resuspended in 45 ml 0.2 M glycine and 
rotated for 1 h to block free binding sites. After centrifugation as described above, the beads were 
washed twice with PBS and then filled up with PBS to an antibody concentration of 1mg/ml (40 mg 
sepharose per ml). Coupled antibody was stored at 4°C. 
Econo columns were rinsed with 70% EtOH and PBS and assembled at 4°C. 2 ml of coupled antibody 
were added to each column. With PBS, the pump rate of the peristaltic pumps was set to 10 rpm 
and the flow rate of pumps was fine-tuned and adjusted to each other. Columns were set up that 
HLA I molecules were isolated first followed by HLA II. After washing the system, PBS was 
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exchanged by solubilisation buffer. The cell lysate (see 2.2.17) was then linearly aspirated until it 
reached the outlet and was run over columns cyclically overnight at 10 rpm. After the affinity 
chromatography, the system was washed linearly with PBS for 30 min and H2O for 1 h at 10 rpm. 
Elution was carried out by incubating the columns four times for 15 min with 100-300 µl 0.2% TFA 
on a shaker. 10 µl of 10% TFA was added only at the first elution step to quickly decrease the pH. 
After each incubation, eluates were pushed into LoBind Eppendorf tubes with a syringe. 
During the elution, 3 kDa and 10 kDa Amicon filter units (Millipore) were prepared and washed. 
HLA-I and HLA-II ligands were separated from remaining HLA chains, antibody fragments and 
unspecifically bound proteins by 3 kDa and 10 kDa filters, respectively. Each washing step was 
performed by adding 500 µl of the respective solution and centrifugation for 15 min at 13,000 rpm. 
Flow through and retentate were discarded by tapping on tissue towels. One washing step with 
Baker H2O was followed by 0.1 N NaOH, Baker H2O and two times 0.2% TFA.  
Eluate of the affinity chromatography was centrifuged for 5 min at 13,000 rpm to sediment 
aggregates. The supernatant was transferred to the prepared Amicon filter units and also 
centrifuged at 13,000 rpm until the eluate was completely run through the filter. Flow through was 
transferred to LoBind Eppendorf tubes and the filter unit was washed once with 450 µl ABE to elute 
remaining peptides. The peptide solution was then concentrated to a volume of 30-50 µl by 
lyophilisation.  
To desalt and purify the peptide solution, ZipTipC18® Pipette Tips were employed. 10 µl of different 
solutions were therefore aspirated and dispensed repeatedly without introducing air into the tip. 
First, ABE was aspirated and dispensed ten times to wash the pipette tip, followed by equilibrating 
with A* ten times. The sample, which was centrifuged before for 5 min at 13,000 rpm and 4°C, was 
loaded by slowly pipetting ten times in the peptide solution. To desalt the sample, A* was slowly 
aspirated and dispensed three times. Afterwards, peptides were eluted by quickly pipetting ten 
times in 35 µl ABE. The steps from equilibration to elution were repeated five times in total. The 
ABE-peptide solution was reduced to 1-5 µl in a vacuum concentrator, filled up with 25 µl ALoad, and 
stored in -80°C until mass spectrometric analyses were performed. 
2.2.19 Analysis of HLA ligands by LC-MS/MS 
HLA ligand extracts (see 2.2.18) were separated by reversed-phase liquid chromatography 
(nanoUHPLC, UltiMate 3000RSLCnano, Dionex) using a 75 µm x 25 cm PepMap C18 column 
(Thermo Fisher Scientific). Linear gradients were applied ranging from 2.4% to 32% AcN over the 
course of 90 min. Cell extracts were analyzed in an online coupled LTQ Orbitrap Fusion Lumos mass 
Material and Methods 47 
spectrometer (Thermo Fisher Scientific) using a top speed CID method leading to Orbitrap MS/MS 
spectra. 
2.2.20 Database search and filtering 
The SEQUEST HT search engine [390] were used to search the human and HCMV proteome. 
Fragment spectra were searched against a concatenated FASTA consisting of the reviewed Swiss-
Prot human (March 2014; 20,271) and HCMV proteomes (March 2014; 400 sequences). The search 
combined data of technical replicates and was not restricted by enzymatic specificity. Precursor 
mass tolerance was set to 5 ppm and fragment mass tolerance to 0.02 Da. Oxidized methionine was 
allowed as the only dynamic modification. FDR was estimated using the Percolator algorithm [391]. 
Identifications were filtered to an FDR of 5% assessed on peptide spectrum match (PSM) level, 
search engine rank = 1 and peptide lengths of 8–12 amino acids. Peptide identifications were 
annotated to their respective HLA motifs using both SYFPEITHI [24] with a normalized score of 
≥ 50% and NetMHCpan (version 3.0) [392] with a percentile rank < 2% as cutoffs. Peptides fulfilling 
the cutoff in either or both prediction tools were designated predicted HLA ligands. In case of 
multiple possible annotations, the HLA allotype yielding the best rank/score was selected, if 
matching with the HLA typing of the respective cell line. Peptides were tested in donor samples of 
different HLA restrictions if the two algorithms resulted in inconsistent allotype annotations. 
2.2.21 Whole proteome prediction 
Whole proteome predictions were performed by Leon Bichmann. SYFPEITHI and NetMHCpan3.0 
were employed for the in silico epitope prediction [393] of the whole HCMV proteome using a 
concatenated FASTA consisting of the reviewed Swiss-Prot HCMV AD169 proteome (March 2014; 
193 sequences) and the reviewed sequences of UL133, UL135, UL136, UL138-UL142, UL144-UL148, 
UL150,and UL147A of strain Merlin [239]. The additional proteins are part of the ULb’ region that is 
included in the used BAC construct. 
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3 Results 
3.1 Novel EBV-derived, HLA-A*01-restricted T cell epitopes 
3.1.1 Prediction of HLA-A*01-restricted epitope candidates 
The first step for the identification of HLA-A*01 restricted T cell epitopes from EBV antigens was the 
prediction of candidate epitopes. Therefore, the complete proteome of the prototype strain B95-8 
was cut in 9mers, 10mers, 11mers, 12mers, and 13mers and prediction was performed with 
SYFPEITHI and NetMHC 3.4. Peptides with a SYFPEITHI score of ≥ 60 were selected (Supplemental 
Table 1 to Supplemental Table 5). From this list of 598 peptides, the highest scoring peptides were 
tested for their immunogenicity. The peptides were ranked according to their SYFPEITHI score and 
all peptides above a defined threshold (Table 7) were synthesized and tested. For 12mers and 
13mers, the additional criteria of a NetMHC score of < 50 nM had to be fulfilled. Selection criteria 
are listed in Table 7. 
Table 7: Selection criteria for immunogenicity testing. 
Length Tested peptides 
9mers SYFPEITHI score ≥ 67.5 
10mers SYFPEITHI score ≥ 69.23 
11mers SYFPEITHI score ≥ 69.23 
12mers SYFPEITHI score ≥ 73.17 AND NetMHC 3.4 < 50 nM 
13mers SYFPEITHI score ≥ 73.17 AND NetMHC 3.4 < 50 nM 
 
Additional peptides with lower scores were tested if they were already synthesized for other 
projects and were ready to use. 
 
3.1.2 Identification of T cell epitopes via IFNγ ELISpot screening 
The immunogenicity of all selected peptides was evaluated with IFNγ ELISpot assays. In order to 
increase the number of peptide-specific memory T cells above the detection limit, PBMCs of 
healthy donors were pre-stimulated with peptide and three times with IL-2 over twelve days. In 
total, 171 peptides were tested (Table 9). The peptide ETDQMDTIYQCY from the protein gB could 
not be produced and was abandoned after three attempts. On the basis of our experience with 
epitope prediction studies, we expected the majority of the peptides to be non-immunogenic. 
Hence, 134 peptides were tested in pools first to reduce the amount of necessary ELISpot assays. 
For this purpose, 15 peptide pools, containing nine peptides each, were generated and each pool 
was tested with six different HLA-A*01-positive donors. If the pool was able to elicit an IFNγ 
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response in two or more donors, the peptides of this pool were individually tested in subsequent 
ELISpot assays. Peptides of all other pools were not further evaluated. Figure 6 shows the number 
of IFNγ spot forming cells (SFC) of each donor stimulated with different peptide pools. Positive 
results are depicted by black rhombs, negative results by grey rhombs. Spot counts exceeding the 
threshold of 1,000 were reduced to 1,000, as all counts above this value are not reliable. Table 8 
lists the numbers of positive donors of each peptide pool. 
 
 
Figure 6: ELISpot results of peptide pools containing EBV-derived, HLA-A*01-restricted peptides. Depicted are numbers 
of IFNγ SFC for each tested PBMC culture minus the spot numbers of the negative control of the PBMCs. Positive 
evaluated PBMC cultures are depicted in black, negative tested PBMC cultures in grey. Peptide pools were tested once in 
technical duplicates in six different HLA-matched PBMC cultures. Bars represent the mean IFNγ SFC. Abbreviations: SFC, 
spot forming cells. 
Table 8: ELISpot results of peptide pools. Six PBMC samples per pool were stimulated for 12 days prior to the 
ELISpot assay. Peptides of positive pools (green background) were further tested individually. 
Pool Positive/tested Pool Positive/tested Pool Positive/tested 
Pool 1 0/6 Pool 6 1/6 Pool 11 1/6 
Pool 2 0/6 Pool 7 0/6 Pool 12 3/6 
Pool 3 2/6 Pool 8 5/6 Pool 13 4/6 
Pool 4 1/6 Pool 9 4/6 Pool 14 0/6 
Pool 5 2/6 Pool 10 2/6 Pool 15 3/6 
 
Seven of the tested peptide pools stimulated peptide-specific memory T cells only in one or in none 
of the PBMC samples and were therefore excluded from further testing. Peptides of pools 3, 5, 8, 9, 
10, 12, 13, and 15, however, were then individually screened for immunogenicity in at least six 
different HLA-matched donors. The results of the ELISpot screening are listed in Table 9. Of 109 
individually tested peptides, 29 elicited an IFNγ response in at least one of the tested PBMC 
samples. All peptide lengths that were predicted are present in this set of epitopes (Figure 7). With 
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nine unique epitopes, 9mers were most common followed by 10mers; but also 11mers, 12mers, 
and 13mers were not as rarely represented as observed in other HLA types. 
The novel epitopes represented 20 different proteins expressed in various expression stages. 
Twenty-two epitopes originated from genes expressed during the lytic phase of the viral life cycle; 
six from the early expression stage (e.g. RIR1, BBLF2, DUT) and 16 from the late expression stage 
(e.g. BILF1, BDLF2, PORTL, CEP2, LTP). However, no peptide from the immediate-early genes BZLF1 
and BRLF1 (Rta) were immunogenic. A small fraction of four epitopes represented proteins 
produced during latency (LMP1, LMP2, EBNA2, EBNA6). 
 
 
Figure 7: Length distribution (A) and expression program of source antigens (B) of the 29 identified epitopes. 
Abbreviation: n.a., not assigned. 
 
Figure 8: ELISpot screening results of EBV-derived epitopes that elicited an IFNγ response in at least two PBMC 
samples. Depicted are numbers of IFNγ SFC for each tested PBMC culture minus the spot numbers of the negative control 
of the PBMCs. Positive evaluated PBMC cultures are depicted in black, negative tested PBMC cultures in grey. Epitopes 
were tested once in technical duplicates in at least seven different HLA-A*01-positive PBMC cultures. Bars represent the 
mean IFNγ SFC. Abbreviations: SFC, spot forming cells. 
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Figure 8 shows the IFNγ ELISpot results of the 20 epitopes that were able to stimulate memory T 
cells in two or more PBMC samples, ordered from the epitope with the highest recognition rate to 
the lowest from left to right. 
The response rate for each peptide was determined as the percentage of responding PBMC 
cultures of all tested cultures. According to their response rate, peptides were assigned to three 
categories: dominant epitopes (≥ 50% response rate), subdominant epitopes (< 50% response rate), 
and non-immunogenic. Seven of the 29 epitopes were dominant epitopes with a response rate of ≥ 
50%, with CETSLVARY (BILF1) being the epitope with the highest response rate. CTESLVARY was 
able to elicit an IFNγ immune response in all tested PBMC samples after a 12-day stimulation and 
thus reached a response rate of 100%. The mean number of IFNγ SFC was 837, which was the 
highest of all epitopes. The second-best epitope achieving a recognition rate of 69.5% was an 
unusually long peptide: the 13mer MSDWTGGALLVLY originating from the latent protein LMP1. 
Four other peptides were also found to be dominant epitopes with response rates ranging from 
50% to 58%. One of them, CTESLVARYY, was a length variant of the epitope with the highest 
response rate and was therefore not further analyzed. A general trend can be observed in Figure 8: 
peptides with a high recognition rate also elicited higher mean spot counts in ELISpots after 12-day 
stimulation. Since the number of spots after stimulation does not allow any conclusions about the 
original number of peptide-specific memory T cells in the blood, the peptides were also examined 
in ex vivo ELISpot assays (without previous stimulation). 
 
Table 9: IFNγ ELISpot results of all tested EBV-derived, HLA-A*01-restricted peptides. 
Antigen Position Sequence 
SYFPEITHI [% 
max. score] 
NetMHC 
[nM] 
Peptide 
pool No. 
ELISpot RR  
(12 d stim.) 
BILF1 258-266 CTESLVARY 80.0 8 8 23/23 (100%) 
LMP1 44-56 MSDWTGGALLVLY 75.6 6 12 16/23 (70%) 
LMP2 484-493 ESEERPPTPY 69.2 55 13 14/24 (58%) 
BILF1 258-267 CTESLVARYY 74.4 18 8 4/7 (57%) 
BDLF2 402-410 LTDRSFPAY 85.0 7  18/31 (56%) 
RIR1 604-612 CSDAFYPFY 72.5 6 5 11/22 (50%) 
PORTL 220-228 RSDEYVAYY 75.0 7 9 8/16 (50%) 
CEP2 313-323 FSDLYSRAMLY 79.5 5 13 7/16 (44%) 
LTP 1058-1070 YTSIEWDYRELLY 75.6 7  3/8 (38%) 
RIR1 149-157 ESDMEVFDY 75.0 8 5 10/29 (35%) 
BBLF2 468-479 TSDTRRALGGLY 75.6 7 15 7/22 (32%) 
LTP 314-323 TSDSFPAARY 76.9 14 3 4/15 (27%) 
LTP 2540-2549 PTDVLNPSFY 82.1 15  4/15 (27%) 
DUT 198-208 FSDQTVFLNKY 82.1 6  4/17 (24%) 
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Table 9 continued (1/4)    
Antigen Position Sequence 
SYFPEITHI [% 
max. score] 
NetMHC 
[nM] 
Peptide 
pool No. 
ELISpot RR  
(12 d stim.) 
gB 584-595 MTEVCQATSQYY 75.6 9 3 2/10 (20%) 
EBNA6 380-392 DVELESSDDELPY 75.6 376 8 2/13 (15%) 
n.c. 79-87 PDEYWYLLY 67.5 1730  2/13 (15%) 
RIR1 149-158 ESDMEVFDYY 74.4 13 5 2/14 (14%) 
gB 584-594 MTEVCQATSQY 79.5 16  2/15 (13%) 
UL32 167-175 AIDIQLHFY 67.5 17  2/15 (13%) 
gH 61-72 VTEDLASMLNRY 78.1 9  1/10 (10%) 
ITP 908-920 LNERVEHALELGY 75.6 4999 5 1/13 (8%) 
BILF1 23-32 ATEDACTKSY 79.5 161 8 1/14 (7%) 
gM 71-80 YLEPPEMFVY 69.2 95 9 1/15 (7%) 
HELI 648-658 LLDYASTTENY 69.2 66 9 1/15 (7%) 
UL92 167-179 SSEKVVDVVLSLY 80.5 25 13 1/15 (7%) 
EBNA2 112-120 PLDRDPLGY 72.5 25 13 1/15 (7%) 
gB 131-139 ETDQMDTIY 80.0 7  1/15 (7%) 
UL32 115-124 FEDYALLCYY 69.2 607  1/18 (6%) 
DPOL 388-396 ILDRARHIY 67.5 114  0/18 
TRM1 373-384 PPEVAELSELLY 80.5 11878  0/10 
TRX1 259-270 PADARLYVALTY 75.6 40  0/10 
CEP2 24-35 LSDASTPQMKVY 73.2 16  0/10 
TRM1 622-634 SSEHLHALTHSLY 80.5 11  0/10 
UL32 185-197 SSDMIRNANLGYY 75.6 6  0/10 
LTP 241-253 ETEDPRIFMLEHY 75.6 38  0/8 
LTP 2020-2032 ETESPCDPLNPAY 75.6 44  0/8 
MTP 1237-1247 GTDAWRFAMNY 79.5 8  0/8 
DPOL 903-913 STELSRKLSAY 84.6 39  0/8 
BRRF1 143-153 GSDYTAVSLQY 82.1 11  0/8 
BRRF1 278-290 VTDAITLPDCAEY 78.1 7  0/8 
HELI 654-663 TTENYTLLGY 87.2 9  0/8 
TRM1 755-764 DSDRPLILLY 84.6 58  0/8 
UL17 83-92 YCDEGLPELY 69.2 51  0/8 
LTP 714-722 TLDTARSQY 67.5 384 3 0/8 
LTP 2034-2043 SADTQEPLNY 74.4 162 3 0/8 
LTP 1060-1070 SIEWDYRELLY 71.8 329 3 0/8 
LTP 3138-3148 IADLERLKFLY 71.8 33 3 0/8 
gB 148-156 TKDGLTRVY 67.5 14816 3 0/8 
gB 656-664 DLEGIFREY 67.5 9058 3 0/8 
gB 635-644 NIDFASLELY 71.8 40 3 0/8 
UL95 10-19 PDDPMLARRY 69.2 10639 10 0/8 
BDLF3 170-180 VPDERQPSLSY 71.8 5013 10 0/8 
BDLF2 228-237 GRDFGVPLSY 71.8 10212 10 0/8 
MCP 985-993 RPEQLFAEY 70.0 15890 10 0/8 
MCP 706-714 VGDESVGQY 67.5 1940 10 0/8 
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Table 9 continued (2/4)    
Antigen Position Sequence 
SYFPEITHI [% 
max. score] 
NetMHC 
[nM] 
Peptide 
pool No. 
ELISpot RR  
(12 d stim.) 
MCP 804-813 HADVLEKIFY 69.2 280 10 0/8 
UL25 375-383 ALEALMLVY 75.0 32 10 0/8 
LF2 304-313 ITELEYNNTY 76.9 91 10 0/8 
ICP27 416-425 HDEVEFLGHY 66.7 4562 10 0/8 
TRM1 443-453 ATERLFCGGVY 76.9 16 15 0/8 
TRM1 527-537 LSDALKRKEQY 76.9 36 15 0/8 
BKRF4 47-55 VSDTDESDY 75.0 12 15 0/8 
BKRF4 86-94 PSDSDESDY 72.5 17 15 0/8 
BBLF2 490-499 AADLGLTWAY 71.8 328 15 0/8 
BBLF2 186-196 HSESPGQLDVY 76.9 46 15 0/8 
 n.c. 
674-684 
152-162 
ATEHGLSPTAY 74.4 15 15 0/8 
BTRF1 250-260 NPDLLPLQHLY 69.2 1055 15 0/8 
DNBI 206-218 NSDLSRCMHEALY 75.6 7  0/8 
AN 94-105 ATDEQRTVLCSY 78.1 7  0/7 
TRM3 357-366 SADQATSFLY 69.2 111  0/7 
LF2 264-273 LDDVIIAFRY 69.2 2974  0/7 
n.c. 28-36 STRACVLLY 67.5 542  0/7 
GP350 804-814 GGDSTTPRPRY 69.2 3857  0/7 
PORTL 118-127 VRDLLTTNIY 69.2 5440 9 0/7 
HELI 314-324 GLELSPDILAY 71.8 215 9 0/7 
HELI 639-651 TSDEPLLHGLLDY 85.4 8 9 0/7 
HELI 653-663 STTENYTLLGY 69.2 45 9 0/7 
AN 236-246 KSEFDPIYPSY 71.8 213 9 0/7 
AN 78-88 SKDGPSLKSIY 69.2 13423 9 0/7 
DNBI 767-776 FPDTKLSSLY 66.7 1897 12 0/7 
DNBI 691-701 DLDAALQGRVY 69.2 1424 12 0/7 
BARF1 204-214 KNDKEEAHGVY 69.2 9374 12 0/7 
gH 523-532 DRDAWHLPAY 69.2 6147 12 0/7 
gH 62-72 TEDLASMLNRY 74.4 3550 12 0/7 
gH 469-479 GTESGLFSPCY 74.4 39 12 0/7 
gH 555-566 SSDREVRGSALY 80.5 14 12 0/7 
UL25 548-556 ASDDYDRLY 77.5 10 12 0/7 
ICP27 381-389 VVETLSSSY 62.5 285 13 0/7 
EBNA2 464-474 TTESPSSDEDY 74.4 33 13 0/7 
UL92 171-179 VVDVVLSLY 67.5 18 13 0/7 
UL92 15-27 GTDEPNPRHLCSY 75.6 11 13 0/7 
TEG2 48-57 CGETNEGLEY 69.2 917 13 0/7 
LTP 2024-2032 PCDPLNPAY 67.5 394  0/6 
LF2 263-273 LLDDVIIAFRY 69.2 14  0/6 
ICP27 415-425 RHDEVEFLGHY 69.2 7226  0/6 
LF1 421-429 NLDAGRIFY 70.0 21  0/6 
LF1 418-429 RSDNLDAGRIFY 80.5 8  0/6 
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Table 9 continued (3/4)    
Antigen Position Sequence 
SYFPEITHI [% 
max. score] 
NetMHC 
[nM] 
Peptide 
pool No. 
ELISpot RR  
(12 d stim.) 
n.c. 78-87 VPDEYWYLLY 76.9 534  0/6 
ITP 521-533 SSELLRSLLWVRY 75.6 19 5 0/6 
RIR1 654-662 LPEALRQRY 67.5 14986 5 0/6 
RIR1 52-61 YLEVFSDKFY 66.7 87 5 0/6 
RIR1 195-205 SSEWDVTQALY 74.4 26 5 0/6 
RIR1 715-725 SYELGLKTIMY 66.7 10831 5 0/6 
GP42 176-185 SLDGGTFKVY 71.8 474 8 0/6 
BZLF1 25-33 AFDQATRVY 70.0 11562 8 0/6 
BZLF1 172-180 DSELEIKRY 70.0 3423 8 0/6 
BZLF1 8-18 SEDVKFTPDPY 69.2 5048 8 0/6 
BZLF1 170-180 ECDSELEIKRY 66.7 3253 8 0/6 
KITH 465-473 VNDAYHAVY 67.5 1135 1 Pool 
KITH 156-166 GADSTSRSFMY 64.1 82 1 Pool 
MTP 382-390 ALDTVRYDY 70.0 77 1 Pool 
MTP 175-183 LFDNALRKY 67.5 12537 1 Pool 
MTP 426-434 ALELFSALY 65.0 69 1 Pool 
MTP 650-658 PLDLPLADY 65.0 528 1 Pool 
MTP 1073-1082 VRDNTFLDKY 71.8 2244 1 Pool 
MTP 531-540 ACDMAGCQHY 66.7 459 1 Pool 
MTP 105-117 ALEASGNNYVYAY 65.9 268 1 Pool 
IL10H 151-160 MSEFDIFINY 69.2 43 2 Pool 
UL32 115-123 FEDYALLCY 70.0 622 2 Pool 
UL32 243-251 PGDVGRGLY 70.0 3311 2 Pool 
UL32 472-481 VCDSLITLVY 76.9 83 2 Pool 
UL32 114-123 FFEDYALLCY 71.8 104 2 Pool 
UL32 139-149 GMDFLHILIKY 71.8 32 2 Pool 
LTP 2723-2731 ASEQGPIVY 77.5 23 2 Pool 
LTP 1062-1070 EWDYRELLY 72.5 3647 2 Pool 
MTP 101-113 GTESALEASGNNY 75.6 63 2/4 Pool 
EAR 42-50 PEDTVVLRY 75.0 1755 4 Pool 
EAR 41-50 SPEDTVVLRY 71.8 10525 4 Pool 
UL32 185-196 SSDMIRNANLGY 90.2 7 4 Pool 
UL34 236-247 FSEAETEDEASY 73.2 11 4 Pool 
LTP 1603-1613 NTDLEAPYAEY 87.2 9 4 Pool 
TRX1 329-340 ATDGWRRSAFNY 78.1 14 4 Pool 
gB 654-664 VFDLEGIFREY 69.2 5421 4 Pool 
ITP 318-327 LLEPSGALFY 71.8 40 4 Pool 
EAD 192-200 NPDLYVTTY 65.0 9316 6 Pool 
EAD 202-211 SGEACLTLDY 71.8 4275 6 Pool 
EAD 105-114 AVEQASLQFY 66.7 132 6 Pool 
BMRF2 238-248 HAEVFFGLSRY 69.2 146 6 Pool 
PRIM 261-269 SADLVRYVY 70.0 87 6 Pool 
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Table 9 continued (4/4)    
Antigen Position Sequence 
SYFPEITHI [% 
max. score] 
NetMHC 
[nM] 
Peptide 
pool No. 
ELISpot RR  
(12 d stim.) 
gN 43-51 LTEAQDQFY 77.5 8 6 Pool 
DPOL 96-104 VYDILETVY 70.0 6003 6 Pool 
DPOL 879-887 VIDILNQAY 67.5 23 6 Pool 
DPOL 262-271 HRDSYAELEY 74.4 1300 6 Pool 
DPOL 957-966 KTEMAEDPAY 74.4 195 7 Pool 
DPOL 445-454 CRDKLSLSDY 71.8 3568 7 Pool 
GP350 143-151 HAEMQNPVY 62.5 159 7 Pool 
GP350 312-324 SQDMPTNTTDITY 75.6 396 7 Pool 
GP350 319-331 TTDITYVGDNATY 75.6 9 7 Pool 
EBNA4 328-336 TNEEIDLAY 65.0 1282 7 Pool 
EBNA4 809-820 TSDKIVQAPIFY 80.5 7 7 Pool 
EBNA6 41-51 ASERLVPEESY 69.2 111 7 Pool 
EBNA6 382-392 ELESSDDELPY 69.2 99 7 Pool 
MCP 1216-1225 NQEVAEGLIY 69.2 4530 11 Pool 
MCP 525-535 PTEDFLHPSNY 74.4 21 11 Pool 
MCP 789-799 DHDFRLHLGPY 69.2 7887 11 Pool 
MCP 829-841 GVDFQHVAQTLAY 75.6 16 11 Pool 
DNBI 519-527 PDDEPRYTY 65.0 11636 11 Pool 
DNBI 588-596 YKDLVKSCY 65.0 8712 11 Pool 
DNBI 153-162 ITEAFKERLY 76.9 65 11 Pool 
DNBI 292-301 SHETPASLNY 69.2 12336 11 Pool 
DNBI 518-527 RPDDEPRYTY 66.7 13837 11 Pool 
LMP2 410-420 LTEWGSGNRTY 74.4 40 14 Pool 
KR2 295-303 RLDLQSLGY 75.0 18 14 Pool 
KR2 103-111 LYDSVTELY 67.5 266 14 Pool 
KR2 72-82 RCDHLPITCEY 69.2 250 14 Pool 
KR2 295-307 RLDLQSLGYSLLY 82.9 10 14 Pool 
BFRF2 44-56 LLDLGLACLDLSY 78.1 16 14 Pool 
TRM1 746-754 PPDGLYLTY 72.5 6421 14 Pool 
TRM1 771-779 FKDLYALLY 72.5 32 14 Pool 
TRM1 376-384 VAELSELLY 70.0 25 14 Pool 
n.c., not characterized; RR, response rate; Pool, peptides were only tested in pools. 
 
Ex vivo ELISpot was performed with 16 randomly selected HLA-matched PBMC samples stimulated 
overnight with the most immunogenic epitopes. Only the two epitopes with the highest recognition 
rate, CTESLVARY and MSDWTGGALLVLY, stimulated detectable numbers of peptide-specific 
memory T cells in several donors with a recognition rate of 37.5% and 18.8%, respectively (Table 
10). Thus, the initial number of peptide-specific T cells appears to be in fact higher for epitopes with 
high recognition rates in some cases. All other specificities have such low cell numbers in peripheral 
blood that they are not detectable by this assay. However, the significant increase in the response 
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rate in 12-day ELISpots compared to ex vivo ELISpots and the high spot counts after stimulation 
demonstrate the immense proliferation capability of EBV-specific memory T cells.  
 
Figure 9: Parallel recognition of several epitopes by PBMC cultures. Shown is an ELISpot plate with four PBMC samples 
(2709, 2734, 2747, and 2701) after 12-day stimulation with nine test peptides, the positive and the negative control. The 
adenovirus epitope LTDLGQNLY and PHA served as positive control and the HIV epitope GSEELRSLY and medium served as 
negative control. 
Parallel testing of several epitopes in 12-day ELISpot assays revealed multiple memory responses in 
each PBMC sample (Figure 9). PBMC cultures recognized different sets and different numbers of 
epitopes. A maximum of seven epitopes was recognized in parallel by PBMCs from donor 2734 
while other PBMC cultures recognized only three epitopes (2709, 2747). In all tested PBMC 
samples, CTESLVARY elicited the strongest response among the EBV-specific epitopes. Apart from 
that, no clear hierarchy could be observed. 
 
3.1.3 Evaluation of functionality and HLA specificity of EBV-specific memory T cells 
While IFNγ ELISpot assays are highly sensitive and efficient in detecting activated memory T cells, 
almost no conclusions can be drawn regarding the type of the activated cells and their HLA 
restriction. ‘Mismatch’ ELISpots in which PBMCs are tested that are not HLA-matched can provide a 
first indication of the HLA restriction of the reactive cells. Therefore, 16 PBMC samples, which were 
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HLA-A*01-negative, were stimulated with the ten epitopes with the highest immunogenicity for 12 
days. Only one epitope was able to stimulate memory T cells in HLA-A*01-negative samples in the 
following ELISpot: two PBMC cultures pulsed with MSDWTGGALLVLY showed IFNγ SFCs. Both 
donors are HLA-A*03- and HLA-B*44-positive, but none of the binding motifs match the epitope. 
This may suggest a binding of HLA-II molecules. 
In order to validate the functionality and the HLA restriction of the stimulated T cells, ICS and 
tetramer staining was performed. The cells underwent 12-day stimulation prior to both of the 
assays and the same initial gating strategy was applied for all analyses; first, the lymphocytes were 
gated using the forward scatter (FSC) and side scatter. FSC-area (FSC-A) versus FSC-height was then 
used to exclude doublets from the analyses. Lastly, FSC-A was plotted against Aqua live/dead to 
allow for the gating of living, Aqua live/dead-negative cells. 
ICS was performed to determine the functionality of the stimulated T cells and whether the 
respective response to dominant epitopes was mediated by CD4+ or CD8+ T cells. For this purpose, 
CD8-PerCP was plotted against CD4-APC-Cy7 to enable gating of the CD8+ and the CD4+ population. 
Both populations were then separately analyzed for their TNF (PacificBlue) and IFNγ (PE) 
production (Figure 10B). The TNF+, IFNγ+, and double-positive populations of the cells stimulated 
with the test peptide had to be at least twice as large as those of the negative control to be 
considered positive. All dominant epitopes caused an IFNγ and TNF secretion by CD8+ T cells in at 
least two tested donors with LTDRSFPAY being the exception with no TNF production.  
HLA tetramer staining was then performed to validate the HLA restriction of the stimulated 
memory T cells. CD8+ T cells were therefore gated from the living cell population and plotting of 
CD8-PerCP against tetramer-PE enabled the identification of CD8+tetramer+ cells (Figure 10C). The 
tetramer+ population of the tetramer of interest had to be at least twice as large as that of the 
negative control to be considered positive. Specific, tetramer+ T cell populations could be detected 
for all dominant epitopes in at least one donor sample (Table 10). This indicates that T cells 
activated by the tested epitopes can recognize this peptide in complex with HLA-A*01:01 and are 
therefore restricted to HLA-A*01. 
The activation of CD8+ T cells in the ICS and the positive tetramer staining with donor PBMCs 
stimulated with MSDWTGGALLVLY confirmed the HLA-A*01 restriction of this epitope. The positive 
PBMC cultures in the mismatch ELISpot, however, indicated a binding of this peptide by other HLA 
allotypes. Either the same epitope can be bound by different HLA allotypes or the relatively long 
peptide harbors different epitopes. 
In total, the HLA restriction to HLA-A*01 and the functionality of the peptide-specific cells could be 
confirmed for all dominant epitopes. 
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Table 10: Summary of ELISpot, tetramer staining and ICS results for the epitopes with the highest 
recognition rates in ELISpot assays. 
Antigen Position Sequence 
ELISpot 
response rate 
(12 d stim.) 
ELISpot 
response rate 
(ex vivo) 
ICS 
Tetramer 
staining 
BILF1 258-266 CTESLVARY 23/23 (100.0%) 6/16 (37.5%) CD8+, IFNγ+, TNF+ positive 
LMP1 44-56 MSDWTGGALLVLY 16/23 (69.5%) 3/16 (18.8%) CD8+, IFNγ+, TNF+ positive 
LMP2 484-493 ESEERPPTPY 14/24 (58.3%) 0/16 CD8+, IFNγ+, TNF+ positive 
BILF1 258-267 CTESLVARYY 4/7 (57.1%) - - - 
BDLF2 402-410 LTDRSFPAY 18/31 (55.6%) 0/16 CD8+, IFNγ+, TNF- positive 
RIR1 604-612 CSDAFYPFY 11/22 (50.0%) 0/16 CD8+, IFNγ+, TNF+ positive 
PORTL 220-228 RSDEYVAYY 8/16 (50.0%) 0/16 CD8+, IFNγ+, TNF+ positive 
CEP2 313-323 FSDLYSRAMLY 7/16 (43.8%) 0/16 CD8+, IFNγ+, TNF+ - 
 
 
 
 
Figure 10: Characterization of CTESLVARY and its specific memory T cells. Shown are exemplary results of an ELISpot 
assay (A), an ICS (B), and a tetramer staining (C) with PBMCs of donor 2544 pulsed with CTESLVARY or negative control. 
The cells were stimulated for 12 days prior to each assay. The HIV-derived peptide GSEELRSLY served as negative control 
for the ELISpot and the ICS. The negative control of the tetramer staining was a HLA-A*01-tetramer with GSEELRSLY. 
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3.2 Naturally presented HCMV-derived T cell epitopes 
3.2.1 Identification of naturally presented HCMV-derived ligands 
The infection of human foreskin fibroblast cell lines with mutant HCMV lacking immunoevasins 
US2-US11 (ΔUS2-11) enabled the isolation of HCMV-derived HLA ligands from the cell surface and 
the identification by LC-MS/MS. As shown in Figure 11, the infection of fibroblasts with WT 
AD169VarL usually leads to a drastic decrease of the HLA-I surface expression. However, infection 
with ΔUS2-11 led to a clear increase in HLA-I expression, almost reaching the levels of uninfected 
cells (mock). Infection and HLA-I expression analysis were performed by Liane Bauersfeld from the 
group of Dr. Anne Halenius in Freiburg. 
 
 
Figure 11: Cell surface expression of HLA-I. HF-99/7 fibroblasts were mock-treated or infected with AD169VarL wild-type 
virus or deletion mutants with an MOI of 5. Cell surface expression of HLA-I (W6/32) was analysed by flow cytometry at 
48 h.p.i. Shown are representative results of two experiments. Adapted from Dr. Anne Halenius, Freiburg. 
For the identification of HCMV-derived HLA ligands, HF-99/7 cells were infected with ΔUS2-11 
(n = 1) or mock treated (n = 1) and ligands were isolated with immunoaffinity purification. The 
sequences were then identified via liquid chromatography-coupled tandem-mass spectrometry (LC-
MS/MS) in three technical replicates. MS analyses identified 3052 peptides in the mock treated 
sample and 5793 peptides in the infected sample. SYFPEITHI and NetMHCpan 3.0 predicted 2839 
(mock) and 5511 (ΔUS2-11) to be binders, which represents a purity of 93% and 95%, respectively.  
 
Table 11: Summary of mass spectrometry analyses of HF-99/7 cells either infected with ΔUS2-11 or mock 
treated. 
Sample Peptides Binders Purity 
HCMV-derived 
binders 
HCMV source 
proteins 
HF-99/7 mock 3052 2839 93% 0 0 
HF-99/7 ΔUS2-11 5793 5511 95% 181 80 
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Of these binders, 37, 44, 21, 43, 17, and 4 viral peptides (altogether 181) were restricted to HLA-
A*01:01, -A*03:01, -B*08:01, -B*51:01, -C*01:02, and -C*07:01, respectively (Figure 12). The HLA 
annotation of 15 peptides was ambiguous.  
 
Figure 12: Distribution of HLA restrictions among the 181 HF-99/7 ligands. Ligands were predicted with SYFPEITHI and 
NetMHCpan 3.0. Ligands are designated ambiguous when the prediction tools were inconsistent in their restriction 
assignment. 
The infection time of 48 h was chosen to enable the detection of peptides originating from proteins 
with various expression kinetics. Indeed, the source proteins of the identified ligands represent all 
classes or profiles of gene expression as described by Weekes et al. [264] (Figure 13). The 
distribution of ligands mirrors well the proportions of proteins assigned to each profile by Weekes 
et al.  
All identified HCMV-derived ligands are listed in Supplemental Table 6. 
 
 
Figure 13: Distribution of temporal profiles among identified ligands of the HF-99/7 cell line (A) and proteins as 
assigned by Weekes et al. (B). ND, not determined; Tp, temporal profile. 
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3.2.2 IFNγ ELISpot screening for HCMV-derived T cell epitopes 
All ligands with a SYFPEITHI score of ≥ 70% or a NetMHC IC50 of ≤ 50 nM or a percentile rank of 
< 0.5% were further evaluated for their immunogenicity. Therefore, peptides were tested for 
memory T cell responses in at least seven different HCMV-seropositive, HLA-matched individuals by 
IFNγ ELISpot assay with prior 12-day stimulation. Of the HLA-A*01:01, -A*03:01, -B*08:01, 
and -B*51:01-restricted ligands, 32, 39, 20, and 30, respectively, were tested in ELISpot (Figure 14). 
Some HLA-C-restricted peptides were tested randomly. However, they were not further evaluated 
and included in the analyses since the healthy blood donors were not typed for HLA-C. It was 
therefore impossible to draw conclusions from those immunogenicity assays, especially for rare 
HLA types such as C*01:02. Of the 32 tested, HLA-A*01-restricted peptides, 16 were able to elicit an 
IFNγ response in PBMCs of at least one healthy blood donor. For HLA-A*03-restricted peptides, 13 
out of 39 peptides were recognized by memory T cells. For HLA-B*08 and -B*51-restricted peptides, 
10 out of 20 and 12 out of 30, respectively, were immunogenic in at least one PBMC sample. 
Overall, the proportion of epitopes among the identified peptides was 31%. The response rate for 
each peptide was determined as the percentage of positively tested donor samples out of tested 
samples. Based on the response rate peptides were grouped into three categories: negative (no 
memory response in any individual), subdominant (recognized by < 50% of individuals), and 
dominant (recognized by ≥ 50% of individuals). Two to five peptides of each HLA restriction were 
shown to be dominant epitopes with a response rate of ≥ 50%. The numbers of identified, tested, 
and immunogenic peptides for each HLA type are summarized in Figure 14. 
 
 
Figure 14: Distribution of tested, subdominant, and dominant HCMV ligands restricted to HLA-A and -B allotypes. 
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Figure 15 to Figure 18 depict the IFNγ ELISpot screening results of all epitopes in the form of 
numbers of spot forming cells (SFC) for each PBMC culture. PBMC samples with a positively 
evaluated spot count are depicted in black, PBMCs evaluated as negative in grey. 
 
 
Figure 15: ELISpot screening results of HLA-A*01:01-restricted epitopes. Depicted are numbers of IFNγ SFC for each 
tested PBMC culture minus the spot numbers of the negative control of the PBMCs. Positive evaluated PBMC cultures are 
depicted in black, negative tested PBMC cultures in grey. Epitopes were tested once in technical duplicates in at least 
seven different HLA-matched PBMC cultures. Bars represent the mean IFNγ SFC. Abbreviations: SFC, spot forming cells. 
 
Figure 16: ELISpot screening results of HLA-A*03:01-restricted epitopes. Depicted are numbers of IFNγ SFC for each 
tested PBMC culture minus the spot numbers of the negative control of the PBMCs. Positive evaluated PBMC cultures are 
depicted in black, negative tested PBMC cultures in grey. Epitopes were tested once in technical duplicates in at least 
seven different HLA-matched PBMC cultures. Bars represent the mean IFNγ SFC. Abbreviations: SFC, spot forming cells. 
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Figure 17: ELISpot screening results of HLA-B*08:01-restricted epitopes. Depicted are numbers of IFNγ SFC for each 
tested PBMC culture minus the spot numbers of the negative control of the PBMCs. Positive evaluated PBMC cultures are 
depicted in black, negative tested PBMC cultures in grey. Epitopes were tested once in technical duplicates in at least 
seven different HLA-matched PBMC cultures. Bars represent the mean IFNγ SFC. Abbreviations: SFC, spot forming cells. 
 
 
 
Figure 18: ELISpot screening results of HLA-B*51:01-restricted epitopes. Depicted are numbers of IFNγ SFC for each 
tested PBMC culture minus the spot numbers of the negative control of the PBMCs. Positive evaluated PBMC cultures are 
depicted in black, negative tested PBMC cultures in grey. Epitopes were tested once in technical duplicates in at least 
seven different HLA-matched PBMC cultures. Bars represent the mean IFNγ SFC. Abbreviations: SFC, spot forming cells. 
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Normalized spot counts in IFNγ ELISpot assays after 12-day stimulation were donor dependent and 
in part highly variable. While some PBMC cultures stimulated with one peptide showed very high 
numbers of SFCs, sometimes out of the countable range (“too numerous to count”), other PBMC 
cultures reached numbers barely above the threshold for being evaluated as positive. The epitopes 
in Figure 15 to Figure 18 are ordered according to their response rate beginning with the epitopes 
with the highest recognition rate on the left. It can be seen that the average number of specific 
memory T cells after 12-day stimulation is usually higher for highly immunogenic epitopes 
compared to the average spot counts of peptides with lower recognition rates. Interestingly, some 
peptides with low response rates such as US3492-101 (GSDALPAGLY, A*01:01), IE2/UL122113-121 
(SVSSAPLNK, A*03:01), and IE2/UL122449-457 (MPVTHPPEV, B*51:01) showed very high numbers of 
SFCs in those few PBMC cultures that were tested positive.  
In total, ELISpot screening identified 50 unique T cell epitopes with specific memory T cells in at 
least one of the tested donors (Table 12). Of these 50 epitopes, four epitopes were already known 
and published: UL105715-723 (YADPFFLKY, HLA-A*01:01), UL44245-253 (VTEHDTLLY, HLA-A*01:01), 
UL123184-192 (KLGGALQAK, HLA-A*03:01), and UL83116-123 (LPLKMLNI, HLA-B*51:01). Thirteen of the 
epitopes identified in this work were dominant epitopes, ten of them novel epitopes discovered in 
this work and first published in “Identification of HCMV-derived T cell epitopes in seropositive 
individuals through viral deletion models.” in the Journal of Experimental Medicine [394]. The 
dominant epitope UL2661-69 (LPYPRGYTL) was predicted to bind HLA-B*08 as well as HLA-B*51 and 
was therefore tested for both allotypes. Interestingly, it was able to elicit IFNγ responses in HLA-
B*08-positive and HLA-B*51-positive donor samples as well as in “mismatch” donor samples that 
were typed for neither of them. 
The recognition rate of all T cell epitopes in ELISpot assays after 12-day stimulation is listed in Table 
12. 
Table 12: HCMV-derived T cell epitopes. 
ID Sequence 
Tested 
HLA 
ELISpot response 
rate (12 d stim.) 
ELISpot response 
rate (ex vivo) † 
UL105715-723 YADPFFLKY [395] A*01:01 15/15 (100%) 90.9 
UL44245-253 VTEHDTLLY [296] A*01:01 13/14 (92.9%) 100.0 
UL69569-578 RTDPATLTAY A*01:01 19/23 (82.6%) 66.7 
US28122-130 ITEIALDRY A*01:01 14/24 (58.3%) 14.3 
UL55657-665 NTDFRVLELY A*01:01 9/16 (56.3%) 0.0 
UL3682-91 FVEGPGFMRY A*01:01 5/14 (35.7%)   
UL148282-290 SLDRFIVQY A*01:01 5/14 (35.7%)   
UL25370-379 YTSRGALYLY A*01:01 3/14 (21.4%)   
UL861346-1354 TSETHFGNY A*01:01 3/15 (20.0%)   
US3492-101 GSDALPAGLY A*01:01 3/16 (18.8%)   
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Table 12 continued (1/1)    
ID Sequence 
Tested 
HLA 
ELISpot response 
rate (12 d stim.) 
ELISpot response 
rate (ex vivo) † 
UL481607-1617 VTDYGNVAFKY A*01:01 3/16 (18.8%)   
IRS1/TRS1464-474 LLDELGAVFGY A*01:01 2/13 (15.4%)   
UL112/UL113124-134 ISENGNLQVTY A*01:01 3/20 (15.0%)   
UL105616-624 VTDPEHLMM A*01:01 2/14 (14.3%)   
UL105360-369 DLDFGDLLKY A*01:01 2/16 (12.5%)   
UL78222-232 YSDRRDHVWSY A*01:01 1/16 (6.3%)   
UL77228-236 GLYTQPRWK A*03:01 16/21 (76.2%) 50.0 
UL57790-798 RVKNRPIYR A*03:01 14/23 (60.9%) 33.3 
UL3651-60 RSALGPFVGK A*03:01 6/15 (40.0%)   
UL123184-192 KLGGALQAK [396] A*03:01 6/15 (40.0%)   
US33A13-21 KLGYRPHAK A*03:01 11/29 (37.9%)   
US24136-145 RVYAYDTREK A*03:01 4/11 (36.4%)   
UL25580-588 GVSSVTLLK A*03:01 5/14 (35.7%)   
UL843-11 RVDPNLRNR A*03:01 5/15 (33.3%)   
UL70698-706 SVRLPYMYK A*03:01 4/16 (25.0%)   
UL79237-245 RTFAGTLSR A*03:01 3/14 (21.4%)   
UL571044-1052 RLADVLIKR A*03:01 2/13 (15.4%)   
UL70697-706 RSVRLPYMYK A*03:01 2/15 (13.3%)   
UL122113-121 SVSSAPLNK A*03:01 1/14 (7.1%)   
UL34180-188 LPHERHREL B*08:01 20/22 (90.9%) 85.7 
UL2661-69 LPYPRGYTL B*08:01 11/16 (68.8%) 16.7 
UL13465-473 YLVRRPMTI B*08:01 11/22 (50.0%) 33.3 
UL36199-207 VMKFKETSF B*08:01 5/13 (38.5%)   
UL84239-247 TPLLKRLPL B*08:01 4/14 (28.6%)   
UL40170-178 HLKLRPATF B*08:01 3/13 (23.1%)   
UL84500-507 FISSKHTL B*08:01 3/14 (21.4%)   
UL147A2-10 SLFYRAVAL B*08:01 4/22 (18.2%)   
UL4426-34 QLRSVIRAL B*08:01 2/14 (14.3%)   
UL1481-8 MLRLLFTL B*08:01 1/14 (7.1%)   
UL83116-123 LPLKMLNI  B*51:01 12/15 (80.0%) 87.5 
UL38156-164 FPVEVRSHV B*51:01 15/23 (65.2%) 0.0 
UL2661-69 LPYPRGYTL B*51:01 10/16 (62.5%) 33.3 
UL56503-511 DARSRIHNV B*51:01 8/15 (53.3%)   
UL71330-338 IPPPQIPFV B*51:01 6/15 (40.0%)   
US28158-166 IAIPHFMVV B*51:01 5/15 (33.3%)   
US2365-73 IPHNWFLQV B*51:01 5/15 (33.3%)   
UL33162-170 VPAAVYTTV B*51:01 5/15 (33.3%)   
UL1466-74 FPAHDWPEV B*51:01 2/15 (13.3%)   
UL122449-457 MPVTHPPEV B*51:01 2/15 (13.3%)   
UL75540-549 FPDATVPATV B*51:01 1/15 (6.7%)   
UL481322-1331 LPYLSAERTV B*51:01 1/15 (6.7%)   
†Ex vivo ELISpot assays were performed using donors that were positively tested in ELISpot assays with prior  
12-day stimulation. 
Abbreviation: nt, not tested 
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The ELISpot assay with prior stimulation is a highly sensitive method to detect peptide-specific 
memory T cells. The prior stimulation allows the amplification of small numbers of specific memory 
T cells that can later be detected in the ELISpot assay. However, due to the immense proliferative 
capacity of memory T cell, it does not allow direct conclusions about the initial number of memory 
T cells in the blood. To address this and to exclude possible competitive effects among the different 
epitopes during the 12-day amplification, ex vivo IFNγ ELISpots without pre-stimulation were 
performed. For this purpose, dominant epitopes were retested with PBMC samples of previously 
tested positive donors. Only a few of the epitopes with the highest recognition rates elicited 
frequent, detectable responses ex vivo (Table 12). In most cases, memory T-cell numbers were too 
small to be detectable ex vivo but underwent, in part massive, amplification (up to 1,000-fold) upon 
pre-stimulation. Figure 19 shows exemplarily the ELISpot results of two HLA-B*08-restricted 
epitopes: UL34180-188 (LPHERHREL) and UL2661-69 (LPYPRGYTL). The graph shows again the high, 
donor- and peptide-dependent variability in peptide-specific memory T cell numbers after 12-day 
stimulation. The initial number of specific memory T cells in the blood and their proliferative 
capacity also varied considerably between donors. Many PBMC cultures (2736, 2825, 3061) showed 
no detectable or barely detectable spot counts ex vivo but had high numbers of reactive, peptide-
specific cells after stimulation. In contrast, donor 3025 had already considerable amounts of 
UL34180-188-specific memory T cells without any pre-stimulation. Except for one donor (2736), 
UL2661-69-specific cells showed a rather low proliferative capacity overall. 
 
 
Figure 19: Comparison of IFNγ SFC in ex vivo ELISpots (black) and ELISpots with prior 12-day amplification (grey). Shown 
are exemplary results of two independent experiments with PBMCs of five donors (coded by four-digit numbers) each for 
two B*08 epitopes (UL34180-188 and UL2661-69). SFC, spot forming cells. 
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3.2.3 Evaluation of functionality and HLA specificity of HCMV-specific memory T cells 
Functional activity of memory T cells after 12-day stimulation with HCMV peptides was tested by 
ICS via detection of IFNγ and TNF. ICS was performed with all dominant epitopes and some 
arbitrarily selected epitopes that were close to the threshold of dominant epitopes. The TNF+, IFNγ+ 
and double-positive populations of cells stimulated with the test peptide had to be at least twice as 
large as those of the negative control to be considered positive. 
All dominant epitopes except YLVRRPMTI (UL13465-473) caused CD8+ memory T cell-mediated 
responses. This is probably due to the fact that all available PBMC samples tested for YLVRRPMTI 
showed relatively low spot counts and therefore low numbers of specific T cells in the ELISpot. The 
lower sensitivity of flow cytometric assays compared to ELISpot might be responsible for the failure 
to detect these cells by ICS. The subdominant epitope SLDRFIVQY elicited a CD4+ T cell-mediated 
immune response. Exemplary results of the ICS with the immunodominant B*08 epitope 
LPHERHREL are depicted in Figure 21B. 
Tetramer staining was then performed with all dominant and two subdominant epitopes in order to 
validate the HLA-A*01:01 restriction of the peptide-specific T cells. Tetramer stainings were 
performed after prior 12-day stimulation with the 
peptide of interest and negative control peptide. 
This negative control peptide was also refolded 
with the respective HLA and served as the 
negative control in the tetramer staining. For 
some donors and epitopes, freshly thawed cells of 
the same donor served as additional negative 
control for the staining. The CD8+tetramer+ 
population of cells stained with the tetramer of 
interest had to be twice the size of the negative 
control to be determined as positive. All dominant 
epitopes had specific tetramer+ populations in at least two PBMC samples. Even small YLVRRPMTI-
specific, tetramer+ populations were observed in two PBMC cultures although the peptide was not 
able to elicit detectable IFNγ and TNF production in ICS with the same two PBMC samples. The 
possibility that not all peptide-specific cells are also functional might explain this discrepancy. In 
total, the size of tetramer+ T cell populations was highly donor and peptide dependent, which is in 
accordance with observations in ELISpot assays. Specific T cell populations ranged from 0.06% to up 
to 53.56% of CD8+ cells after 12-day amplification. The highest percentage of tetramer+ cells 
reached a PBMC culture stimulated with the B*51-restricted epitope LPLKMLNI (Figure 20). Figure 
Figure 20: Tetramer staining of HLA-B*51-restricted 
epitopes LPLKMLNI. Prior to the staining, PBMCs were 
stimulated for 12 days with LPLKMLNI and negative 
control (DPYKATSAV, human). As negative control for the 
staining served a B*51-DPYKATSAV tetramer. 
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21 shows a representative characterization of the epitope LPHERHREL (B*08) with the ELISpot, ICS, 
and tetramer staining results of one PBMC sample. 
 
Figure 21: Characterization of LPHERHREL and its specific memory T cells. Shown are exemplary results of an ELISpot 
assay (A), an ICS (B), and a tetramer staining (C) with PBMCs of donor 2917 pulsed with LPHERHREL (B*08) or negative 
control peptide. A) The spot count of the test peptide was ‘too numerous to count’ and was therefore set to 1,000. The 
cells were stimulated for 12-days prior to each assay. The HIV-derived peptide GGKKKYKL (B*08) served as negative 
control for the ELISpot and the ICS. The negative control of the tetramer staining was a HLA-B*08-tetramer with 
GGKKKYKL. 
Table 13: Summary of ELISpot, ICS and tetramer staining results for the best HCMV-derived epitopes. Nt, 
not tested. 
ID Sequence 
Tested 
HLA 
ELISpot RR 
(12-d stim.) 
ELISpot RR 
(ex vivo) 
ICS 
Tetramer 
staining 
UL105715-723 YADPFFLKY  A*01:01 100.0% 90.9% CD8+, IFNγ+, TNF+ positive 
UL44245-253 VTEHDTLLY A*01:01 92.9% 100.0% CD8+, IFNγ+, TNF+ positive 
UL69569-578 RTDPATLTAY A*01:01 82.6% 66.7% CD8+, IFNγ+, TNF+ positive 
US28122-130 ITEIALDRY A*01:01 58.3% 14.3% CD8+, IFNγ+, TNF+ positive 
UL55657-665 NTDFRVLELY A*01:01 56.3% 0.0% CD8+, IFNγ+, TNF+ positive 
UL148282-290 SLDRFIVQY A*01:01 35.7% nt  CD4+, IFNγ+, TNF+ nt 
UL77228-236 GLYTQPRWK A*03:01 76.2% 50.0% CD8+, IFNγ+, TNF+ positive 
UL57790-798 RVKNRPIYR A*03:01 60.9% 33.3% CD8+, IFNγ+, TNF+ positive 
UL3651-60 RSALGPFVGK A*03:01 40.0% nt  CD8+, IFNγ+, TNF+ positive 
US33A13-21 KLGYRPHAK A*03:01 37.9% nt  CD8+, IFNγ+, TNF+ positive 
UL34180-188 LPHERHREL B*08:01 90.9% 85.7% CD8+, IFNγ+, TNF+ positive 
UL2661-69 LPYPRGYTL B*08:01 68.8% 16.7% CD8+, IFNγ+, TNF+ positive 
UL13465-473 YLVRRPMTI B*08:01 50.0% 33.3% negative positive 
UL83116-123 LPLKMLNI  B*51:01 80.0% 87.5% CD8+, IFNγ+, TNF+ positive 
UL38156-164 FPVEVRSHV B*51:01 65.2% 0.0% CD8+, IFNγ+, TNF+ positive 
UL2661-69 LPYPRGYTL B*51:01 62.5% 33.3% CD8+, IFNγ+, TNF+ positive 
UL56503-511 DARSRIHNV B*51:01 53.3% nt  CD8+, IFNγ+, TNF+ positive 
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3.2.4 Promiscuous presentation of epitopes 
HLA-specific binding motives usually result in the fact that a peptide can bind well to only one HLA 
allotype. This is supported by the predominantly negative mismatch ELISpot assays. Moreover, 
ligands that were ambiguously predicted such as DARSRIHNV (B*08/B*51) mostly elicited memory 
responses in association with only one of the two predicted HLA allotypes. Nevertheless, as 
mentioned above, there are epitopes that can be recognized in conjunction with multiple HLA 
allotypes - within HLA supertypes and in between. The ligand LPYPRGYTL (UL2661-69) identified in 
this work was predicted to bind B*08 and B*51 and was able to stimulate T cells of different PBMC 
donors harboring either of both HLA types. Interestingly, the ELISpot response rates with B*08- and 
B*51-positive donors were relatively similar with 68.8% and 62.5%, respectively. Due to the 
unusual anchor residue at position five (Figure 22A), HLA-B*08 is prone to bind peptides that can 
also be bound by other HLAs although it is not part of any HLA supertype. The HLA restriction of this 
peptide was verified by tetramer staining for both HLA types (Figure 22B). However, in a following 
mismatch ELISpot with HLA-B*08-/B*51- donors, two HLA-B*14+ donors showed strong IFNγ 
responses. 
  
Figure 22: A) Binding motives of HLA-B*08:01, -B*51:01 and -B*14:02 obtained from NetMHC [25, 397]. B) Tetramer 
staining of HLA-B*08-, -B*51-, and -B*14-positive PBMC cultures with LPYPRGYTL-tetramers of the respective HLA type. 
Prior to the staining, PBMCs were stimulated for 12 days with LPYPRGYTL and the respective negative control peptide 
(B*08: GGKKKYKL (HIV), B*51: DPYKATSAV (human), B*14: DRLQTALLV (human)). HLA-matched tetramers with the 
respective negative control peptide served as negative controls in the staining. 
Subsequent ICS with those reactive, HLA-B*14+ PBMCs demonstrated a CD8+ T cell-mediated 
response. The peptide matched the binding motif of HLA-B*14:02 quite well (Figure 22A) and was 
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therefore refolded with HLA-B*14:02. The following tetramer staining with PBMCs of the two PBMC 
donors positively tested in ELISpot validated the restriction to HLA-B*14:02. Both B*14:02+ PBMC 
samples were also stained with B*08:01-LPYPRGYTL and B*51:01-LPYPRGYTL tetramers as controls. 
Surprisingly, B*08:01-LPYPRGYTL and B*51:01-LPYPRGYTL tetramers stained specific T cells in both 
HLA-B*08-/B*51-/B*14+ PBMC cultures (Figure 23). This binding seemed to be specific since 
B*08:01-LPYPRGYTL and B*51:01-LPYPRGYTL tetramers did not stain specific population in 
unstimulated samples. Stimulated HLA-B*08+/B*14- PBMCs that showed B*08:01-LPYPRGYTL 
tetramer-positive populations displayed no staining by B*51:01-LPYPRGYTL and HLA-B*51+/B*14- 
and B*51:01-LPYPRGYTL tetramer-positive PBMCs showed no staining with the B*08:01-LPYPRGYTL 
tetramer. Moreover, staining of both B*14:02+ PBMC samples with irrelevant viral HLA-B*08 and -
B*51 tetramers was also negative which excludes unspecific binding of the HLA complex to the TCR. 
This observation is remarkable since T cells are usually restricted by one HLA allotype. The fact that 
PBMCs of one donor recognize one peptide with three different HLA allotypes, two of which he 
does not express, indicates that the peptide-HLA complexes must be very similar in their spatial 
structure. Subsequent ELISpot assays with HLA-B*14+ donors revealed a recognition rate of 40.0%. 
Epitope LPYPRGYTL is therefore presented and recognized on three different HLA allotypes, which 
are all assigned to different supertypes. 
 
 
Figure 23: Tetramer staining of two B*14+ PBMC cultures with LPYPRGYTL tetramers. PBMCs of donors 2773 and 3071 
were stimulated for 12 days with LPYPRGYTL and negative control peptides (B*08: GGKKKYKL (HIV), B*51: DPYKATSAV 
(human), B*14: DRLQTALLV (human)). Tetramers with the negative control peptide and the respective HLA allotype 
served as negative controls for the staining. All negative controls had 0.00% or 0.01% tetramer+ populations and are not 
shown in this figure. 
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3.2.5 Comparison of mass spectrometry-based identification of ligands and the 
in silico prediction of candidate epitopes 
To compare the mass spectrometry-based approach of identifying naturally presented epitopes 
with an established in silico prediction method, Leon Bichmann applied the prediction tools 
SYFPEITHI and NetMHCpan3.0 to the proteome of HCMV. All HCMV-derived peptides were ranked 
according to their prediction score and the position of the dominant epitopes within this dataset 
was determined (Table 14). For both algorithms, SYFPEITHI and NetMHC, 25 of the 26 identified 
dominant epitopes are among the top-scoring 2% of all predicted peptides. This is in line with 
previous experience that the top 2% of predicted peptides with SYFPEITHI usually contain the 
natural T-cell epitopes [24]. NetMHC categorizes its predicted peptides into weak (affinity < 500 
nM, %rank < 2) and strong binders (affinity < 50 nM, %rank < 0.5). Thus, it would be necessary to 
test approximately 1,300 (SYFPEITHI) or 2,000 (NetMHC) peptides for each HLA-I allotype and 
length variant in order to screen epitopes from the entire HCMV proteome within these thresholds. 
Therefore, evidence of presentation on HLA molecules considerably reduced the number of 
possible candidates to be tested, as opposed to HLA binding prediction alone. 
 
Table 14: Position of dominant epitopes within whole proteome prediction. 
   NetMHCpan3.0 SYFPEITHI 
HLA 
Restric-
tion 
Sequence 
Total 
number 
of 
peptides* 
NetMHC 
percentile 
rank [%] 
Position 
within 
ranked 
peptides 
Epitope 
within % 
top 
predicted 
peptides 
Norma-
lized 
score [%] 
Position 
within 
ranked 
peptides 
Epitope 
within % 
top 
predicted 
peptides 
A*01 
YADPFFLKY 67116 0.01 8 0.012 82.5 3 0.004 
VTEHDTLLY 67116 0.01 7 0.010 85.0 2 0.003 
RTDPATLTAY 66919 0.01 8 0.012 87.2 2 0.003 
ITEIALDRY 67116 0.02 16 0.024 75.0 14 0.021 
NTDFRVLELY 66919 0.01 7 0.010 87.2 1 0.001 
A*03 
GLYTQPRWK 67116 0.15 84 0.125 59.1 269 0.401 
RVKNRPIYR 67116 0.50 305 0.454 52.3 1099 1.637 
B*08 
LPHERHREL 67116 0.08 176 0.262 62.8 104 0.155 
LPYPRGYTL 67116 0.06 133 0.198 55.8 361 0.538 
YLVRRPMTI 67116 0.04 105 0.156 46.5 1339 1.995 
B*51 
LPLKMLNI 67296 0.25 32 0.040 68.4 53 0.079 
LPYPRGYTL  67116 0.01 13 0.019 63.2 219 0.326 
FPVEVRSHV 67116 0.03 40 0.060 63.2 180 0.268 
DARSRIHNV 67116 3.50 3430 5.111 60.5 306 0.456 
* numbers of 9mer and 10mer peptides spanning the whole proteome 
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3.2.6 Infection of further cell lines allows the expansion of HLA types and epitopes 
The HLA restriction of the identified T cell epitopes is limited to the HLA types of the infected cell 
line HF-99/7. In order to expand the set of HLA types and T cell epitopes, fibroblast cell lines 
HF-99/5 and HF-γ were also infected with ΔUS2-11. Apart from the differences in the HLA type, the 
new infection scheme with an MOI of only 1 and the harvest after 4 days should allow the isolation 
of a different set of ligands. Not all fibroblasts would be infected at the beginning due to the low 
MOI, and the long incubation period together with the HCMV life cycle of 2-3 days should result in 
cells in different infection stages. The infection and cell culture of cell lines was performed by Liane 
Bauersfeld from the working group of Dr. Anne Halenius in Freiburg. The isolation of HLA ligands 
was carried out by Ana Marcu. 
Table 15: Summary of mass spectrometry analyses of HF-99/5 and HF-γ cells either infected with ΔUS2-11. 
Sample Peptides Binders Purity 
HCMV-derived 
binders 
HCMV source 
proteins 
HF-99/5 ΔUS2-11 7448 6768 93% 348 99 
HF-γ ΔUS2-11 10555 9703 92% 538 122 
 
The peptide sequences were identified via LC-MS/MS in three technical replicates. MS analyses 
identified 7448 peptides in the HF-99/5 sample and 10555 in the HF-γ sample. SYFPEITHI and 
NetMHCpan 4.0 [398] predicted 6768 (HF-99/5) and 9703 (HF-γ) to be binders, which represents a 
purity of 93% and 92%, respectively. From the HF-99/5 sample and the HF-γ sample, 348 and 538 
unique HCMV-derived ligands, respectively, could be identified. There was an overlap of 115 
ligands, which were identified in both cell lines. Although the cell lines do not share any HLA types, 
they harbor the supertypes HLA-A*03/A*11 and HLA-A*23/A*24, which explains this considerable 
overlap. The 348 HF-99/5 ligands originate from 99 different source proteins while the 538 HF-γ 
ligands represent 121 different proteins. In total, the infection of HF-99/5 and HF-γ cells enabled 
the identification of 696 novel HLA ligands; 75 ligands were already identified on HF-99/7 cells. 
The distribution of the HLA restrictions among the identified ligands is shown in Figure 24. While 
the proportions of HLA-A and -B ligands were almost equally distributed in HF-99/7 (Figure 12), 
they are distributed very differently in the two newly analyzed cell lines. HF-99/5 cells presented a 
significantly higher proportion of HA-A ligands than of HLA-B ligands (Figure 24A). In contrast, more 
than half of the HF-γ ligands were predicted to be HLA-B ligands with HLA-B*15:01 owing by far the 
greatest share (Figure 24B). With proportions of 12% each, the HLA-C ligands of HF-99/5 and HF-γ 
take up a similar proportion as in the HF-99/7 cell line (11%). The in general smaller proportion of 
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HLA-C ligands is in line with the fact that HLA-C molecules are less abundant than HLA-A and -B 
molecules on the cell surface [399, 400]. 
  
Figure 24: Distribution of HLA restrictions among the HF-99/5 (A) and HF-γ ligands (B). HLA ligands were assigned with 
SYFPEITHI and NetMHCpan 4.0. Ligands are designated ambiguous when the prediction tools were inconsistent in their 
restriction assignment. 
The new infection scheme considerably changed the composition of the temporal expression 
profiles reflected by the HLA ligands in comparison to the HF-99/7 infection scheme (Figure 25). 
The proportion of Tp5 peptides increased significantly, while the proportion of all other profiles 
decreased, with Tp3 shrinking the most. 
 
 
Figure 25: Distribution of temporal profiles defined by Weekes et al. (left) among identified ligands of the HF-99/7, HF-
99/5 and HF-γ cell line. ND, not determined; Tp, temporal profile. 
In total, the infection of two other cell lines enabled the identification of 696 novel ligands, which 
can be subjected to immunogenicity testing in the future. 
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4 Discussion 
4.1 EBV-derived, HLA-A*01 restricted T cell epitopes 
T cell responses against EBV play a crucial role in fighting the virus. In order to optimally employ this 
part of the immune defense for therapeutic approaches, a detailed knowledge of the T cell epitopes 
is indispensable. A positive example is the successful use of an EBV peptide pool in adoptive T-cell 
transfer. The PepTivator® EBV Select (Miltenyi Biotec) containing 43 different HLA-I and-II-restricted 
peptides efficiently stimulates EBV-specific T cells in almost all donors in vitro (personal 
communication with Dr. Britta Eiz-Vesper and [401]). 
In principle, the T cell epitope landscape of EBV is well studied. TheIEDB [26], which catalogs 
experimental data on T cell epitopes, currently lists 652 EBV-derived epitopes (accessed 
27.04.2020). There are well characterized, dominant epitopes for all common HLA types: 
GLCTLVAML (ICP27, A*02) [402], RLRAEAQVK (EBNA3, A*03) [403], AVFDRKSDAK (EBNA4, A*11) 
[404], RPPIFIRRL (EBNA3, B*07) [405], RAKFKQLL (BZLF1, B*08) [406], VEITPYKPTW (EBNA4, B*44) 
[407], and many more. However, there is a blatant gap concerning HLA-A*01-restricted epitopes. 
Not a single HLA-A*01 restricted epitope is mentioned in an epitope list from 2015 by Taylor et al. 
[160] who claims to list all EBV-derived, CD8+ T cell epitopes identified to this date. Even the IEDB 
lists merely seven peptides that have only been tested for their binding properties to HLA-A*01 but 
not been proven as T cell epitopes. This work therefore intended to fill this gap by revealing novel 
HLA-A*01-restricted EBV epitopes. 
Different approaches can be employed to identify epitope candidates. In this part of the work, 
candidate epitopes were identified by in silico prediction with SYFPEITHI and NetMHC. The size of 
the viral proteome allowed a prediction with the complete proteome without focusing on specific 
antigens. This unbiased approach resulted in hundreds of potentially HLA-A*01-binding peptides. 
Of these, 171 top scoring peptides were selected to be tested for their immunogenicity in PBMCs of 
healthy donors via IFNγ ELISpot assay. The first assays were performed with peptide pools 
containing nine peptides each in order to reduce the amount of necessary ELISpot assays. This 
allowed the swift elimination of 62 weakly or non-immunogenic peptides. The rest of the predicted 
peptides were tested individually. Of these, 29 (26.6%) stimulated specific memory T cells in at least 
one PBMC sample. All length variants that were predicted (9mers, 10mers, 11mers, 12mers, and 
13mers) were represented in the set of epitopes. HLA-I molecules generally prefer 9mer peptides 
for binding. Therefore, it is not surprising that most of the identified epitopes had a length of nine 
amino acids. However, many longer peptides were observed and the length distribution was less 
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focused on 9mers than usual for HLA-I molecules [408]. This is in line with previous observations 
that HLA-A*01 presents longer ligands more frequently than most other HLA allotypes [408, 409]. 
The response rate of the 29 epitopes is loosely correlated with the mean response intensity in 
individual donor samples meaning that frequently recognized epitopes often elicited higher spot 
counts in ELISpot assays after stimulation compared to weakly immunogenic epitopes. This is 
apparently reflected by the size of the original peptide-specific memory T cell population in the 
blood since only the two most frequently recognized epitopes stimulated detectable numbers of 
memory T cells in ex vivo ELISpots.  
Seven of the 29 epitopes were defined as dominant epitopes with an ELISpot response rate of 
> 50% of healthy, HLA-matched donor PBMCs. However, one of the dominant epitopes 
(CTESLVARYY) was a length variant of the top epitope CTESLVARY. The restriction by HLA-A*01 and 
the presence of reactive, multifunctional memory T cells was confirmed for all dominant epitopes 
via HLA-A*01:01 tetramer staining and ICS. The only exception is the peptide LTDRSFPAY, which 
could not trigger TNF production in ICS.  
ELISpots with HLA-mismatched donors indicate that most of the dominant epitopes are exclusively 
recognized in the context of HLA-A*01. Only MSDWTGGALLVLY elicited responses in HLA-A*01-
negative donor samples. Especially long peptides can harbor several epitopes that bind to different 
HLA-I types or even to class I and class II types. ICS with other epitopes occasionally shows activated 
CD8+ T cells in one donor and CD4+ T cells in another. Since the ‘mismatch’ ELISpot was performed 
with only 16 donor samples, it cannot be ruled out that rare HLA types may bind those epitopes. 
Furthermore, it cannot be excluded that the epitopes can also be presented by other members of 
the HLA-A*01 supertype, since both ‘matched’ and ‘mismatched’ ELISpots were performed with 
donor samples that do not exhibit supertype members such as HLA-A*26, -A*30, -A*32. 
Interestingly, the 29 epitopes originate from 20 different proteins, and no focus on a particular 
antigen could be observed. However, there was a clear dominance of lytic proteins over latent 
proteins. The focus of CD8+ T cell-mediated responses on lytic antigens was already demonstrated 
before [410, 411]. However, the usual hierarchy of immunodominance is described as IE > E > L 
with IE antigens being predominantly targeted by the T cell response and with rare responses to L 
antigens [402, 412]. Pudney et al. claimed that this hierarchy would directly reflect the immune 
evasion and the efficiency of antigen presentation in lytically infected cells [412]. This cannot be 
confirmed by this work since late proteins are by far the most frequent source of identified 
epitopes; also the most frequently recognized epitope CTESLVARY stems from the late antigen 
BILF1. Moreover, not a single epitope from the IE proteins BZLF1 (Zta) and BRLF1 (Rta) were 
identified although several peptides from those proteins were predicted binders and were tested 
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for their immunogenicity. Even when considering the seven dominant epitopes alone, the 
mentioned hierarchy cannot be confirmed. Four epitopes originated from late lytic proteins, two 
from latent proteins, and only one from early lytic proteins. 
The CD8+ T cell responses to latent EBV antigens were reported to be mainly focused on the 
EBNA3A, -3B, and 3C proteins followed by responses to LMP2, EBNA2. Responses against EBNA-LP, 
LMP1 were rarely detected and memory T cells against EBNA1 were not detected at all in early 
studies [183, 184]. Later studies, however, revealed CD8+ memory responses against EBNA1 in 
individuals with particular HLA types such as HLA-B*35:01, -B*07, and -B*53 [413]. Moreover, 
strong, dominant responses to EBNA2, EBNA-LP, and LMP2 epitopes restricted to particular HLA 
types were then detected questioning the original hierarchy. In contrast, LMP1 still remained an 
outlier with occasional and weak responses (reviewed by [414]). Interestingly, the highly 
immunogenic epitopes MSDWTGGALLVLY and ESEERPPTPY originate from LMP1 and LMP2, 
respectively. Epitopes from LMP1 could be of special interest since LMP1 is the key oncoprotein of 
EBV-mediated tumorigenesis [415], and such epitopes could be targets for anti-cancer therapies.  
Apart from that, it is noteworthy that no epitope was identified from the highly immunogenic 
antigen BZLF1 [416]. In total, it seems that there are no generally applicable rules concerning the 
immunodominance of particular antigens across different HLA allotypes. Rather, the respective HLA 
allotype seems to select its antigens and therefore determines the hierarchy of antigens as T cell 
targets. 
This work presents an unbiased analysis of the complete HLA-A*01-restricted T cell response to 
EBV. All EBV B95-8 proteins contained in the Swiss-Prot database were included in this analysis, and 
all peptides exceeding a threshold prediction score were tested for immunogenicity. Nevertheless, 
it can never be excluded that epitopes have lower prediction scores and were thus not 
characterized in this work. Three (YLEKESIYY, respiratory syncytial virus; LFETDPVTFLY, 
YMESVFQMY, both herpes simplex virus 1) of twelve dominant, HLA-A*01-restricted viral epitopes 
analyzed in our working group for other studies exhibited prediction scores slightly below the cut-
off threshold for immunogenicity testing and had response rates of 50%-75%. However, well 
characterized, dominant epitopes with response rates of > 75% had predictions scores well above 
the thresholds set here. Therefore, we are confident not to have missed any strong HLA-A*01-
restricted epitope. 
All epitopes except one are novel epitopes that have never before been described as T cell 
epitopes. ESEERPPTPY was previously discovered and characterized as a T cell epitope by Huisman 
et al. [417] and was also validated in a MD project of our working group [418]. 
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Parallel testing of highly immunogenic epitopes demonstrated that up to seven epitopes restricted 
by the same HLA type can be recognized by one donor. Nevertheless, the most immunogenic 
epitope CTESLVARY was clearly the immunodominant epitope with the strongest responses of all 
epitopes in all tested donors. Curiously, the peptide pool containing CTESVARY could not stimulate 
memory T cells in all PBMC cultures, although the epitope had a 100% recognition rate in individual 
tests. However, the PBMC culture that was evaluated as negative showed a slight unspecific 
activation and the spot count was just below three times the negative control. 
In summary, this part of the work provides an unbiased, comprehensive analysis of the HLA-A*01-
restricted T cell response to EBV and revealed 28 novel EBV-derived epitopes, among them 
CTESVARY with an overwhelming recognition frequency. 
 
4.2 Naturally presented HCMV-derived T cell epitopes 
Various immune evasion strategies employed by HCMV strongly interfere with HLA-I presentation 
of viral peptides on the host cell surface. However, ∼10% of the memory T cell compartment of 
seropositive individuals consists of HCMV-specific T cells [299], and this number can dramatically 
rise in the elderly [419]. 
With the approach described here, it was possible to bypass immune evasion by the US6 family 
genes and perform the direct isolation and identification of physiologically relevant HCMV-specific 
HLA ligands by MS. These data clearly confirm that memory T cell responses toward peptides 
derived from viral proteins of all expression stages and functional areas can be detected in 
immunocompetent HCMV carriers. The fact that memory T cells specific for a significant proportion 
of these ligands are present in HCMV-seropositive individuals clearly indicates priming of naive T 
cells against these antigens at any time during infection. 
HLA-I ligands can either originate from mature proteins that are degraded at the end of their 
functional lifetime, also termed ‘retirees’, or from defective ribosomal products (DRiPs), which are 
rapidly degraded after their synthesis [420]. To which extent those sources contribute to the HLA-I 
ligandome is still debated [421]. Although late proteins (Tp5) should not be produced for the first 
time until about 48 h.p.i., peptides could be isolated from these proteins at this time point. This 
suggests that at least the majority of these peptides originated from DRiPs and not from proteins 
that were degraded after their normal lifetime. 
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By now, the initial perception that HCMV-specific T cell responses are directed only against a few 
immunodominant antigens has been challenged by several groups. Using predictive bioinformatics 
and functional T cell assays, Elkington et al. [296] identified numerous novel HCMV epitopes from a 
heterogeneous group of 14 preselected proteins (pp28 [UL99], pp50 [UL112-UL113], pp65 [UL83], 
pp150 [UL32], pp71 [UL82], gH [UL75], gB [UL55], IE1 [UL123], US2, US3, US6, US11, UL16, and 
UL18) as T cell targets. Sylwester et al. [299] analyzed overlapping 15mer peptides from 213 HCMV 
ORFs by cytokine flow cytometry. Of the tested ORFs, 70% were shown to be immunogenic for CD4+ 
and/or CD8+ T cells. Immunogenicity was influenced only modestly by ORF expression kinetics and 
function. Interestingly, besides pp65 and IE1, UL48 was the only tested ORF recognized by CD8+ T 
cells of >50% of tested donors. In contrast to that particular finding, from a total of 50 identified 
immunogenic HCMV-derived peptides, 13 epitopes, representing 13 different proteins, were 
classified as dominant in our study. However, Sylwester et al. only stimulated the cells for 6 h 
before staining and flow cytometry analysis. Considering our ex vivo ELISpot results, their approach 
certainly underestimates the presence of HCMV-specific T cells. We found immunogenic peptides 
from 36 HCMV proteins, confirming previous findings that HCMV-specific CD8+ T cell immunity in 
healthy virus carriers is based on a broad repertoire of HCMV antigens. We were able to validate 
four previously known epitopes, but some well-established epitopes such as YSEHPTFTSQYpp65/UL83 
(A*01) [422], RIKEHMLKKIE1/UL123 (A*03) [423], QIKVRVDMVIE1/UL123 (B*08), and ELRRKMMYMIE1/UL123 
(B*08) [296] were not detected in our assays. While our approach has technical limitations, other 
reasons for the lack of detection of some dominant epitopes are imaginable. The HLA-I antigen 
presentation pathway could be insufficient for processing of specific peptides in the infected 
fibroblasts. To assess this, in future studies we will apply IFNγ to induce the HLA-I antigen 
presentation machinery before infection, as IFNγ induction strongly improves antigen presentation 
to CD8+ T cells [424] and may as well induce HLA-II expression for elution and characterization of 
class II ligands [4]. In addition, ligandome analysis at different time points during infection could 
yield peptides of different quality. The lack of three established IE1 epitopes indicates that the 48 
h.p.i. time point might be too late to efficiently obtain epitopes of the IE expression stage. 
Moreover, it should be taken into account that expression of one or combinations of several 
immunoevasins could result in different HLA-I ligandome qualities. In experiments carried out by 
Stefanie Spalt, who established this approach with another cell line and different HCMV mutants, it 
could be observed that HLA-B*44:02 ligand numbers were strongly induced in ΔUS2-6-infected cells 
compared to ΔUS2-6/ΔUS11-infected cells, i.e., in the presence of US11 expression [394]. The group 
of Anne Halenius has begun to address the molecular mechanism behind this phenomenon and it 
seems that immunoevasins target different HLA gene products in distinct manners [425]. Thus, 
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immunoevasins affect not only the efficiency, but also the quality of antigen presentation. Finally, it 
cannot be excluded that the ΔUS2-11 deletion mutant virus still expresses factors, such as pp71, 
that interfere with HLA-I peptide loading and presentation. 
 
The broad CD8+ T cell response against HCMV detected in healthy donors clearly shows that 
inhibition of HLA-I antigen presentation by immunoevasins is not sufficient to prevent the induction 
of CD8+ T cells [298], emphasizing the role of priming of CD8+ T cells through cross-presentation 
[312]. However, HCMV will have a major impact, not only quantitatively, but also qualitatively, on 
antigen processing and presentation in the infected cells. This could partly explain why a large 
portion of HCMV-derived HLA ligands failed to elicit a memory response in seropositive donors. 
Also, different expression/presentation patterns in different cell types could have an effect on 
memory responses [426, 427]. Such non-immunogenic ligands might not be processed and 
presented during an infection in vivo or are not recognized by naive T cells. Furthermore, donors 
might lack specific naive T cells, leaving a hole in the T cell repertoire [428-430]. Despite the large 
number of non-immunogenic HLA ligands identified, all these peptides are naturally presented on 
HLA molecules, providing a solid foundation for epitope screening. By using in silico analyses only, it 
would have been necessary to screen several thousands of peptides to identify our set of epitopes, 
as opposed to 181 in our approach. 
 
The infection of another two cell lines with a different infection scheme allowed the identification 
of 696 novel peptides, most of which originate from late (Tp5) proteins. Infection of various cell 
cultures expressing distinct HLA allotypes with different HCMV deletion mutants will allow for 
deeper and broader insights into the quality of viral CD8+ T cell targets. Moreover, methods such as 
ribosome profiling will enable the identification of novel ORFs that might be a source of additional 
viral T cell epitopes [231, 233]. The presence of a broad range of specific memory T cells in healthy 
seropositive individuals suggests that strategies using subdominant epitopes and targeting multiple 
antigens in vaccination and cellular therapies may be beneficial for sustainable virus control [431-
433]. Therefore, the identification of a large number of immunogenic HCMV-derived cytotoxic T cell 
targets for the most frequent HLA restrictions is, in our opinion, indispensable for the development 
and improvement of such therapies. 
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5 Summary 
Both human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are widespread in the 
population. They can cause severe morbidity and mortality, especially in immunocompromised 
hosts. Apart from the standard treatment with antiviral drugs, T cell-based immune therapies such 
as adoptive T cell transfer have been successfully used in recent years. A prerequisite for this 
treatment is the comprehensive knowledge about virus-specific T cell epitopes.  
The T cell epitopes of both viruses have already been the subject of numerous studies. 
Nevertheless, the epitope mapping in both cases shows certain gaps. In EBV there is a striking gap 
in HLA-A*01-restricted epitopes. While dominant epitopes are known and characterized for all 
other common HLAs, not a single useful HLA-A*01-restricted epitope has been described. In 
contrast, due to the size of HCMV, studies on its epitopes have mostly focused on specific antigens, 
which also prevented comprehensive mapping. The aim of this work was therefore the 
identification and characterization of novel HCMV-specific and HLA-A*01-restricted, EBV-specific T 
cell epitopes.  
To this end, epitope prediction was performed to identify HLA-A*01-binding peptides throughout 
the entire EBV proteome. From this list of peptides, 171 peptides were evaluated for 
immunogenicity using IFNγ ELISpot assays. Subsequently, the HLA restriction of strongly 
immunogenic peptides was verified via flow cytometry. Of the tested peptides, 29 were 
immunogenic; seven of them were dominant epitopes. For all dominant epitopes the HLA-A*01 
restriction was confirmed and reactive CD8+ T cells in healthy donors were identified. 
In the second project, candidate HCMV epitopes were isolated as HLA ligands from cell lines 
infected with HCMV mutants and then sequenced by mass spectrometry. Of the 181 ligands, 50 
(30%) could be characterized as epitopes. For all 13 dominant epitopes the predicted HLA 
restriction could be confirmed. The infection of two further cell lines allowed the isolation of 
hundreds of new peptides, which can be subjected to immunogenicity testing. Since the HLA 
ligands originate from more than 100 different proteins, this method is ideally suited for an 
unbiased, comprehensive analysis of the epitopes throughout the entire proteome. 
In summary, novel, strongly immunogenic epitopes were identified for both viruses, which could be 
employed for vaccination and antigen-specific immunotherapy in the future. 
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6 Zusammenfassung 
Das Humane Cytomegalievirus (HCMV) und das Epstein-Barr-Virus sind weitverbreitet in der 
Bevölkerung. Beide können schwere Erkrankungen auslösen, die vor allem in immunsupprimierten 
Infizierten lebensgefährlich werden können. Neben Standardtherapien werden seit geraumer Zeit 
T-Zell-basierte Immuntherapien wie der adoptive T-Zell-Transfer erfolgreich zur Behandlung 
eingesetzt. Voraussetzung dafür ist die möglichst umfangreiche Kenntnis der Virus-spezifischen 
T-Zell-Epitope.  
Die T-Zell-Epitope beider Viren waren bereits Gegenstand zahlreicher Studien. Dennoch weist die 
Epitopkartierung in beiden Fällen gewisse Lücken auf. Bei EBV gibt es eine eklatante Lücke bei HLA-
A*01-restringierten Epitopen. Während für alle anderen häufigen HLA-Allotypen dominante 
Epitope bekannt und charakterisiert sind, ist kein einziges HLA-A*01-restringiertes Epitop 
beschrieben. Aufgrund der Größe von HCMV haben sich Studien bezüglich seiner Epitope dagegen 
meist auf bestimmte Antigene konzentriert, was ebenfalls eine umfassende Kartierung verhinderte. 
Ziel dieser Arbeit war es deshalb, neue HCMV-spezifische und HLA-A*01-restringierte, EBV-
spezifische T-Zell-Epitope zu identifizieren und zu charakterisieren.  
Im Falle von EBV wurde hierfür eine Epitopvorhersage durchgeführt, welche die potenziell HLA-
A*01-bindenen Peptide im gesamten EBV-Proteom identifizieren sollte. Aus dieser Liste wurden 
171 Peptide mittels IFNγ ELISpot Assays auf ihre Immunogenität hin untersucht und nachfolgend 
die HLA-Restriktion stark immunogener Peptide mittels Durchflusszytometrie verifiziert. Von den 
untersuchten Peptiden waren 29 immunogen; sieben davon waren dominante Epitope. Für alle 
dominanten Epitope konnte die HLA-A*01-Restriktion bestätigt und reaktive CD8+ T-Zellen in 
gesunden Spendern identifiziert werden. 
Im Gegensatz dazu wurden im zweiten Projekt potenzielle HCMV-Epitope als HLA-Liganden aus mit 
Virusmutanten infizierten Zelllinien isoliert und danach mittels Massenspektrometrie sequenziert. 
Von den 181 Liganden konnten 50 (30%) als Epitope charakterisiert werden. Für alle 13 dominanten 
Epitope konnte nachfolgend die vorhergesagte HLA-Restriktion bestätigt werden. Die Infektion von 
zwei weiteren Zelllinien erlaubte die Isolation hunderter neuer Peptide, die einer 
Immunogenitätstestung unterzogen werden können. Da die HLA-Liganden aus über 100 
verschiedenen Proteinen stammen, eignet sich diese Methode hervorragend für eine umfangreiche 
Analyse der Epitope über das gesamte Proteom hinweg. 
Für beide Viren konnten damit neue, stark immunogene Epitope identifiziert werden, die in Zukunft 
für Antigen-spezifische Immuntherapien Verwendung finden können. 
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Abbreviations 
aAPC Artificial antigen presenting cell 
APC    Allophycocyanin 
APC Antigen presenting cell 
BAC Bacterial artificial chromosome 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CDR Complementarity determining region 
CNX Calnexin 
CRT Calreticulin 
CTL Cytotoxic T cell 
DC Dendritic cells 
DMSO Dimethyl sulfoxide 
DN double-negative 
DRiPs Defective ribosomal products 
DTT Dithiothreitol 
EBV Epstein-Barr virus 
EDTA Ethylendiaminetetraacetic acid 
ELISpot Enzyme-linked immunospot assay 
ER Endoplasmic reticulum 
ERAP ER aminopeptidase 
f.c.  Final concentration 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
GM-CSF Granulocyte macrophage colony stimulating factor 
HCMV Human cytomegalovirus 
HLA Human leukocyte antigen 
HLA-I HLA class I 
HLA-II HLA class II 
h.p.i. Hours post infection 
HSA Human serum albumin 
ICS Intracellular cytokine staining 
Abbreviations 83 
IE Immediate-early 
IFN Interferon 
IL Interleukin 
IM Infectious mononucleosis 
ITAM Immunoreceptor tyrosine-based activation motif 
LC-MS/MS Liquid chromatography-coupled tandem-mass spectrometry 
LB-Amp/Cam Lysogeny broth with ampicillin and chloramphenicol 
MACS Magnetic activated cell sorting 
MHC Major histocompatibility complex 
MIEP Major immediate-early promoter 
MOI Multiplicity of infection 
MS Mass spectrometry 
NK cell Natural killer cell 
OD Optical density 
ORF Open reading frame 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline 
PE R-Phycoerythrin 
Pen/Strep  Penicillin/Streptomycin 
PerCP Peridinin chlorophyll protein 
PLC Peptide loading complex 
PMSF Phenylmethylsulfonyl fluoride 
pp Phosphoprotein 
PSM Peptide spectrum matches 
RT Room temperature 
SFC Spot forming cells 
TAA Tumor-associated antigen 
TAP Transporter associated with antigen processing 
TBS Tris-buffered saline 
TCM T cell medium 
TCR T cell receptor 
TGF Transforming growth factor 
TH cell T helper cell 
TNF Tumor necrosis factor 
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Treg Regulatory T cell 
Tris Tris(hydroxymethyl)aminomethane 
UL Unique long 
US Unique short 
VCA Viral capsid antigen 
WT Wild type 
β2m β2-microglobulin 
β-Me β-Mercaptoethanol 
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Supplemental Table 1: HLA-A*01:01 epitope prediction from the EBV proteome for 9mers. 
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 3.4 
score 
Immunoge-
nicity testing 
Internal 
No. 
P03225 BDLF2 402-410 LTDRSFPAY 85.0 7 yes 151025 
P03188 GB 131-139 ETDQMDTIY 80.0 7 yes 140542 
P03208 BILF1 258-266 CTESLVARY 80.0 8 yes 151186 
P03186 LTP 2723-2731 ASEQGPIVY 77.5 23 yes 151068 
P03196 GN 43-51 LTEAQDQFY 77.5 8 yes 151074 
P03233 UL25 548-556 ASDDYDRLY 77.5 10 yes 150081 
P03182 EAR 42-50 PEDTVVLRY 75.0 1755 yes 164211 
P03190 RIR1 149-157 ESDMEVFDY 75.0 8 yes 151054 
P03213 PORTL 220-228 RSDEYVAYY 75.0 7 yes 151087 
P03233 UL25 375-383 ALEALMLVY 75.0 32 yes 150073 
P13288 KR2 295-303 RLDLQSLGY 75.0 18 yes 151016 
P30117 BKRF4 47-55 VSDTDESDY 75.0 12 yes 151092 
P03186 LTP 1062-1070 EWDYRELLY 72.5 3647 yes 154015 
P03190 RIR1 604-612 CSDAFYPFY 72.5 6 yes 151055 
P12978 EBNA2 112-120 PLDRDPLGY 72.5 25 yes 151023 
P25939 TRM1 746-754 PPDGLYLTY 72.5 6421 yes 151242 
P25939 TRM1 771-779 FKDLYALLY 72.5 32 yes 154197 
P30117 BKRF4 86-94 PSDSDESDY 72.5 17 yes 151090 
P03179 MTP 382-390 ALDTVRYDY 70.0 77 yes 110142 
P03184 UL32 115-123 FEDYALLCY 70.0 622 yes 151088 
P03184 UL32 243-251 PGDVGRGLY 70.0 3311 yes 151094 
P03193 PRIM 261-269 SADLVRYVY 70.0 87 yes 
150104 
154209 
P03198 DPOL 96-104 VYDILETVY 70.0 6003 yes 140513 
P03206 BZLF1 25-33 AFDQATRVY 70.0 11562 yes 80090  
P03206 BZLF1 172-180 DSELEIKRY 70.0 3423 yes 8138 
P03226 MCP 985-993 RPEQLFAEY 70.0 15890 yes 150085 
P25939 TRM1 376-384 VAELSELLY 70.0 25 yes 154192 
Q8AZJ5 LF1 421-429 NLDAGRIFY 70.0 21 yes 154206 
P03177 KITH 465-473 VNDAYHAVY 67.5 1135 yes 151029 
P03179 MTP 175-183 LFDNALRKY 67.5 12537 yes 110146 
P03184 UL32 167-175 AIDIQLHFY 67.5 17 yes 154055 
P03186 LTP 714-722 TLDTARSQY 67.5 384 yes 154016 
P03186 LTP 2024-2032 PCDPLNPAY 67.5 394 yes 151072 
P03188 GB 148-156 TKDGLTRVY 67.5 14816 yes 140543 
P03188 GB 656-664 DLEGIFREY 67.5 9058 yes 151014 
P03190 RIR1 654-662 LPEALRQRY 67.5 14986 yes 151056 
P03198 DPOL 388-396 ILDRARHIY 67.5 114 yes 141412 
P03198 DPOL 879-887 VIDILNQAY 67.5 23 yes 141415 
P03226 MCP 706-714 VGDESVGQY 67.5 1940 yes 154053 
P0CK56 UL92 171-179 VVDVVLSLY 67.5 18 yes 151181 
P13288 KR2 103-111 LYDSVTELY 67.5 266 yes 151018 
Q2MG95 
 
79-87 PDEYWYLLY 67.5 1730 yes 154279 
Q9QCF2 
 
28-36 STRACVLLY 67.5 542 yes 154210 
P03179 MTP 426-434 ALELFSALY 65.0 69 yes 110279 
P03179 MTP 650-658 PLDLPLADY 65.0 528 yes 110281 
P03186 LTP 2337-2345 LRDFVKQAY 65.0 8949 no 
 
P03186 LTP 3140-3148 DLERLKFLY 65.0 1084 no 
 
P03187 VP19 151-159 LTRMANLLY 65.0 44 no 
 
P03190 RIR1 197-205 EWDVTQALY 65.0 4871 no 
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Supplemental Table 1 continued (1/1)     
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 3.4 
score 
Immunoge-
nicity testing 
Internal 
No. 
P03191 EAD 192-200 NPDLYVTTY 65.0 9316 yes 110283 
P03193 PRIM 276-284 FNEGTFKRY 65.0 11418 no 
 
P03203 EBNA4 328-336 TNEEIDLAY 65.0 1282 yes 110285 
P03207 BRRF1 165-173 IADVCRSGY 65.0 741 no 
 
P03213 PORTL 30-38 LFEILQGKY 65.0 9797 no 
 
P03213 PORTL 388-396 GLEKERELY 65.0 1926 no 
 
P03213 PORTL 564-572 YIEDLGRKY 65.0 1538 no 
 
P03217 AN 238-246 EFDPIYPSY 65.0 10204 no 
 
P03227 DNBI 519-527 PDDEPRYTY 65.0 11636 yes 111205 
P03227 DNBI 588-596 YKDLVKSCY 65.0 8712 yes 111206 
P03231 GH 328-336 LKDIIGICY 65.0 7743 no 
 
P03231 GH 650-658 DFDNLHVHY 65.0 7092 no 
 
P13288 KR2 55-63 IDDMTETLY 65.0 1306 no 
 
P13288 KR2 327-335 GFDRSDPLY 65.0 4748 no 
 
P30118; 
Q8AZJ7 
YBL2 422-430 EADATWWLY 65.0 10 no 
 
P03179 MTP 105-113 ALEASGNNY 62.5 2091 no 
 
P03186 LTP 155-163 LAEVLHGSY 62.5 305 no 
 
P03186 LTP 1605-1613 DLEAPYAEY 62.5 7296 no 
 
P03188 GB 134-142 QMDTIYQCY 62.5 53 no 
 
P03190 RIR1 322-330 YGEEFEREY 62.5 7433 no 
 
P03198 DPOL 282-290 REDSSWPSY 62.5 11168 no 
 
P03200 GP350 143-151 HAEMQNPVY 62.5 159 yes 110375 
P03204 EBNA6 975-983 PKDAKQTDY 62.5 13850 no 
 
P03208 BILF1 24-32 TEDACTKSY 62.5 14830 no 
 
P03211 EBNA1 409-417 VGEADYFEY 62.5 9416 no 
 
P03212 GL 41-49 ALENISDIY 62.5 665 no 
 
P03214; 
Q777D7 
HELI 496-504 GHEQPEYVY 62.5 19300 no 
 
P03215 GM 86-94 IADCVAFIY 62.5 55 no 
 
P03222 UL17 84-92 CDEGLPELY 62.5 2656 no 
 
P03226 MCP 51-59 KFEVLLGVY 62.5 14929 no 
 
P03226 MCP 380-388 AVESLQKMY 62.5 3703 no 
 
P03226 MCP 503-511 VDEFYDNKY 62.5 11034 no 
 
P03231 GH 125-133 PLEKQLFYY 62.5 206 no 
 
P0CAP6 RIR2 191-199 HTRAASLLY 62.5 178 no 
 
P13285 LMP2 104-112 RDDSSQHIY 62.5 2301 no 
 
P13288 KR2 130-138 GQDKALVDY 62.5 5337 no 
 
Q04360 ICP27 381-389 VVETLSSSY 62.5 285 yes 81085 
 
 
Supplemental Table 2: HLA-A*01:01 epitope prediction from the EBV proteome for 10mers. 
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 
3.4 score 
Immunoge-
nicity testing 
Internal 
No. 
P03214; 
Q777D7 
HELI 654-663 TTENYTLLGY 87.2 9 yes 
150099, 
161099 
P25939 TRM1 755-764 DSDRPLILLY 84.6 58 yes 154202 
P03186 LTP 2540-2549 PTDVLNPSFY 82.1 15 yes 151071 
P03208 BILF1 23-32 ATEDACTKSY 79.5 161 yes 154194 
P03184 UL32 472-481 VCDSLITLVY 76.9 83 yes 154056 
P03186 LTP 314-323 TSDSFPAARY 76.9 14 yes 151067 
P03227 DNBI 153-162 ITEAFKERLY 76.9 65 yes 110154 
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Supplemental Table 2 continued (1/1)     
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 
3.4 score 
Immunoge-
nicity testing 
Internal 
No. 
P0C725 LF2 304-313 ITELEYNNTY 76.9 91 yes 151077 
Q2MG95 
 
78-87 VPDEYWYLLY 76.9 534 yes 150221 
P03186 LTP 2034-2043 SADTQEPLNY 74.4 162 yes 151073 
P03190 RIR1 149-158 ESDMEVFDYY 74.4 13 yes 151057 
P03198 DPOL 262-271 HRDSYAELEY 74.4 1300 yes 141416 
P03198 DPOL 957-966 KTEMAEDPAY 74.4 195 yes 141422 
P03208 BILF1 258-267 CTESLVARYY 74.4 18 yes 154195 
P03179 MTP 1073-1082 VRDNTFLDKY 71.8 2244 yes 110180 
P03182 EAR 41-50 SPEDTVVLRY 71.8 10525 yes 151022 
P03184 UL32 114-123 FFEDYALLCY 71.8 104 yes 150188 
P03188 GB 635-644 NIDFASLELY 71.8 40 yes 150044 
P03189 V120 318-327 LLEPSGALFY 71.8 40 yes 151190 
P03191 EAD 202-211 SGEACLTLDY 71.8 4275 yes 90301 
P03198 DPOL 445-454 CRDKLSLSDY 71.8 3568 yes 141427 
P03205 GP42 176-185 SLDGGTFKVY 71.8 474 yes 140510 
P03225 BDLF2 228-237 GRDFGVPLSY 71.8 10212 yes 151028 
P30118 YBL2 490-499 AADLGLTWAY 71.8 328 yes 154207 
P03180 IL10H 151-160 MSEFDIFINY 69.2 43 yes 140512 
P03184 UL32 115-124 FEDYALLCYY 69.2 607 yes 150213 
P03213 PORTL 118-127 VRDLLTTNIY 69.2 5440 yes 150103 
P03215 GM 71-80 YLEPPEMFVY 69.2 95 yes 150035 
P03219 TRM3 357-366 SADQATSFLY 69.2 111 yes 154205 
P03220 UL95 10-19 PDDPMLARRY 69.2 10639 yes 151185 
P03222 UL17 83-92 YCDEGLPELY 69.2 51 yes 154054 
P03226 MCP 804-813 HADVLEKIFY 69.2 280 yes 151081 
P03226 MCP 1216-1225 NQEVAEGLIY 69.2 4530 yes 150072 
P03227 DNBI 292-301 SHETPASLNY 69.2 12336 yes 150091 
P03231 GH 523-532 DRDAWHLPAY 69.2 6147 yes 150025 
P0C725 LF2 264-273 LDDVIIAFRY 69.2 2974 yes 151078 
P0CK51 TEG2 48-57 CGETNEGLEY 69.2 917 yes 150094 
P13285 LMP2 484-493 ESEERPPTPY 69.2 55 yes 
70020, 
110293 
P03179 MTP 531-540 ACDMAGCQHY 66.7 459 yes 111230 
P03186 LTP 714-723 TLDTARSQYY 66.7 38 no 
 
P03186 LTP 2551-2560 HEDPPLPVGY 66.7 11460 no 
 
P03189 V120 911-920 RVEHALELGY 66.7 958 no 
 
P03190 RIR1 52-61 YLEVFSDKFY 66.7 87 yes 154007 
P03191 EAD 105-114 AVEQASLQFY 66.7 132 yes 110316 
P03198 DPOL 342-351 CEDIEGVEVY 66.7 8496 no 
 
P03213 PORTL 249-258 TFDSPVQRLY 66.7 787 no 
 
P03213 PORTL 502-511 VVDNQGQRLY 66.7 111 no 
 
P03224 BDLF3 171-180 PDERQPSLSY 66.7 15041 no 
 
P03226 MCP 502-511 IVDEFYDNKY 66.7 148 no 
 
P03227 DNBI 518-527 RPDDEPRYTY 66.7 13837 yes 110278 
P03227 DNBI 767-776 FPDTKLSSLY 66.7 1897 yes 110282 
P03231 GH 204-213 LPDLRGPFSY 66.7 11991 no 
 
P0CAP6 RIR2 256-265 LGDIGQAPLY 66.7 1114 no 
 
P0CK51 TEG2 17-26 DVDGGIINLY 66.7 325 no 
 
P0CK58 BALF1 63-72 PDDKVAESSY 66.7 13206 no 
 
P12978 EBNA2 451-460 PADLDESWDY 66.7 461 no 
 
P13288 KR2 54-63 NIDDMTETLY 66.7 42 no 
 
P13288 KR2 95-104 HADNATVKLY 66.7 224 no 
 
P13288 KR2 312-321 LADSTHKIPY 66.7 226 no 
 
Q04360 ICP27 416-425 HDEVEFLGHY 66.7 4562 yes 110317 
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Supplemental Table 3: HLA-A*01:01 epitope prediction from the EBV proteome for 11mers. 
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 3.4 
score 
Immunoge-
nicity testing 
Internal 
No. 
P03186 LTP 1603-1613 NTDLEAPYAEY 87.2 9 yes 161074 
P03198 DPOL 903-913 STELSRKLSAY 84.6 39 yes 141434 
P03195 DUT 198-208 FSDQTVFLNKY 82.1 6 yes 151030 
P03207 BRRF1 143-153 GSDYTAVSLQY 82.1 11 yes 150097 
P03179 MTP 1237-1247 GTDAWRFAMNY 79.5 8 yes 151053 
P03188 GB 584-594 MTEVCQATSQY 79.5 16 yes 151015 
P0CK53 UL16 313-323 FSDLYSRAMLY 79.5 5 yes 150086 
P25939 TRM1 443-453 ATERLFCGGVY 76.9 16 yes 154203 
P25939 TRM1 527-537 LSDALKRKEQY 76.9 36 yes 154204 
P30118; 
Q8AZJ7 
YBL2 186-196 HSESPGQLDVY 76.9 46 yes 150276 
P03190 RIR1 195-205 SSEWDVTQALY 74.4 26 yes 151062 
P03196 GN 43-53 LTEAQDQFYSY 74.4 10 no (length variant) 
P03226 MCP 525-535 PTEDFLHPSNY 74.4 21 yes 150083 
P03231 GH 62-72 TEDLASMLNRY 74.4 3550 yes 151020 
P03231 GH 469-479 GTESGLFSPCY 74.4 39 yes 150023 
P12978 EBNA2 464-474 TTESPSSDEDY 74.4 33 yes 151024 
P13285 LMP2 410-420 LTEWGSGNRTY 74.4 40 yes 110190 
Q8AZJ7; 
Q04343 
  
674-684; 
152-162 
ATEHGLSPTAY 74.4 15 yes 151192 
P03184 UL32 139-149 GMDFLHILIKY 71.8 32 yes 151182 
P03186 LTP 1060-1070 SIEWDYRELLY 71.8 329 yes 150063 
P03186 LTP 3138-3148 IADLERLKFLY 71.8 33 yes 151075 
P03214; 
Q777D7 
HELI 314-324 GLELSPDILAY 71.8 215 yes 150100 
P03217 AN 236-246 KSEFDPIYPSY 71.8 213 yes 150027 
P03224 BDLF3 170-180 VPDERQPSLSY 71.8 5013 yes 154193 
P03188 GB 654-664 VFDLEGIFREY 69.2 5421 yes 151017 
P03192 BMRF2 238-248 HAEVFFGLSRY 69.2 146 yes 141405 
P03200 GP350 804-814 GGDSTTPRPRY 69.2 3857 yes 110185 
P03204 EBNA6 41-51 ASERLVPEESY 69.2 111 yes 110189 
P03204 EBNA6 382-392 ELESSDDELPY 69.2 99 yes 110184 
P03206 BZLF1 8-18 SEDVKFTPDPY 69.2 5048 yes 151026 
P03214; 
Q777D7 
HELI 
648-658; 
648-658 
LLDYASTTENY 69.2 66 yes 150101 
P03214; 
Q777D7 
HELI 
653-663; 
653-663 
STTENYTLLGY 69.2 45 yes 150102 
P03217 AN 78-88 SKDGPSLKSIY 69.2 13423 yes 150028 
P03226 MCP 789-799 DHDFRLHLGPY 69.2 7887 yes 150082 
P03227 DNBI 691-701 DLDAALQGRVY 69.2 1424 yes 150092 
P03228 BARF1 204-214 KNDKEEAHGVY 69.2 9374 yes 141409 
P0C725 LF2 263-273 LLDDVIIAFRY 69.2 14 yes 150087 
P13288 KR2 72-82 RCDHLPITCEY 69.2 250 yes 150026 
P30119 BTRF1 250-260 NPDLLPLQHLY 69.2 1055 yes 150098 
Q04360 ICP27 415-425 RHDEVEFLGHY 69.2 7226 yes 71069 
P03186 LTP 3098-3108 STAAPEQDLRY 66.7 61 no 
 
P03188 GB 247-257 RADSFHVRTNY 66.7 436 no 
 
P03190 RIR1 312-322 PKDAGDLERLY 66.7 8638 no 
 
P03190 RIR1 715-725 SYELGLKTIMY 66.7 10831 yes 151064 
P03206 BZLF1 170-180 ECDSELEIKRY 66.7 3253 yes 110313 
P03214; 
Q777D7 
HELI 442-452 EQDEERVKVTY 66.7 3882 no 
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Supplemental Table 3 continued (1/1)     
UniProt 
ID 
Antigen Position Sequence SYFPEITHI 
score 
NetMHC 3.4 
score 
Immunoge-
nicity testing 
Internal 
No. 
P03217 AN 7-17 LEDPMEEMTSY 66.7 4458 no 
 
P03220 UL95 9-19 MPDDPMLARRY 66.7 5661 no 
 
P03226 MCP 539-549 RLELHPLYDIY 66.7 498 no 
 
P03226 MCP 804-814 HADVLEKIFYY 66.7 60 no 
 
P03231 GH 26-36 HLDIEGHASHY 66.7 36 no 
 
P03231 GH 648-658 YFDFDNLHVHY 66.7 413 no 
 
P0C725 LF2 282-292 RWDGESTDIRY 66.7 9714 no 
 
P12978 EBNA2 273-283 SPEPRSPTVFY 66.7 15688 no 
 
P03177 KITH 156-166 GADSTSRSFMY 64.1 82 yes 151052 
 
 
Supplemental Table 4: HLA-A*01:01 epitope prediction from the EBV proteome for 12mers. 
UniProt 
ID 
Antigen Position Sequence 
SYFPEITHI 
score 
NetMHC 3.4 
score 
Immunoge-
nicity testing 
Internal 
No. 
P03184 UL32 185-196 SSDMIRNANLGY 90.2 7 yes 161065 
P03203 EBNA4 809-820 TSDKIVQAPIFY 80.5 7 yes 164259 
P03214; 
Q777D7 
HELI 640-651 SDEPLLHGLLDY 80.5 7503 no  
P03231 GH 555-566 SSDREVRGSALY 80.5 14 yes 161086 
P25939 TRM1 373-384 PPEVAELSELLY 80.5 11878 yes 195129 
P25939 TRM1 753-764 TYDSDRPLILLY 80.5 1184 no  
Q8AZJ5 LF1 418-429 RSDNLDAGRIFY 80.5 8 yes 161097 
P03187 VP19 329-340 ATDGWRRSAFNY 78.1 14 yes 161066 
P03217 AN 94-105 ATDEQRTVLCSY 78.1 7 yes 161080 
P03231 GH 61-72 VTEDLASMLNRY 78.1 9 yes 194241 
P03186 LTP 2214-2225 LGDLLSDSVLTY 75.6 185 no  
P03187 VP19 259-270 PADARLYVALTY 75.6 40 yes 194242 
P03188 GB 131-142 ETDQMDTIYQCY 75.6 8 yes 
not pro-
ducible 
P03188 GB 584-595 MTEVCQATSQYY 75.6 9 yes 195131 
P03193 PRIM 458-469 LPDTCLTRALSY 75.6 3427 no  
P03230 LMP1 373-384 DDDPHGPVQLSY 75.6 3541 no  
P03233 UL25 551-562 DYDRLYFLTLGY 75.6 2186 no  
P30118; 
Q8AZJ7 
YBL2 468-479 TSDTRRALGGLY 75.6 7 yes 161101 
Q04360 ICP27 359-370 TRDYNFVKQLFY 75.6 1504 no  
P03185 UL34 236-247 FSEAETEDEASY 73.2 11 yes 161067 
P03186 LTP 766-777 VPEADALSMIDY 73.2 13814 no  
P0CK53 UL16 24-35 LSDASTPQMKVY 73.2 16 yes 195133 
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Supplemental Table 5: HLA-A*01:01 epitope prediction from the EBV proteome for 13mers. 
UniProt 
ID 
Antigen Position Sequence 
SYFPEITHI 
score 
NetMHC 
3.4 score 
Immunoge-
nicity testing 
Internal 
No. 
P03214; 
Q777D7 
HELI 639-651 TSDEPLLHGLLDY 85.4 8 yes 
161082, 
161100 
P13288 KR2 295-307 RLDLQSLGYSLLY 82.9 10 yes 161091 
P0CK56 UL92 167-179 SSEKVVDVVLSLY 80.5 25 yes 161089 
P25939 TRM1 622-634 SSEHLHALTHSLY 80.5 11 yes 195132 
P03207 BRRF1 278-290 VTDAITLPDCAEY 78.1 7 yes 195134 
P14347 BFRF2 44-56 LLDLGLACLDLSY 78.1 16 yes 161095 
P03179 MTP 101-113 GTESALEASGNNY 75.6 63 yes 164210 
P03184 UL32 185-197 SSDMIRNANLGYY 75.6 6 yes 195135 
P03186 LTP 241-253 ETEDPRIFMLEHY 75.6 38 yes 195136 
P03186 LTP 1058-1070 YTSIEWDYRELLY 75.6 7 yes 194250 
P03186 LTP 2020-2032 ETESPCDPLNPAY 75.6 44 yes 194251 
P03189 V120 521-533 SSELLRSLLWVRY 75.6 19 yes 161072 
P03189 V120 908-920 LNERVEHALELGY 75.6 4999 yes 161075 
P03200 GP350 312-324 SQDMPTNTTDITY 75.6 396 yes 164257 
P03200 GP350 319-331 TTDITYVGDNATY 75.6 9 yes 164258 
P03204 EBNA6 380-392 DVELESSDDELPY 75.6 376 yes 161078 
P03214; 
Q777D7 
HELI 440-452 GTEQDEERVKVTY 75.6 125 no  
P03219 TRM3 598-610 TNEKSKAFERLIY 75.6 10517 no  
P03220 UL95 157-169 PEDPLPWMWALFY 75.6 429 no  
P03226 MCP 829-841 GVDFQHVAQTLAY 75.6 16 yes 161084 
P03226 MCP 1089-1101 HHEMASIDTGLSY 75.6 7399 no  
P03227 DNBI 206-218 NSDLSRCMHEALY 75.6 7 yes 194252 
P03230 LMP1 44-56 MSDWTGGALLVLY 75.6 6 yes 161085 
P03230 LMP1 372-384 DDDDPHGPVQLSY 75.6 4664 no  
P0CK56 UL92 15-27 GTDEPNPRHLCSY 75.6 11 yes 161093 
P03184 UL32 239-251 SQDVPGDVGRGLY 70.7 1305 no  
P03192 BMRF2 36-48 SLEIFSPWQTHVY 70.7 186 no  
P03195 DUT 99-111 PSELKIHLAAFRY 70.7 27 no  
P03198 DPOL 931-943 NEELPQIHDRIQY 70.7 17640 no  
P03214; 
Q777D7 
HELI 142-154 ALEELQRRDLAKY 70.7 1689 no  
P03226 MCP 702-714 GSDVVGDESVGQY 70.7 18 no  
P25939 TRM1 574-586 YWELARMRNHFLY 70.7 4135 no  
P25939 TRM1 683-695 PSDWIETSFNSFY 70.7 7 no  
P25939 TRM1 752-764 LTYDSDRPLILLY 70.7 69 no  
Q04360 ICP27 308-320 LEETIFWLQEITY 70.7 8341 no  
P03179 MTP 1070-1082 FREVRDNTFLDKY 68.3 11289 no  
P03210 BRRF2 262-274 YLEAFRNSDNHFY 68.3 17 no  
P03214; 
Q777D7 
HELI 162-174 AAEFRRTKPRGLY 68.3 2188 no  
P03179 MTP 105-117 ALEASGNNYVYAY 68.3 268 yes 110318 
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Supplemental Table 6: HCMV-derived HLA ligands extracted from HF-99/7 cells. Abbreviations: n.a., not 
annotated; ND, not determined. 
Source Position 
SYFPEITHI 
score [% of 
maximum 
score] 
NetMHC 
score 
[nM] 
NetMHC 
rank [%] 
Sequence 
Predicted 
HLA type 
Temporal protein 
class according to 
Weekes et al.* 
UL31 309-317 66.67 5775 0.60 AAPFGRVSV C*01:02 5 
UL104 506-514 66.67 2666 0.15 AAPFRPLAV C*01:02 5 
UL56 365-373 76.67 2666 0.60 AAPNRIIDL C*01:02 3 
UL105 716-723 n.a. 1815 0.70 ADPFFLKY A*01:01 3 
UL47 400-408 70.97 41 0.17 ALIQPASQK A*03:01 5 
US20 249-259 75.00 788 1.70 ALLSDADWLQK A*03:01 2 
UL56 707-715 70.97 16 0.03 ALYNETFGK A*03:01 3 
UL69 268-276 65.79 1676 0.25 APYPADLKV B*51:01 3 
UL35 453-462 41.94 179 0.70 ASRQTGLTPK A*03:01 5 
UL86 1345-1354 56.41 155 0.12 ATSETHFGNY A*01:01 5 
UL98 337-345 
34.88/ 
57.89 
792/ 
15146 
1.10/ 
3.50 
DAALFRATL 
B*08:01 / 
B*51:01 
3 
UL84 406-413 71.05 28372 13.00 DAPLPYFV B*51:01 5 
UL25 66-73 83.87 33812 18.00 DAPSSFEL C*01:02 5 
TRL4 156-163 61.29 38137 27.00 DAPVAILM C*01:02 ND 
UL56 503-511 
44.19/  
60.53 
235/  
30278 
0.40/  
3.50 
DARSRIHNV 
B*08:01 / 
B*51:01 
3 
UL102 423-430 63.16 26133 10.00 DATFTVHV B*51:01 3 
UL2 16-24 73.68 2906 0.40 DAYPSFGTL B*51:01 ND 
UL98 73-81 46.51 79 0.12 DFMTRVAAL B*08:01 3 
UL16 112-119 57.89 38413 32.00 DGLKMRTV B*51:01 2 
UL115 79-86 57.89 33866 21.00 DGPLSQLI B*51:01 5 
UL56 286-294 
58.14/ 
76.67 
563/ 
13663 
0.80/ 
 2.50 
DIPERIYSL 
B*08:01 / 
C*01:02 
3 
UL105 360-369 82.05 90 0.07 DLDFGDLLKY A*01:01 3 
UL45 592-600 50.00 18307 4.50 DMPVQRLTV C*01:02 5 
US24 485-492 63.16 14490 3.50 DPFPLKSL B*51:01 1 
UL47 968-976 65.79 10670 2.00 DPPAGSTSV B*51:01 5 
US22 57-65 65.79 11633 2.50 DPPALRTYV B*51:01 3 
UL77 296-304 76.32 5129 0.80 DPPDSVATV B*51:01 5 
UL70 306-314 46.51 24 0.03 DVMQKYFSL B*08:01 3 
UL34 243-251 68.42 1797 0.25 EAYRMLFQI B*51:01 3 
UL84 500-507 62.50 154 0.25 FISSKHTL B*08:01 5 
UL14 66-74 50.00 385 0.04 FPAHDWPEV B*51:01 2 
UL95 336-343 63.16 2781 0.40 FPALLPKL B*51:01 3 
UL75 540-549 n.a. 542 0.06 FPDATVPATV B*51:01 5 
UL105 111-118 68.42 186 0.02 FPFRALLV B*51:01 3 
UL38 156-164 63.16 283 0.03 FPVEVRSHV B*51:01 2 
UL73 130-138 
52.50/ 
56.25 
115/ 
6151 
0.09/ 
2.50 
FTATTTKGY 
A*01:01 / 
C*07:01 
5 
UL56 284-292 77.50 17 0.01 FTDIPERIY A*01:01 3 
UL130 196-204 72.50 14 0.01 FTEANNQTY A*01:01 5 
UL148 189-199 41.03 1104 0.50 FVAGHGETDFY A*01:01 5 
UL36 82-91 61.54 132 0.10 FVEGPGFMRY A*01:01 2 
UL77 228-236 70.97 39 0.15 GLYTQPRWK A*03:01 5 
US34 92-101 76.92 21 0.01 GSDALPAGLY A*01:01 ND 
UL11 142-150 70.97 99 0.40 GTLPTTTTK A*03:01 ND 
UL25 580-588 77.42 21 0.07 GVSSVTLLK A*03:01 5 
UL83 519-528 67.74 81 0.40 GVWQPAAQPK A*03:01 5 
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Supplemental Table 6 continued (1/3)     
Source Position 
SYFPEITHI 
score [% of 
maximum 
score] 
NetMHC 
score 
[nM] 
NetMHC 
rank [%] 
Sequence 
Predicted 
HLA type 
Temporal protein 
class according to 
Weekes et al.* 
UL77 596-604 
20.93/ 
50.00 
478/  
14622 
0.7/ 
3.5 
HGLGRLLSV 
B*08:01 / 
B*51:01 
5 
UL40 170-178 74.42 15 0.01 HLKLRPATF B*08:01 3 
UL117 325-334 70.97 94 0.40 HTPQAVATFK A*03:01 2 
UL29 
352-362/ 
674-684 
58.97 464 0.25 HTSPAYDVSEY A*01:01 1 
US28 158-166 63.16 571 0.07 IAIPHFMVV B*51:01 4 
UL34 210-217 50.00 518 0.70 IGHLRHYL B*08:01 3 
UL9 143-152 45.16 88 0.40 ILLYPPTSTY A*03:01 ND 
UL51 125-132 87.50 149 0.25 ILREKTQL B*08:01 5 
US23 65-73 57.89 106 0.01 IPHNWFLQV B*51:01 1 
UL71 330-338 57.89 443 0.05 IPPPQIPFV B*51:01 3 
IRS1 92-99 67.50 1130 1.40 IPVERQAL B*08:01 3 
UL112/ 
UL113 
124-134 69.23 419 0.25 ISENGNLQVTY A*01:01 5 
UL75 601-609 
50.00/  
20.00 
1920/ 
2829 
0.17/ 
 0.30 
ISYPVSTTV 
B*51:01 / 
C*01:02 
5 
US28 122-130 75.00 28 0.02 ITEIALDRY A*01:01 4 
UL123 184-192 80.65 59 0.25 KLGGALQAK A*03:01 1 
US33A 13-21 80.65 24 0.08 KLGYRPHAK A*03:01 ND 
UL78 335-343 87.50 226 0.08 KRAMYSVEL C*07:01 2 
UL148 180-188 86.67 1326 0.04 LAPDLVSSL C*01:02 5 
UL56 154-162 70.00 4561 0.40 LAPEAGLEV C*01:02 3 
UL105 361-369 50.00 12020 4.50 LDFGDLLKY A*01:01 3 
UL97 672-682 48.72 157 0.12 LLATSDGLYLY A*01:01 3 
IRS1/ 
TRS1 
464-474 66.67 263 0.17 LLDELGAVFGY A*01:01 3/4 
UL56 87-95 67.50 27 0.02 LLDRALMAY A*01:01 3 
UL70 304-311 n.a. 1352 0.60 LLDVMQKY A*01:01 3 
UL122 382-389 57.89 3284 0.50 LPFTIPSM B*51:01 ND 
UL34 180-188 62.79 53 0.08 LPHERHREL B*08:01 3 
UL83 116-123 68.42 1710 0.25 LPLKMLNI B*51:01 5 
UL102 62-70 65.79 1995 0.30 LPPAEVRAV B*51:01 3 
UL77 308-315 60.53 6960 1.10 LPQLLPRL B*51:01 5 
UL56 605-613 57.89 367 0.04 LPVESLPLL B*51:01 3 
UL48 1322-1331 n.a. 304 0.03 LPYLSAERTV B*51:01 5 
UL26 61-69 
55.81/  
63.16 
44/  
110 
0.06/ 
0.01 
LPYPRGYTL 
B*08:01 / 
B*51:01  
5 
US22 75-83 68.75 86 0.03 LRNPANWFL C*07:01 3 
UL36 256-264 67.50 23 0.02 LVDTFGVVY A*01:01 2 
TRL4 163-170 52.63 10069 1.80 MARTAISV B*51:01 ND 
UL54 801-811 75.00 148 0.60 MLLDKEQMALK A*03:01 2 
UL20 164-172 55.81 10 0.01 MLLPRQYTL B*08:01 ND 
UL148 1-8 57.5 39 0.05 MLRLLFTL B*08:01 5 
UL117 323-330 60.53 3697 0.60 MPHTPQAV B*51:01 2 
UL36 464-472 60.53 603 0.07 MPPLTPPHV B*51:01 2 
UL122 449-457 55.26 310 0.03 MPVTHPPEV B*51:01 ND 
UL54 815-823 57.89 3086 0.50 NAFYGFTGV B*51:01 2 
UL27 393-400 63.16 20334 6.00 NAVLALRI B*51:01 1 
US23 553-561 63.16 9914 1.80 NAYRTEAEV B*51:01 1 
UL145 20-27 25.00 1640 2.00 NFKHHNAV B*08:01 ND 
UL44 216-223 40.00 476 0.70 NMRINVQL B*08:01 5 
UL38 207-214 47.50 1332 1.70 NSYVRAIL B*08:01 2 
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Source Position 
SYFPEITHI 
score [% of 
maximum 
score] 
NetMHC 
score 
[nM] 
NetMHC 
rank [%] 
Sequence 
Predicted 
HLA type 
Temporal protein 
class according to 
Weekes et al.* 
UL55 657-665 
52.50/ 
68.75 
624/ 
3520 
0.40/ 
1.30 
NTDFRVLEL 
A*01:01 / 
C*07:01 
5 
UL55 657-666 87.18 9 0.01 NTDFRVLELY A*01:01 5 
UL44 26-34 55.81 207 0.30 QLRSVIRAL B*08:01 5 
US24 303-311 25.00 3188 1.10 QMDDPNHYV A*01:01 1 
US32 115-123 38.71 100 0.40 RAYHHRINR A*03:01 ND 
UL148 259-266 47.50 592 0.80 RGYVRYTL B*08:01 5 
UL80 698-706 87.10 11 0.01 RIFVAALNK A*03:01 3 
UL57 1044-1052 77.42 302 1.00 RLADVLIKR A*03:01 5 
UL54 564-572 77.42 96 0.40 RLAKIPLRR A*03:01 2 
US26 200-209 70.27 10769 1.70 RLHDNSISEL C*01:02 3 
UL150 524-532 74.19 169 0.60 RLLLPLSGY A*03:01 5 
UL51 96-105 77.42 20 0.06 RLNFVNAGQK A*03:01 5 
UL135 43-51 77.42 349 1.10 RLPGAASDK A*03:01 1 
UL27 541-549 83.33 281 0.01 RLPQFSSAL C*01:02 1 
UL44 6-15 78.38 5128 0.50 RLSEPPTLAL C*01:02 5 
UL52 557-566 48.39 53 0.25 RQAGVTGIYK A*03:01 5 
TRL9 104-113 58.06 290 0.90 RQGPGFLLEK A*03:01 ND 
UL70 368-376 
48.84/ 
53.12 
421/ 
2006 
0.60/ 
0.70 
RQLERINTL C*07:01 3 
UL36 51-60 58.06 40 0.15 RSALGPFVGK A*03:01 2 
UL36 49-60 n.a. 209 0.70 RSRSALGPFVGK A*03:01 2 
UL70 697-706 48.39 11 0.01 RSVRLPYMYK A*03:01 3 
UL69 569-578 87.18 15 0.01 RTDPATLTAY A*01:01 3 
UL79 237-245 77.42 30 0.10 RTFAGTLSR A*03:01 5 
UL56 302-310 70.97 1439 2.50 RTSEVIVKR A*03:01 3 
UL75 337-345 
52.50/ 
75.00 
288/ 
 8210 
0.20/ 
3.50 
RTVEMAFAY 
A*01:01 / 
C*07:01 
5 
UL84 3-11 70.97 2562 3.50 RVDPNLRNR A*03:01 5 
UL6 225-233 87.10 34 0.12 RVGNGTLSK A*03:01 ND 
UL57 790-798 70.97 108 0.50 RVKNRPIYR A*03:01 5 
US24 136-145 80.65 15 0.03 RVYAYDTREK A*03:01 1 
UL36 52-60 38.71 122 0.50 SALGPFVGK A*03:01 2 
UL89 237-245 64.52 109 0.50 SIGYVAHQK A*03:01 5 
UL70 313-321 67.50 28 0.03 SLDNFLHDY A*01:01 3 
UL148 282-290 67.50 116 0.09 SLDRFIVQY A*01:01 5 
UL45 502-510 61.29 59 0.25 SLFGRPVSR A*03:01 5 
U147A 2-10 67.44 30 0.04 SLFYRAVAL B*08:01 ND 
UL105 713-722 74.19 8 0.01 SLYADPFFLK A*03:01 3 
UL21A 4-12 57.89 875 0.12 SPVPQLTTV B*51:01 ND 
UL55 576-584 78.12 1770 0.60 SRPVVIFNF C*07:01 5 
UL32 764-772 53.33 20643 5.50 SSPMTTTST C*01:02 5 
UL70 490-498 
57.50/   
62.50 
24/   
5527 
0.02/   
2.50 
STSPETQFY 
A*01:01 / 
C*07:01 
3 
UL70 490-499 58.97 26 0.02 STSPETQFYY A*01:01 3 
UL32 771-780 70.97 69 0.30 STSQKPVLGK A*03:01 5 
UL128 127-135 70.00 3965 0.30 SVPYRWINL C*01:02 ND 
UL78 351-361 68.75 1577 3.00 SVRDVAEAVKK A*03:01 2 
UL70 698-706 67.74 15 0.03 SVRLPYMYK A*03:01 3 
UL122 113-121 77.42 59 0.25 SVSSAPLNK A*03:01 ND 
UL105 537-545 80.00 4896 0.50 TAPDSRETL C*01:02 3 
US14 150-158 90.00 2379 0.12 TAPIGISSL C*01:02 3 
UL44 246-253 n.a. 406 0.25 TEHDTLLY A*01:01 5 
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Source Position 
SYFPEITHI 
score [% of 
maximum 
score] 
NetMHC 
score 
[nM] 
NetMHC 
rank [%] 
Sequence 
Predicted 
HLA type 
Temporal protein 
class according to 
Weekes et al.* 
UL104 589-597 67.50 65 0.06 TLDPVPEAY A*01:01 5 
UL11 199-206 65.00 604 0.80 TPKTHVEL B*08:01 ND 
UL84 239-247 62.79 20 0.02 TPLLKRLPL B*08:01 5 
UL112/ 
UL113 
304-313 76.92 38 0.03 TSEAVAFLNY A*01:01 5 
UL86 1346-1354 72.50 123 0.09 TSETHFGNY A*01:01 5 
UL83 502-510 
50.00/  
58.06 
1518/  
4716 
0.60/  
5.00 
TVQGQNLKY 
A*01:01 / 
A*03:01 
5 
UL34 383-391 52.63 2694 0.40 VAATPSPSV B*51:01 3 
UL33 254-261 60.53 16653 4.00 VALQTPYV B*51:01 5 
UL43 163-171 57.89 6064 1.00 VGYFGHLNI B*51:01 5 
UL13 331-339 73.33 651 0.01 VIPPAPTVL C*01:02 1 
UL89 177-185 64.52 44 0.17 VLANRVLQY A*03:01 5 
UL98 471-479 67.74 41 0.17 VLSQYYIKK A*03:01 3 
UL36 199-207 62.79 109 0.17 VMKFKETSF B*08:01 2 
UL33 162-170 65.79 225 0.02 VPAAVYTTV B*51:01 5 
UL57 962-970 60.53 143 0.01 VPAPMAATV B*51:01 5 
UL115 184-192 65.79 578 0.07 VPPSLFNVV B*51:01 5 
UL21A 108-115 63.16 7223 1.20 VPRPHPMI B*51:01 ND 
UL92 146-154 60.53 482 0.06 VPVISQLFI B*51:01 5 
UL105 616-624 63.33 5552 0.60 VSPYTTEEM C*01:02 3 
US28 182-190 39.47 5340 0.80 VSYPIILNV B*51:01 4 
UL105 916-924 52.50 94 0.07 VTDPEHLMM A*01:01 3 
UL48 1607-1617 82.05 31 0.03 VTDYGNVAFKY A*01:01 5 
UL44 245-252 66.67 30287 29.00 VTEHDTLL C*07:01 5 
UL44 245-253 85.00 6 0.01 VTEHDTLLY A*01:01 5 
UL44 245-254 48.72 138 0.10 VTEHDTLLYV A*01:01 5 
US24 481-490 77.42 17 0.04 VTYSDPFPLK A*03:01 1 
UL56 581-590 66.67 43 0.04 VVDVGDQFTY A*01:01 3 
UL31 233-241 77.42 86 0.40 VVLQPLITK A*03:01 5 
UL78 375-384 67.74 203 0.70 VVVTTTTSEK A*03:01 2 
UL105 715-723 82.50 6 0.01 YADPFFLKY A*01:01 3 
UL114 199-207 55.81 28 0.03 YLIDRRRHL B*08:01 2 
UL13 465-473 46.51 32 0.04 YLVRRPMTI B*08:01 1 
UL3 69-77 68.42 510 0.06 YPPSWSRTI B*51:01 ND 
UL16 162-170 
51.16/  
47.37 
1454/  
2912 
1.80/  
0.40 
YPRPPGSGL 
B*08:01 / 
B*51:01 
2 
UL78 222-232 76.92 22 0.02 YSDRRDHVWSY A*01:01 2 
UL83 363-371 32.50 4145 1.40 YSEHPTFTS A*01:01 5 
UL25 370-379 64.10 13 0.01 YTSRGALYLY A*01:01 5 
UL70 404-412 57.50 89 0.07 YTTGTLTRY A*01:01 3 
UL104 269-277 
47.50/  
64.52 
172/  
1709 
0.12/  
3.00 
YVAAEPLAY 
A*01:01 / 
A*03:01 
5 
UL105 723-731 
48.84/  
46.67 
464/  
822 
0.70/  
0.01 
YVKPPSLAL 
B*08:01 / 
C*01:02 
3 
 
114  Danksagung 
9 Danksagung 
Zu allererst möchte ich meinen beiden Betreuern Prof. Dr.  Stefan Stevanović und Prof. Dr. Hans-
Georg Rammensee danken. Vielen Dank für euer Vertrauen, die großartige Betreuung, die 
konstruktive Kritik und die viele Unterstützung in allen Belangen.  
Den Kampf mit der Bürokratie haben einem Lynne Yakes, Jürgen Frank, Carmen Höner und Gerhard 
Hörr erheblich erleichtert oder gänzlich abgenommen. Vielen Dank dafür. 
Viele hundert Peptide wurden durch mich oder meine Studenten getestet. Ermöglicht haben das 
Patricia, Nici, Marion, Camille, Mirijam, Uli, die Hiwis und alle die sonst noch mit der Peptidsynthese 
geholfen haben. Dankeschön! 
Auch der gesamten AG Gouttefangeas möchte ich danken. Sie war und ist eine nicht versiegende 
Quelle an Wissen über T-Zellen, Durchflusszytometrie und Protokolloptimierungen.  
Bedanken möchte ich mich darüber hinaus bei meinen früheren Kollegen Janet, Lea, Heiko, Linus, 
Daniel, Nico und Armin, die mich nicht erst zum Doktor sondern schon zu meiner Hiwi-Zeit herzlich 
aufgenommen haben und immer ein offenes Ohr für einen Neuling hatten. Besonderen Dank gilt 
dabei Stefanie Spalt, die mir mit der Etablierung des Infektionsmodels mit HCMV-Mutanten nicht 
nur den Weg zu meinem Projekt geebnet hat, sondern mir auch immer mit Rat und Tat zur Seite 
stand. 
Auch meinen aktuellen Kollegen der AG Stevanović und AG Walz möchte ich für die tolle 
Arbeitsatmosphäre, die gemeinsamen Kongresse, die fröhlichen Abende und die erbauenden 
Gespräche danken. Insbesondere Kollegen wie Moni, Ana, Annika, Tatjana und Timo, welche 
inzwischen zu Freunden geworden sind, haben die Doktorarbeit zu einer wundervollen Zeit 
gemacht. Ich werde diese Zeit mit euch vermissen. 
Ich möchte außerdem allen meinen Freunden außerhalb des Instituts danken, die mich durch diese 
Zeit und mein Leben begleitet haben und begleiten – insbesondere meinem „Team Awesome“ 
gebührt ein riesiges Dankeschön. 
Zuletzt gilt ein besonderer Dank meiner Familie: Danke für eure Unterstützung in jeglicher Hinsicht, 
euren Glauben an mich und eure Liebe.  Vielen lieben Dank an Jörg, der mir in allen Lebenslagen zur 
Seite steht und mein Leben noch reicher macht, als es ohnehin schon ist. 
 
